



## **Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection**

Downloaded from <https://aidsinfo.nih.gov/guidelines> on 2/17/2019

Visit the *AIDSinfo* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <https://aidsinfo.nih.gov/e-news>.

**Table 1. Outline of the Guidelines Development Process**

Topic	Comment
<b>Goal of the Guidelines</b>	Provide guidance to HIV care practitioners on the optimal use of ARV agents in infants, children, and adolescents (through mid-puberty) living with HIV in the United States.
<b>Panel Members</b>	The Panel is composed of approximately 35 voting members who have expertise in management of HIV infection in infants, children, and adolescents. Members include representatives from the Committee on Pediatric AIDS of the American Academy of Pediatrics and community representatives with knowledge of pediatric HIV infection (e.g., parents and caregivers of children and youth living with HIV). The Panel also includes at least one representative from each of the following HHS agencies: Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Health Resources and Services Administration (HRSA), and the National Institutes of Health (NIH). A representative from the Canadian Pediatric AIDS Research Group participates as a nonvoting, <i>ex officio</i> member of the Panel. The U.S. government representatives are appointed by their respective agencies; nongovernmental members are selected after an open announcement to call for nominations. Each member serves on the Panel for a 3-year term with an option for reappointment. A list of current members can be found in the <a href="#">Panel Roster</a> .
<b>Financial Disclosure</b>	All members of the Panel submit an annual financial disclosure statement in writing, reporting any association with manufacturers of ARV drugs or diagnostics used for management of HIV infections. A list of the latest disclosures is available on the <i>AIDSinfo</i> website ( <a href="http://aidsinfo.nih.gov">http://aidsinfo.nih.gov</a> ).
<b>Users of the Guidelines</b>	Providers of care to infants, children, and adolescents living with HIV in the United States
<b>Developer</b>	Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—a working group of OARAC
<b>Funding Source</b>	Office of AIDS Research, NIH and HRSA
<b>Evidence Collection</b>	A standardized review of recent, relevant literature related to each section of the guidelines is performed by a technical assistance consultant (through funding from HRSA) and provided to individual Panel section working groups. The recommendations are generally based on studies published in peer-reviewed journals. The Panel may occasionally use unpublished data to revise the guidelines, particularly when the new information relates to dosing or patient safety. These data come from presentations at major conferences or from the FDA and/or drug manufacturers.
<b>Recommendation Grading</b>	Described in <a href="#">Table 2</a> .
<b>Method of Synthesizing Data</b>	Each section of the guidelines is assigned to a small group of Panel members with expertise in the area of interest. The members synthesize the available data and propose recommendations to the Panel. The Panel discusses all proposals during monthly teleconferences. Proposals are modified based on Panel discussion and then distributed with ballots to all Panel members for concurrence and additional comments. If there are substantive comments or votes against approval, the recommended changes and areas of disagreement are brought back to the full Panel (by email or teleconference) for additional review, discussion, and further modification to reach a final version acceptable to all Panel members. The recommendations in these final versions represent endorsement from a consensus of members and are included in the guidelines as official Panel recommendations.
<b>Other Guidelines</b>	<p>These guidelines focus on infants, children, and adolescents in early puberty (SMR I–III) living with HIV. Guidance for treatment of adolescents in late puberty (SMR IV–V) is provided by the <a href="#">Panel on Antiretroviral Guidelines for Adults and Adolescents</a>.</p> <p>Separate guidelines outline the use of ART in pregnant women with HIV infection (including maternal and infant interventions for prevention of perinatal transmission), <a href="#">ART for nonpregnant adults and postpubertal adolescents with HIV infection</a>, and <a href="#">ARV prophylaxis</a> for those who experience occupational or nonoccupational exposure to HIV. These guidelines are also available on the <i>AIDSinfo</i> website (<a href="http://www.aidsinfo.nih.gov">http://www.aidsinfo.nih.gov</a>).</p>
<b>Update Plan</b>	The full Panel meets monthly by teleconference to review data that may warrant modification of the guidelines. Smaller working groups of Panel members hold additional teleconferences to review individual drug sections or other specific topics (e.g., <a href="#">What to Start</a> ). Updates may be prompted by new drug approvals (or new indications, formulations, or frequency of dosing), new significant safety or efficacy data, or other information that may have a significant impact on the clinical care of patients. In the event of significant new data that may affect patient safety, the Panel may issue a warning announcement and post accompanying recommendations on the <i>AIDSinfo</i> website until the guidelines can be updated with appropriate changes. All sections of the guidelines will be reviewed, with updates as appropriate, at least once a year.
<b>Public Comments</b>	A 2-week public comment period follows release of the updated guidelines on the <i>AIDSinfo</i> website. The Panel reviews comments received to determine whether additional revisions to the guidelines are indicated. The public may also submit comments to the Panel at any time at <a href="mailto:contactus@aidsinfo.nih.gov">contactus@aidsinfo.nih.gov</a> .

**Table 2. Rating Scheme for Recommendations**

Strength of Recommendation	Quality of Evidence for Recommendation
<p><b>A:</b> Strong recommendation for the statement</p> <p><b>B:</b> Moderate recommendation for the statement</p> <p><b>C:</b> Optional recommendation for the statement</p>	<p><b>I:</b> One or more randomized trials <u>in children</u><sup>a</sup> with clinical outcomes and/or validated laboratory endpoints</p> <p><b>I*:</b> One or more randomized trials <u>in adults</u>, with clinical outcomes and/or validated laboratory endpoints plus accompanying data <u>in children</u><sup>a</sup> from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes</p> <p><b>II:</b> One or more well-designed, nonrandomized trials or observational cohort studies <u>in children</u><sup>a</sup> with long-term clinical outcomes</p> <p><b>II*:</b> One or more well-designed, nonrandomized trials or observational cohort studies <u>in adults</u> with long-term clinical outcomes plus accompanying data <u>in children</u><sup>a</sup> from one or more smaller nonrandomized trials or cohort studies with clinical outcome data</p> <p><b>III:</b> Expert opinion</p>

<sup>a</sup> Studies that include children or children and adolescents, but not studies limited to post-pubertal adolescents

**Table 3. Sample Schedule for Clinical and Laboratory Monitoring of Children Before and After Initiation of Antiretroviral Therapy**

	Entry Into Care <sup>a</sup>	Pre-Therapy <sup>b</sup>	ART Initiation <sup>c</sup>	Weeks 1–2 on Therapy	Weeks 2–4 on Therapy	Every 3–4 Months <sup>d</sup>	Only Required Every 6–12 Months <sup>e</sup>	ARV Switch
History and Physical	√	√	√	√	√	√		√
Adherence Evaluation		√	√	√	√	√		√
CD4 Count	√	√	√			√		√
Plasma Viral Load	√	√	√		√	√		√
Resistance Testing	√							√
CBC with Differential	√	√	√		√	√		√
Chemistries <sup>f</sup>	√	√	√		√	√		√
Lipid Panel	√		√				√	
Random Plasma Glucose <sup>g</sup>			√				√	
Urinalysis	√		√				√	
Hepatitis B Screening <sup>h,i</sup>		√						√

<sup>a</sup> See text for details on recommended laboratory tests to obtain.

<sup>b</sup> Readiness for ARV adherence is assessed prior to starting ART. If abacavir is being considered as part of the regimen, send HLA-B\*5701 testing prior to initiation of that ARV and choose an alternative ARV if HLA-B\*5701 is positive (see [Abacavir](#) in [Appendix A: Pediatric Antiretroviral Drug Information](#)). Genotype resistance testing is recommended if not already performed (see [Antiretroviral Drug-Resistance Testing](#) in the [Adult and Adolescent Antiretroviral Guidelines](#)). Send tests appropriate to the toxicities expected from each patient's ART regimen and history (see text).

<sup>c</sup> If ART is initiated within 30 to 90 days of a pre-therapy lab result, repeat testing may not be necessary.

<sup>d</sup> CD4 cell count, **CBC, and chemistries** can be monitored less frequently (every 6–12 months) in children and youth who are adherent to therapy and have CD4 cell values well above the threshold for opportunistic infection risk, sustained viral suppression, and stable clinical status for more than 2 to 3 years. **Viral load testing every 3 to 4 months is generally recommended to monitor ARV adherence.**

<sup>e</sup> If lipids have been abnormal in the past, more frequent monitoring might be needed. For patients treated with TDF, more frequent urinalysis should be considered.

<sup>f</sup> **Chemistries refer to a comprehensive metabolic panel.**

<sup>g</sup> **Random plasma glucose collected in a gray top tube.**

<sup>h</sup> Recommended when considering starting ARV drugs with activity against hepatitis B, specifically lamivudine-, emtricitabine-, and tenofovir-containing regimens.

<sup>i</sup> Recommended only when individual previously demonstrated no immunity to hepatitis B.

**Key to Acronyms:** ART = antiretroviral therapy; ARV = antiretroviral; CBC = complete blood count; CD4 = CD4 T lymphocyte; TDF = tenofovir disoproxil fumarate

**Table 4. Primary, FDA-Approved Assays to Monitor Viral Load**

Assay	Abbott Real Time	NucliSens EasyQ v 2.0	COBAS Ampliprep/TaqMan v 2.0	Versant v 1.0
<b>Method</b>	Real-time RT-PCR	Real-time NASBA	Real-time RT-PCR	Real-time RT-PCR
<b>Dynamic Range (copies/mL)</b>	40–10 <sup>7</sup>	25–10 <sup>7</sup>	20–10 <sup>7</sup>	37–11x10 <sup>7</sup>
<b>Specimen volume<sup>a</sup></b>	0.2–1 mL	0.1–1 mL	1 mL	0.5 mL
<b>Manufacturer</b>	Abbott	bioMerieux	Roche	Siemens

<sup>a</sup> Smaller volumes for children can be accommodated.

**Key to Acronyms:** FDA = Food and Drug Administration; NASBA = nucleic acid sequence-based amplification; RT-PCR = reverse transcription polymerase chain reaction

**Table 5. HIV Infection Stage<sup>a</sup> Based on Age-Specific CD4 Cell Count or Percentage**

Stage	Age on Date of CD4 Test					
	<1 Year	%	1 to <6 Years	%	≥6 Years	%
	Cells/μL		Cells/μL		Cells/μL	
<b>1</b>	≥1,500	≥34	≥1,000	≥30	≥500	≥26
<b>2</b>	750–1,499	26–33	500–999	22–29	200–499	14–25
<b>3</b>	<750	<26	<500	<22	<200	<14

<sup>a</sup> The stage is based primarily on the CD4 cell count; the CD4 cell count takes precedence over the CD4 percentage, and the percentage is considered only if the count is missing. If a Stage 3-defining opportunistic illness has been diagnosed (Table 6), then the stage is 3 regardless of CD4 test results.

Source: Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection—United States, 2014. *MMWR* 2014;63(No. RR-3):1-10.

**Key to Acronyms:** CD4 = CD4 T lymphocyte

**Table 6. HIV-Related Symptoms** (page 1 of 2)

<b>Mild HIV-Related Symptoms</b>
Children with 2 or more of the conditions listed, but none of the conditions listed in Moderate Symptoms category: <ul style="list-style-type: none"><li>• Lymphadenopathy (<math>\geq 0.5</math> cm at more than 2 sites; bilateral at 1 site)</li><li>• Hepatomegaly</li><li>• Splenomegaly</li><li>• Dermatitis</li><li>• Parotitis</li><li>• Recurrent or persistent upper respiratory tract infection, sinusitis, or otitis media</li></ul>
<b>Moderate HIV-Related Symptoms</b>
<ul style="list-style-type: none"><li>• Anemia (hemoglobin <math>&lt; 8</math> g/dL [<math>&lt; 80</math> g/L]), neutropenia (white blood cell count <math>&lt; 1,000/\mu\text{L}</math> [<math>&lt; 1.0 \times 10^9/\text{L}</math>]), and/or thrombocytopenia (platelet count <math>&lt; 100 \times 10^3/\mu\text{L}</math> [<math>&lt; 100 \times 10^9/\text{L}</math>]) persisting for <math>\geq 30</math> days</li><li>• Bacterial meningitis, pneumonia, or sepsis (single episode)</li><li>• Candidiasis, oropharyngeal (thrush), persisting (<math>&gt; 2</math> months) in children aged <math>&gt; 6</math> months</li><li>• Cardiomyopathy</li><li>• Cytomegalovirus infection, with onset before 1 month</li><li>• Diarrhea, recurrent or chronic</li><li>• Hepatitis</li><li>• Herpes simplex virus (HSV) stomatitis, recurrent (<math>&gt; 2</math> episodes within 1 year)</li><li>• HSV bronchitis, pneumonitis, or esophagitis with onset before 1 month</li><li>• Herpes zoster (shingles) involving at least 2 distinct episodes or more than 1 dermatome</li><li>• Leiomyosarcoma</li><li>• Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex</li><li>• Nephropathy</li><li>• Nocardiosis</li><li>• Persistent fever (lasting <math>&gt; 1</math> month)</li><li>• Toxoplasmosis, onset before 1 month</li><li>• Varicella, disseminated (complicated chickenpox)</li></ul>

### Stage-3-Defining Opportunistic Illnesses in HIV Infection

- Bacterial infections, multiple or recurrent<sup>a</sup>
- Candidiasis of bronchi, trachea, or lungs
- Candidiasis of esophagus
- Cervical cancer, invasive<sup>b</sup>
- Coccidioidomycosis, disseminated or extrapulmonary
- Cryptococcosis, extrapulmonary
- Cryptosporidiosis, chronic intestinal (>1 month duration)
- Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month
- Cytomegalovirus retinitis (with loss of vision)
- Encephalopathy attributed to HIV<sup>c</sup>
- HSV: chronic ulcers (>1 month duration) or bronchitis, pneumonitis, or esophagitis (onset at age >1 month)
- Histoplasmosis, disseminated or extrapulmonary
- Isosporiasis, chronic intestinal (>1 month duration)
- Kaposi sarcoma
- Lymphoma, Burkitt (or equivalent term)
- Lymphoma, immunoblastic (or equivalent term)
- Lymphoma, primary, of brain
- *Mycobacterium avium* complex or *Mycobacterium kansasii*, disseminated or extrapulmonary
- *Mycobacterium tuberculosis* of any site, pulmonary, disseminated, or extrapulmonary
- *Mycobacterium*, other species or unidentified species, disseminated or extrapulmonary
- *Pneumocystis jirovecii* (previously known as *Pneumocystis carinii*) pneumonia
- Pneumonia, recurrent<sup>b</sup>
- Progressive multifocal leukoencephalopathy
- Salmonella septicemia, recurrent
- Toxoplasmosis of brain, onset at age >1 month
- Wasting syndrome attributed to HIV<sup>c</sup>

<sup>a</sup> Only among children aged <6 years.

<sup>b</sup> Only among adults, adolescents, and children aged ≥6 years.

<sup>c</sup> Suggested diagnostic criteria for these illnesses, which might be particularly important for HIV encephalopathy and HIV wasting syndrome, are described in the following references:

- Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR*. 1994;43(No. RR-12).
- Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR*. 1992;41(No. RR-17).

Modified from:

- Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR*. 1994;43(No. RR-12).
- Centers for Disease Control and Prevention: Revised Surveillance Case Definition for HIV Infection—United States, 2014. *MMWR*. 2014;63(No. RR-3):1-10.

**Table 7. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children**

An ART regimen for treatment-naïve children generally contains one NNRTI **or** one PI boosted with RTV or COBI **or** one INSTI plus a two-NRTI backbone. *Preferred* regimens are designated based on efficacy, ease of administration, and acceptable toxicity. *Alternative* regimens have also demonstrated efficacy, but have more limited experience in children or less favorable ease of administration than *Preferred* regimens. Regimens should be individualized based on the advantages and disadvantages of each combination (see [Table 8](#)).

Children who are receiving effective and tolerable ART regimens can continue with those regimens as they age, even if the combinations they are receiving are no longer *Preferred* regimens.

<b>Preferred Regimens</b>		
<b>Age</b>	<b>Regimens</b>	<b>Fixed-Dose Combination Available</b>
Infants, Birth to Age <14 Days <sup>a,b</sup>	2 NRTIs <b>plus</b> NVP	No
	2 NRTIs <b>plus</b> RAL	No
Children Aged ≥14 Days to <3 Years	2 NRTIs <b>plus</b> LPV/r	No
	2 NRTIs <b>plus</b> RAL <sup>c</sup>	No
Children Aged ≥3 Years to <6 Years	2 NRTIs <b>plus</b> ATV/r	No
	2 NRTIs <b>plus</b> twice-daily DRV/r <sup>d</sup>	No
	2 NRTIs <b>plus</b> RAL <sup>c</sup>	No
Children Aged ≥6 Years to <12 Years	2 NRTIs <b>plus</b> ATV/r	No
	2 NRTIs <b>plus</b> DTG <sup>e</sup>	No
Adolescents Aged ≥12 Years and SMR 1–3	2 NRTIs <b>plus</b> ATV/r	No
	2 NRTIs <b>plus</b> DTG <sup>e</sup>	FDC available
	2 NRTIs <b>plus</b> once-daily DRV/r <sup>d</sup>	No
	2 NRTIs <b>plus</b> EVG/COBI <sup>f</sup>	FDCs available
Adolescents Aged ≥12 Years and SMR 4 or 5	Refer to the <a href="#">Adult and Adolescent Guidelines</a>	No
<b>Alternative Regimens</b>		
<b>Age</b>	<b>Regimens</b>	<b>Fixed-Dose Combination Available</b>
Children Aged >14 Days to <3 Years	2 NRTIs <b>plus</b> NVP <sup>g</sup>	No
Children Aged ≥3 Months to <3 Years and Weighing ≥10 kg	2 NRTIs <b>plus</b> ATV/r	No

**Table 7. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children, continued**

Age	Regimens	Fixed-Dose Combination Available
Children Aged ≥3 Years to <6 Years	2 NRTIs <b>plus</b> EFV <sup>h</sup>	No
	2 NRTIs <b>plus</b> LPV/r	No
Children Aged ≥6 Years to <12 Years	2 NRTIs <b>plus</b> twice-daily DRV/r <sup>d</sup>	No
	2 NRTIs <b>plus</b> EFV <sup>h</sup>	No
	2 NRTIs <b>plus</b> EVG/COBI <sup>f</sup>	FDCs available
	2 NRTIs <b>plus</b> LPV/r	No
	2 NRTIs <b>plus</b> RAL <sup>c</sup>	No
Adolescents Aged ≥12 Years and SMR 1–3	2 NRTIs <b>plus</b> EFV <sup>h</sup>	FDC available
	2 NRTIs <b>plus</b> RAL <sup>c</sup>	No
	2 NRTIs <b>plus</b> RPV <sup>i</sup>	FDC available
<b>Preferred 2-NRTI Backbone Options for Use in Combination with Additional Drugs</b>		
Age	2-NRTI Backbone Options	Fixed-Dose Combination Available
Children, Birth to Age <3 Months	ZDV <b>plus</b> (3TC <b>or</b> FTC) <sup>j</sup>	No
Children Aged ≥3 Months to <6 Years	ABC <b>plus</b> (3TC <b>or</b> FTC) <sup>k</sup>	FDC available
	ZDV <b>plus</b> (3TC <b>or</b> FTC) <sup>j</sup>	FDC available
Children and Adolescents Aged ≥6 Years and SMR 1–3	ABC <b>plus</b> (3TC <b>or</b> FTC) <sup>k</sup>	FDC available
	FTC/TAF <sup>l</sup>	FDC available
Adolescents Aged ≥12 Years and SMR 4 or 5	Refer to the <a href="#">Adult and Adolescent Guidelines</a>	No
<b>Alternative 2-NRTI Backbone Options for Use in Combination with Additional Drugs</b>		
Age	2-NRTI Backbone Options	Fixed-Dose Combination Available
Children Aged ≥3 Months	ZDV <b>plus</b> ABC	No
Children Aged ≥2 Years to 12 Years	TDF <b>plus</b> (3TC <b>or</b> FTC) <sup>m</sup>	FDC available
Children and Adolescents Aged ≥6 Years and SMR 1–3	ZDV <b>plus</b> (3TC <b>or</b> FTC) <sup>j</sup>	FDC available

<sup>a</sup> If treatment is scheduled to begin before a patient is aged 14 days, NVP **or** RAL are *Preferred* agents because they are the only options with dosing information available for this age group. However, there are currently no clinical trial data suggesting that initiating treatment within the first 14 days of life improves outcome (compared with starting after 14 days of age). Clinicians should consult an expert in pediatric HIV infection. Additional considerations regarding the use of NVP **or** RAL in infants aged <14 days can be found in [Antiretroviral Management of Newborns](#). A change from NVP to LPV/r should be considered when the infant is aged ≥14 days and 42 weeks postmenstrual age (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth), based on infant genotype and better outcomes of LPV/r than NVP in children aged <3 years. Data are very limited on the clinical outcomes of using RAL in infants and children aged <2 years.

<sup>b</sup> LPV/r should not be administered to neonates before a postmenstrual age of 42 weeks and postnatal age ≥14 days.

<sup>c</sup> RAL pills or chewable tablets can be used in children aged ≥2 years. Granules can be administered in infants and children from birth to age 2 years.

<sup>d</sup> DRV once daily should not be used in children aged <12 years or weighing <40 kg. DRV once daily should also not be used if any one of the following resistance-associated substitutions are present: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V. DRV/r is an *Alternative* recommendation for children aged ≥6 years to <12 years because there are options that can be administered once daily. It is *Preferred* for adolescents aged ≥12 years who are not sexually mature (SMR 1–3) where once-daily administration is possible.

<sup>e</sup> DTG is recommended only for children and adolescents weighing ≥30 kg. An FDC tablet containing ABC/DTG/3TC (Triumeq) is available.

<sup>f</sup> EVG is currently recommended only in FDC tablets. Tablets containing EVG/COBI/FTC/TAF are recommended as *Preferred* for children

**Table 7. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children,**  
continued

and adolescents weighing  $\geq 35$  kg and as *Alternative* for children aged  $\geq 6$  years and weighing  $\geq 25$  kg.

<sup>g</sup> NVP should not be used in postpubertal girls with CD4 cell counts  $>250/\text{mm}^3$ , unless the benefit clearly outweighs the risk. NVP is FDA-approved for treatment of infants aged  $\geq 15$  days.

<sup>h</sup> EFV is licensed for use in children aged  $\geq 3$  months and weighing  $\geq 3.5$  kg, but it is not recommended by the Panel as initial therapy in children aged  $\geq 3$  months to 3 years. An FDC tablet containing EFV/FTC/TDF (Atripla) is available.

<sup>i</sup> RPV should be administered to adolescents aged  $\geq 12$  years and weighing  $\geq 35$  kg who have an initial viral load  $\leq 100,000$  copies/mL. FDC tablets containing FTC/RPV/TAF (Odefsey) and FTC/RPV/TDF (Complera) are available.

<sup>j</sup> An FDC containing 3TC/ZDV (Combivir and generic) is available.

<sup>k</sup> An FDC containing ABC/3TC (Epzicom and generic) is available.

<sup>l</sup> An FDC containing FTC/TAF is available. FTC/TAF is FDA-approved for children weighing  $\geq 25$  kg when used in the single-tablet regimen EVG/COBI/FTC/TAF or as TAF/FTC in combination with an NNRTI or INSTI. There is insufficient data to recommend use of FTC/TAF in combination with a boosted PI in children weighing  $<35$  kg. For children and adolescents weighing  $\geq 35$  kg, TAF can be used in the single-tablet regimen EVG/COBI/FTC/TAF, or as FTC/TAF in combination with an NNRTI, an INSTI, or a boosted PI.

<sup>m</sup> An FDC containing FTC/TDF (Truvada) is available.

**Key to Acronyms:** 3TC = lamivudine; ABC = abacavir; ATV/r = atazanavir/ritonavir; ART = antiretroviral therapy; CD4 = CD4 T lymphocyte; COBI=cobicistat; DRV = darunavir; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FDA = Food and Drug Administration; **FDC = fixed-dose combination**; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

**Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children<sup>a</sup> (page 1 of 4)**

ARV Class	ARV Agent(s)	Advantages	Disadvantages
INSTIs In Alphabetical Order	All INSTIs	<u>INSTI Class Advantages:</u> <ul style="list-style-type: none"> <li>• Susceptibility of HIV to a new class of ARV drugs</li> <li>• Few drug-drug interactions</li> <li>• Well-tolerated</li> </ul>	<u>INSTI Class Disadvantages:</u> <ul style="list-style-type: none"> <li>• Limited data on pediatric dosing or safety</li> </ul>
	DTG	<ul style="list-style-type: none"> <li>• Once-daily administration</li> <li>• Can give with food</li> <li>• Available in an FDC tablet containing ABC/DTG/3TC (Triumeq) in a single, but large, tablet</li> <li>• Single-agent DTG pills are available in several dosages and are small in size.</li> </ul>	<ul style="list-style-type: none"> <li>• Drug interactions with EFV, FPV/r, TPV/r, and rifampin, necessitating twice-daily dosing</li> <li>• <b>CNS side effects, particularly sleep disturbances</b></li> </ul>
	EVG	<ul style="list-style-type: none"> <li>• Once-daily administration</li> <li>• Available in the following FDC tablets: EVG/COBI/FTC/TDF (Stribild) and EVG/COBI/FTC/TAF (Genvoya)</li> </ul>	<ul style="list-style-type: none"> <li>• COBI has the potential for multiple drug interactions because of metabolism via hepatic enzymes (e.g., CYP3A4).</li> <li>• COBI inhibits tubular secretion of creatinine and may result in increased serum creatinine but normal glomerular clearance.</li> </ul>
	RAL	<ul style="list-style-type: none"> <li>• Can give with food</li> <li>• Available in tablet, chewable tablet, and powder formulations</li> <li>• <b>Once-daily administration (with RAL HD) can be used for treatment-naïve or virologically suppressed children weighing <math>\geq 50</math> kg.</b></li> </ul>	<ul style="list-style-type: none"> <li>• Potential for rare systemic allergic reaction or hepatitis</li> <li>• <b>Powder formulation requires a multistep preparation before administration.</b></li> </ul>

**Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children<sup>a</sup> (page 2 of 4)**

<b>ARV Class</b>	<b>ARV Agent(s)</b>	<b>Advantages</b>	<b>Disadvantages</b>
<b>NNRTIs</b> In Alphabetical Order	All NNRTIs	<p><u>NNRTI Class Advantages:</u></p> <ul style="list-style-type: none"> <li>• Long half-life</li> <li>• Less dyslipidemia and fat maldistribution than PIs</li> <li>• PI-sparing</li> <li>• Lower pill burden than PIs for children taking solid formulation; easier to use and adhere to than PI-based regimens</li> </ul>	<p><u>NNRTI Class Disadvantages:</u></p> <ul style="list-style-type: none"> <li>• Single mutation can confer resistance, with cross-resistance between EFV and NVP</li> <li>• Rare but serious and potentially life-threatening cases of skin rash, including SJS, and hepatic toxicity with all NNRTIs (but highest with NVP )</li> <li>• Potential for multiple drug interactions due to metabolism via hepatic enzymes (e.g., CYP3A4)</li> </ul>
	EFV	<ul style="list-style-type: none"> <li>• Once-daily administration</li> <li>• Available in the FDC EFV/FTC/TDF (Atripla)</li> <li>• Potent ARV activity</li> <li>• Can give with food (but avoid high-fat meals)</li> <li>• Capsules can be opened and added to food</li> </ul>	<ul style="list-style-type: none"> <li>• Neuropsychiatric AEs (bedtime dosing recommended to reduce CNS effects)</li> <li>• Rash (generally mild)</li> <li>• No commercially available liquid</li> <li>• Limited data on dosing for children aged &lt;3 years</li> <li>• No data on dosing for children aged &lt;3 months</li> </ul>
	NVP	<ul style="list-style-type: none"> <li>• Liquid formulation available</li> <li>• Dosing information for young infants available</li> <li>• Can give with food</li> <li>• Extended-release formulation is available that allows for once-daily dosing in older children.</li> </ul>	<ul style="list-style-type: none"> <li>• Reduced virologic efficacy in young infants, regardless of exposure to NVP as part of a peripartum preventive regimen</li> <li>• Higher incidence of rash/HSR than other NNRTIs</li> <li>• Higher rates of serious hepatic toxicity than EFV</li> <li>• Decreased virologic response compared with EFV</li> <li>• Twice-daily dosing necessary in children with BSA &lt;0.58 m<sup>2</sup></li> </ul>
	RPV	<ul style="list-style-type: none"> <li>• Once-daily dosing</li> <li>• Available in the following 1-pill-daily, FDC tablets: FTC/RPV/TDF (Complera) and FTC/RPV/TAF (Odefsey)</li> </ul>	<ul style="list-style-type: none"> <li>• Should not use in patients with HIV viral load &gt;100,000 copies/mL</li> <li>• Low barrier for resistance</li> </ul>
<b>PIs</b> In Alphabetical Order	All PIs	<p><u>PI Class Advantages:</u></p> <ul style="list-style-type: none"> <li>• NNRTI-sparing</li> <li>• Clinical, virologic, and immunologic efficacy are well-documented.</li> <li>• Resistance to PIs requires multiple mutations</li> <li>• When combined with a dual-NRTI backbone, a regimen containing a PI targets HIV at 2 steps of viral replication by inhibiting the activity of viral reverse transcriptase and protease enzymes.</li> </ul>	<p><u>PI Class Disadvantages:</u></p> <ul style="list-style-type: none"> <li>• Metabolic complications, including dyslipidemia, fat maldistribution, insulin resistance</li> <li>• Potential for multiple drug interactions because of metabolism via hepatic enzymes (e.g., CYP3A4)</li> <li>• Higher pill burden than NRTI- or NNRTI-based regimens for patients taking solid formulations</li> <li>• Poor palatability of liquid preparations, which may affect adherence to treatment regimen</li> <li>• Most PIs require RTV boosting, resulting in associated drug interactions.</li> </ul>

**Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children<sup>a</sup> (page 3 of 4)**

ARV Class	ARV Agent(s)	Advantages	Disadvantages
PIs In Alphabetical Order, continued	Boosted ATV	<ul style="list-style-type: none"> <li>Once-daily dosing</li> <li>Powder formulation available</li> <li>ATV has less effect on TG and total cholesterol levels than other PIs (but RTV boosting may be associated with elevations in these parameters).</li> <li>ATV requires a boosting agent. ATV/COBI is available as an FDC tablet (Evotaz), which can reduce the pill burden associated with a boosted-PI regimen. However, the use of ATV/COBI in pediatric patients is still being investigated. RTV is currently the only boosting agent for ATV that is FDA-approved for use in children.</li> </ul>	<ul style="list-style-type: none"> <li>No liquid formulation</li> <li>Food effect (should be administered with food)</li> <li>Indirect hyperbilirubinemia is common, but asymptomatic</li> <li>Must be used with caution in patients with preexisting conduction system defects (can prolong PR interval of ECG)</li> <li>RTV component associated with a large number of drug interactions</li> </ul>
	Boosted DRV	<ul style="list-style-type: none"> <li>Can be used once daily in children aged <math>\geq 12</math> years</li> <li>Liquid formulation available</li> <li>DRV requires a boosting agent. DRV/COBI is available as an FDC tablet (Prezcobix), which can reduce the pill burden associated with a boosted-PI regimen. However, the use of DRV/COBI in pediatric patients is still being investigated. RTV is currently the only boosting agent for DRV that is FDA-approved for use in children.</li> </ul>	<ul style="list-style-type: none"> <li>Pediatric pill burden high with current tablet dose formulations</li> <li>Food effect (should be administered with food)</li> <li>Must be boosted to achieve adequate plasma concentrations</li> <li>Contains sulfa moiety. The potential for cross sensitivity between DRV and other drugs in sulfonamide class is unknown.</li> <li>RTV component associated with a large number of drug interactions</li> <li>Can only be used once daily in the absence of certain PI-associated resistance mutations</li> </ul>
	LPV/r	<ul style="list-style-type: none"> <li>LPV only available coformulated with RTV in liquid and tablet formulations.</li> <li>Tablets can be given without regard to food, but may be better tolerated when taken with meal or snack.</li> </ul>	<ul style="list-style-type: none"> <li>Poor palatability of liquid formulation (bitter taste), although palatability of combination is better than RTV alone</li> <li>Food effect (liquid formulation should be administered with food)</li> <li>RTV component is associated with large number of drug interactions</li> <li>Should not be administered to neonates before a postmenstrual age (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth) of 42 weeks and a postnatal age <math>\geq 14</math> days</li> <li>Must be used with caution in patients with pre-existing conduction system defects (can prolong PR and QT interval of ECG)</li> </ul>
Dual-NRTI Backbones In Alphabetical Order	ABC plus (3TC or FTC)	<ul style="list-style-type: none"> <li>Palatable liquid formulations</li> <li>Can give with food.</li> <li>ABC and 3TC are available in the following FDC tablets: ABC/3TC (Epzicom and generic; for older/larger patients) and ABC/DTG/3TC (Triumeq; a single, large tablet).</li> </ul>	<ul style="list-style-type: none"> <li>Risk of ABC HSR; perform HLA-B*5701 screening before initiation of ABC treatment.</li> </ul>
	FTC/TAF for children aged $\geq 6$ years	<ul style="list-style-type: none"> <li>Once-daily dosing</li> <li>Small tablet size</li> <li>Less TFV-associated renal and bone toxicity with TAF compared to TDF in adults</li> <li>FTC and TAF are available in the following FDC tablets: FTC/TAF (Descovy), EVG/COBI/FTC/TAF (Genvoya), and FTC/RPV/TAF (Odefsey)</li> </ul>	<ul style="list-style-type: none"> <li>Limited data in children</li> <li>Increased lipids</li> </ul>

**Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children<sup>a</sup> (page 4 of 4)**

ARV Class	ARV Agent(s)	Advantages	Disadvantages
Dual-NRTI Backbones In Alphabetical Order, continued	TDF <b>plus</b> (3TC <b>or</b> FTC) for adolescents with SMR 4 or 5	<ul style="list-style-type: none"> <li>• Once-daily dosing for TDF</li> <li>• Resistance is slow to develop</li> <li>• Less mitochondrial toxicity than other NRTIs</li> <li>• Can give with food</li> <li>• Available as reduced-strength tablets and oral powder for use in younger children</li> <li>• FTC and TDF are available in the following FDC tablets: FTC/TDF (Truvada; available in multiple dosages), EFV/FTC/TDF (Atripla), EVG/COBI/FTC/TDF (Stribild), and FTC/RPV/TDF (Complera)</li> </ul>	<ul style="list-style-type: none"> <li>• Limited pediatric experience</li> <li>• Potential bone and renal toxicity; toxicity may be less in post-pubertal children</li> <li>• Appropriate dosing is complicated by numerous drug-drug interactions with other ARV agents, including ddI, LPV/r, ATV, and TPV.</li> </ul>
	ZDV <b>plus</b> (3TC <b>or</b> FTC)	<ul style="list-style-type: none"> <li>• Extensive pediatric experience</li> <li>• ZDV and 3TC are coformulated as single pill (Combivir and generic) for older/larger patients.</li> <li>• Palatable liquid formulations</li> <li>• Can give with food</li> <li>• FTC is available as a palatable liquid formulation administered once daily.</li> </ul>	<ul style="list-style-type: none"> <li>• Bone marrow suppression with ZDV</li> <li>• Lipoatrophy with ZDV</li> </ul>
	ZDV <b>plus</b> ABC	<ul style="list-style-type: none"> <li>• Palatable liquid formulations</li> <li>• Can give with food</li> </ul>	<ul style="list-style-type: none"> <li>• Risk of ABC HSR; perform HLA-B*5701 screening before initiation of ABC treatment</li> <li>• Bone marrow suppression and lipoatrophy with ZDV</li> </ul>

<sup>a</sup> See [Appendix A: Pediatric Antiretroviral Drug Information](#) and [Table 7. Antiretroviral Regimen Considerations as Initial Therapy based on Specific Clinical Scenarios](#) in the [Adult and Adolescent Guidelines](#) for more information.

**Key to Acronyms:** 3TC = lamivudine; ABC = abacavir; AE = adverse event; ARV = antiretroviral; ATV = atazanavir; BSA = body surface area; CNS = central nervous system; COBI = cobicistat; CYP = cytochrome P; ddI = didanosine; DRV = darunavir; DTG = dolutegravir; ECG = electrocardiogram; EFV = efavirenz; EVG = elvitegravir; FDC = fixed-dose combination; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; HSR = hypersensitivity reaction; INSTI = integrase strand transfer inhibitor; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PK = pharmacokinetic; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SJS = Stevens-Johnson Syndrome; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TFV= tenofovir; TG = triglycerides; TPV = tipranavir; TPV/r = tipranavir/ritonavir; ZDV = zidovudine

**Table 9. Antiretroviral Regimens or Components Not Recommended for Initial Treatment of HIV Infection in Children**

<b>Regimen or ARV Component</b>	<b>Rationale</b>
Unboosted <b>ATV</b> -containing regimens in children	Reduced exposure
<b>DRV</b> -based regimens once daily in children aged $\geq 3$ to 12 years	Insufficient data to recommend
Unboosted <b>DRV</b>	Use without ritonavir has not been studied
Dual (full-dose) PI regimens	Insufficient data to recommend Potential for added toxicities
Dual-NRTI combination of <b>ABC plus TDF</b>	Insufficient data to recommend
<b>EFV</b> -based regimens for children aged $< 3$ years	Appropriate dose not determined
<b>T-20</b> -containing regimens	Insufficient data to recommend Injectable preparation
<b>ETR</b> -based regimens	Insufficient data to recommend
<b>FPV</b> -based regimens	Reduced exposure Medication burden
<b>IDV</b> -based regimens	Renal toxicities
<b>LPV/r</b> dosed once daily	Reduced drug exposure
<b>MVC</b> -based regimens	Insufficient data to recommend
<b>NFV</b> -based regimens	Variable PK Appropriate dose not determined in young infants
Regimens containing only NRTIs	Inferior virologic efficacy
Regimens containing 3 drug classes	Insufficient data to recommend
Full-dose <b>RTV</b> or use of <b>RTV</b> as the sole PI	GI intolerance Metabolic toxicity
Regimens containing 3 NRTIs and 1 NNRTI	Added cost and complexity outweighs any benefit
<b>SQV</b> -based regimens	Limited dosing and outcome data
<b>TDF</b> -containing regimens in children aged $< 2$ years	Potential bone toxicity Appropriate dose has yet to be determined
<b>TPV</b> -based regimens	Increased dose of RTV for boosting Reported cases of intracranial hemorrhage

**Key to Acronyms:** ABC = abacavir; ARV = antiretroviral; ATV = atazanavir; DRV = darunavir; EFV = efavirenz; ETR = etravirine; FPV = fosamprenavir; GI = gastrointestinal; IDV = indinavir; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NFV = nelfinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PK = pharmacokinetics; RTV = ritonavir; SQV = saquinavir; T-20 = enfuvirtide; TDF = tenofovir disoproxil fumarate; TPV = tipranavir

**Table 10. ART Regimens or Components Never Recommended for Treatment of HIV Infection in Children**

<b>ART Regimens <u>Never</u> Recommended for Children</b>		
<b>Regimen</b>	<b>Rationale</b>	<b>Exceptions</b>
<b>1 ARV Drug Alone (Monotherapy)</b>	<ul style="list-style-type: none"> <li>• Rapid development of resistance</li> <li>• Inferior antiviral activity compared to combinations that include <math>\geq 3</math> ARV drugs</li> <li>• Monotherapy “holding” regimens are associated with more rapid CD4 declines than non-suppressive ART</li> </ul>	<ul style="list-style-type: none"> <li>• Infants with perinatal HIV exposure and negative virologic tests who are receiving 4 to 6 weeks of ZDV prophylaxis to prevent perinatal transmission of HIV</li> </ul>
<b>2 NRTIs Alone</b>	<ul style="list-style-type: none"> <li>• Rapid development of resistance</li> <li>• Inferior antiviral activity compared to combinations that include <math>\geq 3</math> ARV drugs</li> </ul>	<ul style="list-style-type: none"> <li>• Not recommended for initial therapy.</li> <li>• For patients currently on 2 NRTIs alone who achieve virologic goals, some clinicians may opt to continue this treatment.</li> </ul>
<b>TDF plus ABC plus (3TC or FTC) as a Triple-NRTI Regimen</b>	<ul style="list-style-type: none"> <li>• High rate of early viral failure when this triple-NRTI regimen was used as initial therapy in treatment-naive adults</li> </ul>	<ul style="list-style-type: none"> <li>• No exceptions</li> </ul>
<b>TDF plus ddI plus (3TC or FTC) as a Triple-NRTI Regimen</b>	<ul style="list-style-type: none"> <li>• High rate of early viral failure when this triple-NRTI regimen was used as initial therapy in treatment-naive adults</li> </ul>	<ul style="list-style-type: none"> <li>• No exceptions</li> </ul>
<b>ARV Components <u>Never</u> Recommended as Part of an ARV Regimen for Children</b>		
<b>Regimen</b>	<b>Rationale</b>	<b>Exceptions</b>
<b>ddI and d4T, Individually or Co-Administered</b>	<ul style="list-style-type: none"> <li>• Increased toxicities</li> <li>• ddI plus d4T is <b>contraindicated</b></li> </ul>	<ul style="list-style-type: none"> <li>• No exceptions</li> </ul>
<b>ATV plus IDV</b>	<ul style="list-style-type: none"> <li>• Potential additive hyperbilirubinemia</li> </ul>	<ul style="list-style-type: none"> <li>• No exceptions</li> </ul>
<b>Dual-NNRTI Combinations</b>	<ul style="list-style-type: none"> <li>• Enhanced toxicity</li> </ul>	<ul style="list-style-type: none"> <li>• No exceptions</li> </ul>
<b>Dual-NRTI Combinations:</b>	<ul style="list-style-type: none"> <li>• Similar resistance profile and no additive benefit</li> </ul>	<ul style="list-style-type: none"> <li>• No exceptions</li> </ul>
• <b>3TC plus FTC</b>		
• <b>d4T plus ZDV</b>	<ul style="list-style-type: none"> <li>• Antagonistic effect on HIV</li> </ul>	<ul style="list-style-type: none"> <li>• No exceptions</li> </ul>
<b>NVP as Initial Therapy in Adolescent Girls with CD4 Counts <math>&gt;250</math> cells/mm<sup>3</sup> or Adolescent Boys with CD4 Counts <math>&gt;400</math> cells/mm<sup>3</sup></b>	<ul style="list-style-type: none"> <li>• Increased incidence of symptomatic (including serious and potentially fatal) hepatic events in these patient groups</li> </ul>	<ul style="list-style-type: none"> <li>• Only if benefit clearly outweighs risk</li> </ul>
<b>Unboosted SQV, DRV, or TPV</b>	<ul style="list-style-type: none"> <li>• Poor oral bioavailability</li> <li>• Inferior virologic activity compared with other PIs</li> </ul>	<ul style="list-style-type: none"> <li>• No exceptions</li> </ul>

**Key to Acronyms:** 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; CD4 = CD4 T lymphocyte; d4T = stavudine; ddI = didanosine; DRV = darunavir; FTC = emtricitabine; IDV = indinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; SQV = saquinavir; TDF = tenofovir disoproxil fumarate; TPV = tipranavir; ZDV = zidovudine

**Table 11. Newborn Antiretroviral Management According to Risk of HIV Infection in the Newborn**

Drug selection and dosing considerations are related to the age and gestational age of the newborn. Consultation is available through the National Perinatal HIV Hotline (888-448-8765).

Category	Description	Neonatal ARV Management
<b>Low Risk of Perinatal HIV Transmission</b>	<ul style="list-style-type: none"> <li>Mothers who received ART during pregnancy with sustained viral suppression near delivery and no concerns related to adherence</li> </ul>	ZDV for 4 weeks
<b>Higher Risk of Perinatal HIV Transmission<sup>a,b</sup></b>	<ul style="list-style-type: none"> <li>Mothers who received neither antepartum nor intrapartum ARV drugs</li> <li>Mothers who received only intrapartum ARV drugs</li> <li>Mothers who received antepartum and intrapartum ARV drugs but who have detectable viral load near delivery, particularly if delivery was vaginal</li> <li>Mothers with acute or primary HIV infection during pregnancy or breastfeeding (in which case, the mother should discontinue breastfeeding).<sup>c</sup></li> </ul>	2-drug ARV prophylaxis (NICHHD-HPTN 040/PACTG 1043 regimen) with 6 weeks ZDV and 3 doses of NVP (prophylactic dosage, with doses given within 48 hours of birth, 48 hours after first dose, and 96 hours after second dose)  <i>or</i>  Empiric HIV therapy using either ZDV, 3TC, and NVP (treatment dosage) <i>or</i> ZDV, 3TC, and RAL administered from birth to age 6 weeks. <sup>d</sup>
<b>Presumed Newborn HIV Exposure</b>	<ul style="list-style-type: none"> <li>Mothers with unknown HIV status who test HIV positive at delivery or postpartum or whose newborns have a positive HIV antibody test</li> </ul>	ARV management as above (for higher risk of perinatal HIV transmission)  Infant ARVs should be discontinued immediately if supplemental testing confirms that the mother does not have HIV.
<b>Newborn with HIV<sup>e</sup></b>	<ul style="list-style-type: none"> <li>Positive newborn HIV virologic test/NAT</li> </ul>	3-drug ARV regimen using treatment dosages

<sup>a</sup> See text for evidence supporting a 2-drug ARV prophylaxis regimen and empiric HIV therapy.

<sup>b</sup> See the [Intrapartum care section](#) for guidance on indications for scheduled cesarean delivery and intrapartum IV ZDV to reduce the risk of perinatal HIV transmission for mothers with an elevated viral load at delivery.

<sup>c</sup> Most Panel members would opt to administer empiric HIV therapy to infants whose mothers had acute HIV during pregnancy because of the higher risk for in utero transmission. If acute HIV is diagnosed during breastfeeding, mother should stop breastfeeding.

<sup>d</sup> The optimal duration of empiric HIV therapy in newborns at higher risk of perinatal HIV transmission is unknown. Some Panel members opt to discontinue NVP, RAL, and/or 3TC when a birth NAT returns negative, while others would continue empiric HIV therapy for infants at highest risk of HIV acquisition for 6 weeks. In all cases, ZDV should be continued for 6 weeks. It is recommended that providers consult with an expert in pediatric HIV infection to determine therapy duration based on case-specific risk factors and interim HIV NAT results.

<sup>e</sup> Most Panel members do not recommend delaying the initiation of ART pending results of the confirmatory HIV NAT, given low likelihood of a false-positive HIV NAT.

**Note:** ARV drugs should be initiated as close to the time of birth as possible, preferably within 6 to 12 hours of delivery. See Table 12 for dosing specifics.

**Key to Acronyms:** 3TC = lamivudine; ART = antiretroviral therapy; ARV = antiretroviral; IV = intravenous; NAT = nucleic acid test; NVP = nevirapine; the Panel = Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission; RAL = raltegravir; ZDV = zidovudine

**Table 12. Antiretroviral Dosing Recommendations for Newborns (page 1 of 2)**

<b>Newborns at Low Risk of Perinatal HIV Transmission</b>	
<b>Recommended Regimen</b>	<b>Recommended Duration</b>
• ZDV	• ZDV administered for 4 weeks
<b>Newborns at Higher Risk of Perinatal HIV Transmission</b>	
<b>Recommended Regimen</b>	<b>Recommended Duration</b>
• 2-drug ARV prophylaxis with ZDV and 3 doses of NVP (NICHD-HPTN 040/PACTG 1043 regimen), <i>or</i>	• ZDV administered for 6 weeks; 3 doses of NVP during the first week of life
• Empiric HIV therapy with ZDV/3TC/NVP, <i>or</i>	• ZDV administered for 6 weeks; 3TC and NVP administered for 2–6 weeks, up to 6 weeks of age <sup>a</sup>
• Empiric HIV therapy with ZDV/3TC/RAL	• ZDV administered for 6 weeks; 3TC and RAL administered for 2–6 weeks, up to 6 weeks of age <sup>a</sup>
<b>Newborns with HIV Infection</b>	
<b>Recommended Regimen</b>	<b>Recommended Duration</b>
• HIV therapy with ZDV/3TC/NVP, <i>or</i>	• Lifelong therapy
• HIV therapy with ZDV/3TC/RAL	• Lifelong therapy

<b>Indication</b>																			
<b>Drug</b>	<b>Low Risk Prophylaxis</b>	<b>Higher Risk Prophylaxis: 2-Drug</b>	<b>Higher Risk Prophylaxis: Empiric <u>and</u> HIV Therapy</b>																
<b>ZDV</b> <b>Note:</b> For newborns unable to tolerate oral agents, the IV dose is 75% of the oral dose while maintaining the same dosing interval.	$\geq 35$ Weeks Gestation at Birth: • ZDV 4 mg/kg/dose orally twice daily  Simplified Weight-Band Dosing for Newborns $\geq 35$ Weeks Gestation at Birth: <table border="1" style="margin-left: 20px;"> <thead> <tr> <th>Weight Band (kg)</th> <th>Volume (mL) ZDV 10 mg/mL Oral Syrup Twice Daily</th> </tr> </thead> <tbody> <tr> <td>2 to &lt;3 kg</td> <td>1 mL</td> </tr> <tr> <td>3 to &lt;4 kg</td> <td>1.5 mL</td> </tr> <tr> <td>4 to &lt;5 kg</td> <td>2 mL</td> </tr> </tbody> </table>	Weight Band (kg)	Volume (mL) ZDV 10 mg/mL Oral Syrup Twice Daily	2 to <3 kg	1 mL	3 to <4 kg	1.5 mL	4 to <5 kg	2 mL		$\geq 35$ Weeks Gestation at Birth <i>Birth–4 Weeks:</i> • ZDV 4 mg/kg/dose orally twice daily  <i>Age &gt;4 Weeks:</i> • ZDV 12 mg/kg/dose orally twice daily  Simplified Weight-Band Dosing for Newborns Aged $\geq 35$ Weeks Gestation from Birth to 4 Weeks: <table border="1" style="margin-left: 20px;"> <thead> <tr> <th>Weight Band (kg)</th> <th>Volume (mL) ZDV 10 mg/mL Oral Syrup Twice Daily</th> </tr> </thead> <tbody> <tr> <td>2 to &lt;3 kg</td> <td>1 mL</td> </tr> <tr> <td>3 to &lt;4 kg</td> <td>1.5 mL</td> </tr> <tr> <td>4 to &lt;5 kg</td> <td>2 mL</td> </tr> </tbody> </table>	Weight Band (kg)	Volume (mL) ZDV 10 mg/mL Oral Syrup Twice Daily	2 to <3 kg	1 mL	3 to <4 kg	1.5 mL	4 to <5 kg	2 mL
	Weight Band (kg)	Volume (mL) ZDV 10 mg/mL Oral Syrup Twice Daily																	
	2 to <3 kg	1 mL																	
	3 to <4 kg	1.5 mL																	
4 to <5 kg	2 mL																		
Weight Band (kg)	Volume (mL) ZDV 10 mg/mL Oral Syrup Twice Daily																		
2 to <3 kg	1 mL																		
3 to <4 kg	1.5 mL																		
4 to <5 kg	2 mL																		
$\geq 30$ to <35 Weeks Gestation at Birth <i>Birth to Age 2 Weeks:</i> • ZDV 2 mg/kg/dose orally twice daily  <i>Age 2 Weeks to 4–6 Weeks:</i> • ZDV 3 mg/kg/dose orally twice daily		$\geq 30$ to <35 Weeks Gestation at Birth <i>Birth to Age 2 Weeks:</i> • ZDV 2 mg/kg/dose orally twice daily  <i>Age 2 Weeks to 6–8 Weeks:</i> • ZDV 3 mg/kg/dose orally twice daily  <i>Age &gt;6–8 Weeks:</i> • ZDV 12 mg/kg/dose orally twice daily																	
<30 Weeks Gestation at Birth <i>Birth to Age 4–6 Weeks:</i> • ZDV 2 mg/kg/dose orally twice daily		<30 Weeks Gestation at Birth <i>Birth to Age 4 Weeks:</i> • ZDV 2 mg/kg/dose orally twice daily  <i>Age 4 to 8–10 Weeks:</i> • ZDV 3 mg/kg/dose orally twice daily  <i>Aged &gt;8–10 Weeks:</i> • ZDV 12 mg/kg/dose orally twice daily																	
<b>3TC</b>	N/A	N/A	$\geq 32$ Weeks Gestation at Birth <i>Birth to Age 4 Weeks:</i> • 3TC 2 mg/kg/dose orally twice daily  <i>Age &gt;4 Weeks:</i> • 3TC 4 mg/kg/dose orally twice daily																

**Table 12. Antiretroviral Dosing Recommendations for Newborns (page 2 of 2)**

Indication																											
Drug	Low Risk Prophylaxis	Higher Risk Prophylaxis: 2-Drug	Higher Risk Prophylaxis: Empiric and HIV Therapy																								
<b>NVP</b>	N/A	<p><u>≥32 Weeks Gestation at Birth:</u></p> <ul style="list-style-type: none"> <li>• NVP in 3 doses given               <ol style="list-style-type: none"> <li>1. Within 48 hours of birth,</li> <li>2. 48 hours after the 1st dose, <i>and</i></li> <li>3. 96 hours after the 2nd dose</li> </ol> </li> </ul> <p><u>Birth Weight 1.5 to 2 kg:</u></p> <ul style="list-style-type: none"> <li>• NVP 8 mg per dose orally.</li> </ul> <p><b>Note:</b> No calculation is required for this dose; <b>this is the actual dose, not a mg/kg dose.</b></p> <p><u>Birth Weight &gt;2 kg:</u></p> <ul style="list-style-type: none"> <li>• NVP 12 mg per dose orally.</li> </ul> <p><b>Note:</b> No calculation is required for this dose; <b>this is the actual dose, not a mg/kg dose.</b></p>	<p><u>≥37 Weeks Gestation at Birth</u></p> <p><i>Birth to Age 4 Weeks:</i></p> <ul style="list-style-type: none"> <li>• NVP 6 mg/kg/dose orally twice daily<sup>b</sup></li> </ul> <p><i>Age &gt;4 Weeks:</i></p> <ul style="list-style-type: none"> <li>• NVP 200 mg/m<sup>2</sup> of BSA/dose orally twice daily</li> </ul> <p><u>34 to &lt;37 Weeks Gestation at Birth</u></p> <p><i>Birth to Age 1 Week:</i></p> <ul style="list-style-type: none"> <li>• NVP 4 mg/kg/dose orally twice daily</li> </ul> <p><i>Age 1 to 4 Weeks:</i></p> <ul style="list-style-type: none"> <li>• NVP 6 mg/kg/dose orally twice daily</li> </ul> <p><i>Age &gt;4 Weeks:</i></p> <ul style="list-style-type: none"> <li>• NVP 200 mg/m<sup>2</sup> of BSA/dose orally twice daily</li> </ul> <p><b>Note:</b> NVP dose adjustment at 4 weeks of age is optional for empiric HIV therapy.</p>																								
<b>RAL</b>	N/A	N/A	<p><u>≥37 Weeks Gestation at Birth and Weighing ≥2 kg<sup>c</sup></u></p> <p><i>Birth to Age 6 Weeks:</i></p> <table border="1"> <thead> <tr> <th>Body Weight (kg)</th> <th>Volume (Dose) of Suspension, RAL 10 mg/mL, to be Administered</th> </tr> </thead> <tbody> <tr> <td colspan="2"><b>Birth to 1 Week: Once Daily Dosing</b></td> </tr> <tr> <td>2 to &lt;3 kg</td> <td>0.4 mL (4 mg) once daily</td> </tr> <tr> <td>3 to &lt;4 kg</td> <td>0.5 mL (5 mg) once daily</td> </tr> <tr> <td>4 to &lt;5 kg</td> <td>0.7 mL (7 mg) once daily</td> </tr> <tr> <td colspan="2"><b>1 to 4 Weeks: Twice Daily Dosing</b></td> </tr> <tr> <td>2 to &lt;3 kg</td> <td>0.8 mL (8 mg) twice daily</td> </tr> <tr> <td>3 to &lt;4 kg</td> <td>1 mL (10 mg) twice daily</td> </tr> <tr> <td>4 to &lt;5 kg</td> <td>1.5 mL (15 mg) twice daily</td> </tr> <tr> <td colspan="2"><b>4 to 6 Weeks: Twice Daily Dosing</b></td> </tr> <tr> <td>3 to &lt;4 kg</td> <td>2.5 mL (25 mg) twice daily</td> </tr> <tr> <td>4 to &lt;6 kg</td> <td>3 mL (30 mg) twice daily</td> </tr> </tbody> </table> <p><b>Note:</b> If the mother has taken RAL 2–24 hours prior to delivery, the neonate's first dose of RAL should be delayed until 24–48 hours after birth; additional ARVs should be started as soon as possible.</p>	Body Weight (kg)	Volume (Dose) of Suspension, RAL 10 mg/mL, to be Administered	<b>Birth to 1 Week: Once Daily Dosing</b>		2 to <3 kg	0.4 mL (4 mg) once daily	3 to <4 kg	0.5 mL (5 mg) once daily	4 to <5 kg	0.7 mL (7 mg) once daily	<b>1 to 4 Weeks: Twice Daily Dosing</b>		2 to <3 kg	0.8 mL (8 mg) twice daily	3 to <4 kg	1 mL (10 mg) twice daily	4 to <5 kg	1.5 mL (15 mg) twice daily	<b>4 to 6 Weeks: Twice Daily Dosing</b>		3 to <4 kg	2.5 mL (25 mg) twice daily	4 to <6 kg	3 mL (30 mg) twice daily
Body Weight (kg)	Volume (Dose) of Suspension, RAL 10 mg/mL, to be Administered																										
<b>Birth to 1 Week: Once Daily Dosing</b>																											
2 to <3 kg	0.4 mL (4 mg) once daily																										
3 to <4 kg	0.5 mL (5 mg) once daily																										
4 to <5 kg	0.7 mL (7 mg) once daily																										
<b>1 to 4 Weeks: Twice Daily Dosing</b>																											
2 to <3 kg	0.8 mL (8 mg) twice daily																										
3 to <4 kg	1 mL (10 mg) twice daily																										
4 to <5 kg	1.5 mL (15 mg) twice daily																										
<b>4 to 6 Weeks: Twice Daily Dosing</b>																											
3 to <4 kg	2.5 mL (25 mg) twice daily																										
4 to <6 kg	3 mL (30 mg) twice daily																										

<sup>a</sup> The optimal duration of empiric HIV therapy in newborns at higher risk of perinatal HIV transmission is unknown. Some Panel members opt to discontinue NVP, RAL, and/or 3TC when birth NAT returns negative, while others would continue empiric HIV therapy for infants at the highest risk of HIV acquisition for 6 weeks. In all cases in which the newborn is at higher risk of HIV acquisition, ZDV should be continued for 6 weeks. Consultation with an expert in pediatric HIV to select a therapy duration based on case-specific risk factors and interim HIV NAT results is recommended.

<sup>b</sup> Investigational NVP treatment dose recommended by the Panel; FDA has not approved a dose of NVP for infants <1 month of age.

<sup>c</sup> RAL dosing is increased at 1 and 4 weeks of age because metabolism by UGT1A1 is low at birth and increases rapidly during the next 4 to 6 weeks of life. No dosing information is available for preterm or low birthweight infants.

**Key to Acronyms:** 3TC = lamivudine; ARV = antiretroviral; BSA = body surface area; FDA = Food and Drug Administration; IV = intravenous; N/A = no recommendation; NAT = nucleic acid test; NVP = nevirapine; the Panel = the Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission; RAL = raltegravir; UGT1A1 = uridine diphosphate glucotransferase; ZDV = zidovudine

**Table 13. Evidence-Based Approaches for Monitoring Medication Adherence**

<b>Routine Assessment of Medication Adherence in Clinical Care<sup>a</sup></b>	<b>Description</b>
Monitor viral load.	Viral load monitoring should be done more frequently after initiating or changing medications. <sup>a</sup>
Assess quantitative self-report of missed doses.	Ask patient and/or caregiver about the number of missed doses over defined period (1, 3, or 7 days).
Elicit description of medication regimen.	Ask patient and/or caregiver about the name/appearance, number, frequency of medications.
Assess barriers to medication administration.	Engage the patient and caregiver in dialogue around facilitators and challenges to adherence.
Monitor pharmacy refills.	Approaches include pharmacy-based or clinic-based assessment of on-time medication refills.
Conduct announced and unannounced pill counts.	Approaches include asking patients to bring medications to clinic or home visits, or referral to community health nursing.
<b>Targeted Approaches to Monitor Adherence in Special Circumstances</b>	<b>Description</b>
Implement DOT.	Include brief hospitalization if indicated.
Measure plasma drug concentration.	Can be considered for particular drugs. <sup>b</sup>
<b>Approaches to Monitor Medication Adherence in Research Settings</b>	<b>Description</b>
Measure drug concentrations in hair.	Good measure of adherence over time. <sup>c</sup>
Use electronic monitoring devices.	MEMS caps, Wisepill
Use mobile phone-based technologies.	Interactive voice response, SMS text messaging, <b>mobile apps</b>

<sup>a</sup> See [Clinical and Laboratory Monitoring After Initiation of Combination Antiretroviral Therapy \(or After a Change in Combination Antiretroviral Therapy\)](#) regarding the frequency of adherence assessment after initiating or changing therapy.

<sup>b</sup> See [Role of Therapeutic Drug Monitoring in Management of Pediatric HIV Infection](#) regarding indications for therapeutic drug monitoring.

<sup>c</sup> Sources:

Olds PK, Kiwanuka JP, Nansera D, et al. Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda. *AIDS Care*. 2015;27(3):327-332. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25483955>.<sup>48</sup>

Chawana TD, Gandhi M, Nathoo K, et al. defining a cutoff for atazanavir in hair samples associated with virological failure among adolescents failing second-line antiretroviral treatment. *J Acquir Immune Defic Syndr*. 2017;76(1):55-59. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28520618>.<sup>49</sup>

Pintye J, Bacchetti P, Teeraananchai S, et al. brief report: lopinavir hair concentrations are the strongest predictor of viremia in HIV-infected Asian children and Adolescents on second-line antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2017. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28825944>.<sup>18</sup>

**Key to Acronyms:** apps = applications; DOT = directly observed therapy; MEMS = Medication Event Monitoring System

**Table 14. Strategies to Improve Adherence to Antiretroviral Medications**

<b>Initial Intervention Strategies</b>
• Establish trust and identify mutually acceptable goals for care.
• Obtain explicit agreement on the need for treatment and adherence.
• Identify depression, low self-esteem, substance abuse, or other mental health issues in the child/adolescent and/or caregiver that may decrease adherence. Evaluate and initiate treatment for mental health issues before starting ARV drugs, if possible.
• Identify family, friends, health team members, and others who can support adherence.
• Educate patient and family about the critical role of adherence in therapy outcome, including the relationship between partial adherence and resistance and potential impact on future drug regimen choices. Develop a treatment plan that the patient and family understand and to which they feel committed.
• Work with the patient and family to make specific plans for taking medications as prescribed and supporting adherence. Assist them to arrange for administration in day care, school, and other settings, when needed. Consider home delivery of medications.
• Establish readiness to take medication through practice sessions or other means.
• Schedule a home visit to review medications and determine how they will be administered in the home setting.
• In certain circumstances, consider a brief period of hospitalization at the start of therapy for patient education and to assess tolerability of medications chosen.
<b>Medication Strategies</b>
• Choose the simplest regimen possible, reducing dosing frequency, pill size, and number of pills.
• When choosing a regimen, consider the daily and weekly routines and variations in patient and family activities.
• Choose the most palatable medicine possible (pharmacists may be able to add syrups or flavoring agents to increase palatability).
• Choose drugs with the fewest AEs; provide anticipatory guidance for management of AEs.
• Simplify food requirements for medication administration.
• Prescribe drugs carefully to avoid adverse drug-drug interactions.
• Assess pill-swallowing capacity and offer pill-swallowing training and aids (e.g., pill-swallowing cup, pill glide). Adjust pill size as needed.
<b>Follow-up Intervention Strategies</b>
• Have more than one member of the multidisciplinary team monitor adherence at each visit and in between visits by telephone, email, text, and social media, as needed.
• Provide ongoing support, encouragement, and understanding of the difficulties associated with maintaining adherence to daily medication regimens.
• Use patient education aids including pictures, calendars, and stickers.
• Encourage use of pill boxes, reminders, mobile apps, alarms, and timers.
• Provide follow-up clinic visits, telephone calls, and text messages to support and assess adherence.
• Provide access to support groups, peer groups, or one-on-one counseling for caregivers and patients, especially for those with known depression or drug use issues that are known to decrease adherence.
• Provide pharmacist-based adherence support, such as medication education and counseling, blister packs, refill reminders, automatic refills, and home delivery of medications.
• Consider DOT at home, in the clinic, or in certain circumstances, such as during a brief inpatient hospitalization.
• Consider gastrostomy tube use in certain circumstances.
• Information on other interventions to consider can be found at the <a href="#">Complete Listing of Medication Adherence Evidence-Based Behavioral Interventions</a> .
• Consult the <a href="#">CDC Every Dose Every Day toolkit</a>

**Key to Acronyms:** apps = applications; ARV = antiretroviral; AE = adverse effect; DOT = directly observed therapy

**Table 15a. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity** (Last updated May 22, 2018; last reviewed May 22, 2018) (page 1 of 3)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Global CNS Depression</b>	LPV/r oral solution (contains both ethanol and propylene glycol as excipients)	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• 1–6 days after starting LPV/r</li> </ul> <p><u>Presentation</u></p> <p><i>Neonates/Premature Infants:</i></p> <ul style="list-style-type: none"> <li>• Global CNS depression (e.g., abnormal EEG, altered state of consciousness, somnolence)</li> </ul>	Unknown, rare case reports	<p>Prematurity</p> <p>Low birth weight</p> <p>Aged &lt;14 days (whether premature or term)</p>	Avoid use of LPV/r until a postmenstrual age of 42 weeks and a postnatal age ≥14 days.	<p>Discontinue LPV/r; symptoms should resolve in 1–5 days.</p> <p>If needed, reintroduction of LPV/r can be considered once outside the vulnerable period (i.e., postmenstrual age of 42 weeks and a postnatal age ≥14 days).</p>
<b>Neuropsychiatric Symptoms and Other CNS Manifestations</b>	EFV	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• For many symptoms, onset is 1–2 days after starting EFV</li> <li>• Many symptoms subside or diminish by 2–4 weeks, but may persist in a significant proportion of patients. In one report, 37% of participants experienced persistent symptoms at 12 months and in another report, half of discontinuations occurred after 12 months.</li> </ul> <p><u>Presentation (May Include 1 or More of the Following)</u></p> <p><i>Neuropsychiatric Symptoms:</i></p> <ul style="list-style-type: none"> <li>• Abnormal dreams</li> <li>• Psychosis</li> <li>• Suicidal ideation or attempted/completed suicide</li> </ul> <p><i>Other CNS Manifestations:</i></p> <ul style="list-style-type: none"> <li>• Dizziness</li> <li>• Somnolence</li> <li>• Insomnia or poor sleep quality</li> <li>• Impaired concentration</li> <li>• Seizures (including absence seizures)</li> </ul>	<p>Variable, depending on age, symptom, and assessment method</p> <p><u>Children:</u></p> <ul style="list-style-type: none"> <li>• 24% for any EFV-related CNS manifestations in 1 case series, with 18% of participants requiring drug discontinuation.</li> <li>• <b>11% (5/45 participants)</b> incidence of new-onset seizures reported in 1 study in children aged &lt;36 months, 2 of whom had alternative causes <b>for seizures.</b></li> <li>• Cases of cerebellar dysfunction have been reported in children in association with very high EFV plasma levels.</li> </ul> <p><u>Adults:</u></p> <ul style="list-style-type: none"> <li>• 30% incidence for any CNS manifestations of any severity.</li> <li>• 6% incidence for EFV-related severe CNS manifestations, including suicidality. However, evidence is conflicting about whether EFV use increases the incidence of suicidality.</li> </ul>	<p>Insomnia associated with elevated EFV trough concentration ≥4 mcg/mL</p> <p>Presence of CYP450 polymorphisms that decrease EFV metabolism and cause increased EFV serum concentrations (CYP2B6 516 TT genotype or co-carriage of CYP2B6 516 G/T and 983 T/C variants)</p> <p>Prior history of psychiatric illness or use of psychoactive drugs</p>	<p>Administer EFV on an empty stomach, preferably at bedtime.</p> <p>Prescreen for and avoid use in the presence of psychiatric illness, including depression or suicidal thoughts. Avoid concomitant use of psychoactive drugs.</p> <p>TDM can be considered in the context of a child with mild or moderate <b>EFV-associated toxicity.</b></p>	<p>If symptoms are excessive or persistent, obtain EFV trough concentration. If EFV trough concentration &gt;4 mcg/mL <b>and/or symptoms are severe,</b> strongly consider drug substitution if suitable alternative exists.</p> <p>Alternatively, consider dose reduction with repeat TDM and dose adjustment (with expert pharmacologist input).</p>

**Table 15a. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity (Last updated May 22, 2018; last reviewed May 22, 2018) (page 2 of 3)**

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
Neuropsychiatric Symptoms and Other CNS Manifestations, continued	EFV, continued	<ul style="list-style-type: none"> <li>Cerebellar dysfunction (tremor, dysmetria, ataxia)</li> </ul> <p><b>Note:</b> CNS side effects such as impaired concentration, abnormal dreams, or sleep disturbances may be more difficult to assess in children.</p>	<ul style="list-style-type: none"> <li>1 case series reported 20 women with ataxia which resolved upon EFV discontinuation, but frequency was not reported.</li> </ul>			
	RPV	<p><b>Onset:</b></p> <ul style="list-style-type: none"> <li>Most symptoms occur in the first 4–8 weeks of treatment</li> </ul> <p><u>Presentation</u></p> <p><i>Neuropsychiatric Symptoms:</i></p> <ul style="list-style-type: none"> <li>Depressive disorders</li> <li>Suicidal ideation</li> <li>Abnormal dreams/nightmares</li> </ul> <p><i>Other CNS Manifestations:</i></p> <ul style="list-style-type: none"> <li>Headache</li> <li>Dizziness</li> <li>Insomnia</li> <li>Somnolence</li> </ul>	<p><u>Adults:</u></p> <ul style="list-style-type: none"> <li>CNS/neuro-psychiatric adverse events of all severity grades were reported in 43% of patients at 96 weeks (mostly Grade 1). Depressive disorders of all severity grades were reported in 9% of patients, and were severe, requiring RPV discontinuation in 1% of patients.</li> </ul> <p><u>Children:</u></p> <ul style="list-style-type: none"> <li>Depressive disorders of all severity grades were reported in 19.4% of pediatric patients aged 12–17 years. Severe depressive disorders were reported in 5.6% of patients, including 1 suicide attempt.</li> <li>Somnolence reported in 14% (5/36) of children.</li> </ul>	Prior history of neuropsychiatric illness	Monitor carefully for depressive disorders and other CNS symptoms.	Consider drug substitution in cases of severe symptoms.
	RAL	<p><b>Onset:</b></p> <ul style="list-style-type: none"> <li>As early as 3–4 days after starting RAL</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>Increased psychomotor activity</li> <li>Headaches</li> <li>Insomnia</li> <li>Depression</li> <li>Cerebellar dysfunction (e.g., tremor, dysarthria, ataxia)</li> </ul>	<p><u>Children:</u></p> <ul style="list-style-type: none"> <li>Increased psychomotor activity reported in 1 child.</li> </ul> <p><u>Adults:</u></p> <ul style="list-style-type: none"> <li>Headache</li> <li>Insomnia (&lt;5% in adult trials)</li> <li>Rare case reports of cerebellar dysfunction in adults</li> </ul>	<p>Elevated RAL concentrations</p> <p>Co-treatment with TDF or PPI or inhibitors of UGT1A1</p> <p>Prior history of insomnia or depression</p>	<p>Prescreen for psychiatric symptoms.</p> <p>Monitor carefully for CNS symptoms.</p> <p>Use with caution in the presence of drugs that increase RAL concentration.</p>	Consider drug substitution (RAL or co-administered drug) in cases of severe insomnia or other neuropsychiatric symptoms.

**Table 15a. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity** (Last updated May 22, 2018; last reviewed May 22, 2018) (page 3 of 3)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Neuropsychiatric Symptoms and Other CNS Manifestations, continued</b>	DTG	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• 7–30 days after starting DTG</li> </ul> <p><u>Presentation</u></p> <p><i>Neuropsychiatric Symptoms:</i></p> <ul style="list-style-type: none"> <li>• Depression or exacerbation of preexisting depression</li> <li>• Anxiety</li> <li>• Suicidal ideation or attempted/completed suicide</li> </ul> <p><i>Other CNS Manifestations (Generally Mild):</i></p> <ul style="list-style-type: none"> <li>• Insomnia</li> <li>• Dizziness</li> <li>• Headache</li> </ul>	<p><u>Children:</u></p> <ul style="list-style-type: none"> <li>• CNS symptoms were uncommonly reported in early clinical experience in children and adolescents.</li> </ul> <p><u>Adults:</u></p> <ul style="list-style-type: none"> <li>• Exact frequency of neuropsychiatric symptoms is unknown; case reports of 4 adult patients. Headache, insomnia, and dizziness are common and usually mild. More severe symptoms that require drug discontinuation are less common, occurring in &lt;1% patients in Phase 3 trials, but these severe symptoms are reported with increasing frequency (4% to 10%) in recent post-marketing reports.</li> </ul>	<p>Pre-existing depression or other psychiatric illness</p> <p>Higher frequency of neuropsychiatric symptoms reported when co-administered with ABC</p>	Use with caution in the presence of psychiatric illness, especially depression.	<p>For severe neuropsychiatric symptoms, consider discontinuation of DTG if suitable alternative exists.</p> <p>Discontinuation resulted in resolution of neuropsychiatric symptoms in 3 out of 4 patients (in the fourth patient, symptoms resolved slowly despite DTG continuation).</p> <p>For mild symptoms, continue DTG and counsel patient that symptoms will likely resolve with time.</p>
<b>Intracranial Hemorrhage (ICH)</b>	TPV	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• 7–513 days after starting TPV</li> </ul>	<p><u>Children:</u></p> <ul style="list-style-type: none"> <li>• No cases of ICH reported in children.</li> </ul> <p><u>Adults:</u></p> <ul style="list-style-type: none"> <li>• In premarket approval data in adults, 0.23/100 py or 0.04–0.22/100 py in a retrospective review of 2 large patient databases.</li> </ul>	Unknown; prior history of bleeding disorder or risk factors for bleeding reported for most patients in case series.	Administer TPV with caution in patients with bleeding disorder, known intracranial lesions, or recent neurosurgery.	Discontinue TPV if ICH is suspected or confirmed.

**Key to Acronyms:** ABC = abacavir; ARV = antiretroviral; CNS = central nervous system; CYP = cytochrome P; DTG = dolutegravir; EEG = electroencephalogram; EFV = efavirenz; ICH = intracranial hemorrhage; LPV/r = lopinavir/ritonavir; PPI = proton pump inhibitor; py = patient years; RAL = raltegravir; RPV = rilpivirine; TDF = tenofovir disoproxil fumarate; TDM = therapeutic drug monitoring; TPV = tipranavir; UGT = uridine diphosphate-glucurononyl transferase

## References

1. Food and Drug Association. FDA Drug Safety Communication: Serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. 2011. Available at <http://www.fda.gov/Drugs/DrugSafety/ucm246002.htm>.
2. Haas DW, Ribaud HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. *AIDS*. 2004;18(18):2391-2400. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15622315>.
3. Waters L, Fisher M, Winston A, et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. *AIDS*. 2011;25(1):65-71. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21099666>.
4. Puthanakit T, Tanpaiboon P, Aupibul L, Cressey TR, Sirisanthana V. Plasma efavirenz concentrations and the association with CYP2B6-516G>T polymorphism in HIV-infected Thai children. *Antivir Ther*. 2009;14(3):315-320. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19474465>.
5. Cabrera Figueroa S, Fernandez de Gatta M, Hernandez Garcia L, et al. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. *Ther Drug Monit*. 2010;32(5):579-585. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20720517>.
6. Teppler H, Brown DD, Leavitt RY, et al. Long-term safety from the raltegravir clinical development program. *Current HIV research*. 2011;9(1):40-53. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21198432>.
7. Reiss KA, Bailey JR, Pham PA, Gallant JE. Raltegravir-induced cerebellar ataxia. *AIDS*. 2010;24(17):2757. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20980871>.
8. Strehlau R, Martens L, Coovadia A, et al. Absence seizures associated with efavirenz initiation. *Pediatr Infect Dis J*. 2011;30(11):1001-1003. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21633320>.
9. Rakhmanina NY, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely MN. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? *Ther Drug Monit*. 2010;32(3):273-281. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20445485>.
10. Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. *Ther Drug Monit*. 2010;32(6):782-786. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20926993>.
11. Chan-Tack KM, Struble KA, Birnkrant DB. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System. *AIDS Patient Care STDS*. 2008;22(11):843-850. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19025478>.
12. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. *AIDS*. 2013;27(9):1403-1412. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23343913>.
13. van Dijk JH, Sutcliffe CG, Hamangaba F, Bositis C, Watson DC, Moss WJ. Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings. *PLoS One*. 2013;8(1):e55111. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23372824>.
14. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. *AIDS*. 2013;27(6):939-950. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23211772>.
15. Nachman S, et al. IMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48. Abstract no. TUAB0205. Presented at: 19th International AIDS Conference. 2012. Washington, DC.
16. Madeddu G, Menzaghi B, Ricci E, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. *AIDS*. 2012;26(18):2412-2415. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23032413>.
17. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted

- or completed suicide: an analysis of trial data. *Ann Intern Med*. 2014;161(1):1-10. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24979445>.
18. Mills AM, Antinori A, Clotet B, et al. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks. *HIV Med*. 2013;14(7):391-400. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23298380>.
  19. Napoli AA, Wood JJ, Coumbis JJ, Soitkar AM, Seekins DW, Tilson HH. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. *J Int AIDS Soc*. 2014;17:19214. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25192857>.
  20. Leutscher PD, Stecher C, Storgaard M, Larsen CS. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. *Scand J Infect Dis*. 2013;45(8):645-651. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23427878>.
  21. Group ES, Puls R, Amin J, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naïve adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. *Lancet*. 2014;383(9927):1474-1482. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24522178>.
  22. Smith C, Ryom L, Monforte A, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. *J Int AIDS Soc*. 2014;17(4 Suppl 3):19512. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25394021>.
  23. Ford N, Shubber Z, Pozniak A, et al. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. *J Acquir Immune Defic Syndr*. 2015;69(4):422-429. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25850607>.
  24. Mills A, Garner W, Pozniak A, et al. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF. *Patient*. 2015;8(4):359-371. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26045359>.
  25. García-Navarro C, Jiménez de Ory S, Navarro Gómez ML, et al. Sleep disturbances in a cohort of hiv-infected children and adolescents on antiretroviral treatment. Presented at: 22nd Conference on Retroviruses and Opportunistic Infections. 2015. Seattle, WA.
  26. Kheloufi F, Allemand J, Mokhtari S, Default A. Psychiatric disorders after starting dolutegravir: report of four cases. *AIDS*. 2015;29(13):1723-1725.
  27. Rilpivirine [package insert]. Food and Drug Administration. 2015. Available at [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/202022s0081bledt.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202022s0081bledt.pdf).
  28. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naïve patients: week 96 and week 144 results from the SINGLE randomized clinical trial. *J Acquir Immune Defic Syndr*. 2015. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26262777>.
  29. Lombaard J, Bunupuradah T. Week 48 safety and efficacy of a rilpivirine (TMC278)-based regimen in HIV-infected treatment-naïve adolescents: PAINT phase II trial. Presented at: 7th International Workshop on HIV Pediatrics. 2015. Vancouver, Canada.
  30. Nkhoma ET, Coumbis J, Farr AM, et al. No evidence of an association between efavirenz exposure and suicidality among HIV patients initiating antiretroviral therapy in a retrospective cohort study of real world data. *Medicine (Baltimore)*. 2016;95(3):e2480. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26817882>.
  31. Pinillos F, Dandara C, Swart M, et al. Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. *BMC Infect Dis*. 2016;16:56. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26831894>.
  32. Mollan KR, Tierney C, Eron JJ, et al. Composite CYP2B6/CYP2A6 genotype and risk for suicidality among HIV-infected individuals randomly assigned to initiate efavirenz-containing regimens in AIDS Clinical Trials Group studies. Presented at: 21st International AIDS Conference. 2016. Durban, South Africa.
  33. Arenas-Pinto A, Grund B, Sharma S, et al. Increased risk of suicidal behaviour with use of efavirenz: results from the START trial. Presented at: 21st International AIDS Conference. 2016. Durban, South Africa.
  34. Hauptfleisch MP, Moore DP, Rodda JL. Efavirenz as a cause of ataxia in children. *S Afr Med J*. 2015;105(11):897-898. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26632310>.

35. Bracchi M, Pagani N, et al. Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity. Abstract # P209. Presented at: HIV Drug Therapy Conference. 2016. Glasgow, Scotland, UK.
36. Quercia R, Roberts J. Psychiatric adverse events from the DTG ART-naive phase 3 clinical trials. Abstract # P210. Presented at: HIV Drug Therapy Conference. 2016. Glasgow, Scotland, UK.
37. Fernandez C, Michie K, et al. Adverse events and discontinuation of dolutegravir-based therapy in naive and experienced HIV patients: tertiary HIV centre experience. Abstract # P212. HIV Drug Therapy Conference. 2016. Glasgow, Scotland, UK.
38. de Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. *AIDS*. 2016;30(18):2831-2834. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27824625>.
39. Fettiplace A, Stainsby C, Winston A, et al. Psychiatric symptoms in patients receiving dolutegravir. *J Acquir Immune Defic Syndr*. 2017;74(4):423-431. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27984559>.
40. Viswanathan P, Baro E, Soon G, Sherwat A, Struble KA. Neuropsychiatric adverse events associated with integrase strand transfer inhibitors. Presented at: Conference on Retroviruses and Opportunistic Infections. 2017. Seattle, WA.
41. Todd S, Rafferty P, Walker E, et al. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital. *Int J STD AIDS*. 2017;956462416688127. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28118801>.
42. Variava E, Sigauke FR, Norman J, et al. Brief Report: late efavirenz-induced ataxia and encephalopathy: a case series. *J Acquir Immune Defic Syndr*. 2017;75(5):577-579. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28520619>.
43. Briand C, Dollfus C, Faye A, et al. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study. *J Antimicrob Chemother*. 2017;72(3):837-843. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27999017>.

**Table 15b. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Dyslipidemia**

(Last updated May 22, 2018; last reviewed May 22, 2018) (page 1 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Dyslipidemia</b>	<p><b>PIs:</b></p> <ul style="list-style-type: none"> <li>All PIs, especially RTV-boosted PIs; lower incidence reported with DRV/r and ATV with or without RTV.</li> </ul> <p><b>NRTIs:</b></p> <ul style="list-style-type: none"> <li>Especially d4T<sup>e</sup></li> <li>Lower incidence reported with TDF than TAF</li> </ul> <p><b>NNRTIs:</b></p> <ul style="list-style-type: none"> <li>Lower incidence reported with NVP, RVP, and ETR than EFV</li> </ul>	<p><b>Onset:</b></p> <ul style="list-style-type: none"> <li>As early as 2 weeks to months after beginning therapy</li> </ul> <p><b>Presentation</b></p> <p><b>PIs:</b></p> <ul style="list-style-type: none"> <li>↑LDL-C, TC, and TG</li> </ul> <p><b>NNRTIs:</b></p> <ul style="list-style-type: none"> <li>↑LDL-C, TC, and HDL-C</li> </ul> <p><b>NRTIs:</b></p> <ul style="list-style-type: none"> <li>↑LDL-C, TC, and TG</li> </ul>	<p>Reported frequency varies with specific ARV regimen, duration of ART, and specific laboratory parameters used to diagnose lipid abnormalities.</p> <p>10% to 20% in young children receiving LPV/r.</p> <p>40% to 75% of older children and adolescents with prolonged ART history will have lipid abnormalities.</p> <p>Higher abnormal fasting serum lipids in EVG/COBI/FTC/TAF vs. EVG/COBI/FTC/TDF regimen in studies of treatment-naïve adults.</p> <p>Increase in serum lipids from baseline also noted in adolescents receiving EVG/COBI/FTC/TAF.</p>	<p>Advanced-stage HIV disease</p> <p>High-fat, high-cholesterol diet</p> <p>Lack of exercise</p> <p>Obesity</p> <p>Hypertension</p> <p>Smoking</p> <p>Family history of dyslipidemia or premature CVD</p> <p>Metabolic syndrome</p> <p>Fat maldistribution</p>	<p><b>Prevention:</b></p> <ul style="list-style-type: none"> <li>Low-fat diet</li> <li>Exercise</li> <li>Smoking-prevention counseling</li> <li>Do not use d4T</li> </ul> <p><b>Monitoring<sup>a</sup></b></p> <p><b>Adolescents and Adults:</b></p> <ul style="list-style-type: none"> <li>Monitor 12-hour FLP, which includes TC, HDL-C, non-HDL-C, LDL-C, and TG, every 6–12 months. Obtain FLPs twice (&gt;2 weeks but ≤3 months apart, average results) before initiating or changing lipid-lowering therapy.</li> </ul> <p><b>Children (Aged ≥2 Years) without Lipid Abnormalities or Additional Risk Factors:</b></p> <ul style="list-style-type: none"> <li>Obtain nonfasting screening lipid profiles at entry into care and then, if levels are normal, every 6–12 months. If TG or LDL-C is elevated, obtain fasting blood tests.</li> </ul> <p><b>Children with Lipid Abnormalities and/or Additional Risk Factors:</b></p> <ul style="list-style-type: none"> <li>Obtain 12-hour FLP before initiating or changing therapy and every 6 months thereafter (more often if indicated).</li> </ul> <p><b>Children Receiving Lipid-Lowering Therapy with Statins or Fibrates:</b></p> <ul style="list-style-type: none"> <li>Obtain 12-hour FLP, LFTs, and CK at 4 and 8 weeks, and 3 months after starting lipid therapy.</li> </ul>	<p>Assessment of additional CVD risk factors should be done in all patients. Patients living with HIV are considered to be at moderate risk of CVD.<sup>b</sup></p> <p>Counsel on lifestyle modification and dietary interventions (e.g., a diet low in saturated fat, cholesterol, and refined sugars, particularly in cases of ↑TG, elimination of trans fat in the diet, increase in physical activity, smoking cessation) for an adequate trial period (3–6 months). Consider consultation with dietician.</p> <p>ART regimen changes can be considered. Discontinue d4T or substitute a PI-sparing regimen or PI-based regimen with a more favorable lipid profile.</p> <p>Consider lipid-lowering therapy in consultation with a lipid specialist if ≥6-month trial of lifestyle modification fails.</p> <p>Some experts suggest treating children receiving ARV drugs according to NHLBI cardiovascular risk reduction guidelines for children aged ≥10 years: LDL-C ≥190 mg/dL, regardless of additional risk factors; LDL-C ≥160 mg/dL or LDL-C ≥130 mg/dL based on presence of additional risk factors and risk conditions.<sup>b</sup></p> <p>The minimal goal of therapy should be to achieve and maintain a LDL-C value below 130 mg/dL, while minimizing side effects and maintaining viral control.</p>

**Table 15b. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Dyslipidemia**  
 (Last updated May 22, 2018; last reviewed May 22, 2018) (page 2 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
Dyslipidemia					<ul style="list-style-type: none"> <li>If minimal alterations in AST, ALT, and CK, monitor every 3–4 months in the first year and every 6 months thereafter (or as clinically indicated).</li> <li>Repeat FLPs 4 weeks after increasing doses of antihyperlipidemic agents.</li> </ul>	<p>Statins such as pravastatin, atorvastatin, or rosuvastatin<sup>c</sup> can be considered.<sup>d</sup> <b>Pravastatin has lower lipid-lowering potency compared to other statins.</b> Statin-induced lipid lowering effect appears more pronounced than ARV substitution. Statin-related toxicities include liver enzyme elevation and myopathy, and risk may be increased by drug interactions with ART, particularly PIs.<sup>e</sup> Statins may also increase the risk of insulin resistance and <b>type 2 diabetes mellitus, but data are conflicting.</b> Risks must be weighed against potential benefits. Cholesterol absorption inhibitors (e.g., ezetimibe) can be considered as alternatives.</p> <p>Drug therapy for severe hypertriglyceridemia (TG ≥500 mg/dL) can be considered. Fibrates (gemfibrozil and fenofibrate) and N-3 PUFAs derived from fish oils may be used.</p> <p>The long-term risks of lipid abnormalities in children receiving ART are unclear. However, persistent dyslipidemia in children may lead to premature CVD.</p>

<sup>a</sup> Given the burden of collecting fasting blood samples, some practitioners routinely measure cholesterol and triglycerides from nonfasting blood samples and follow up abnormal values with a test done in the fasted state.

<sup>b</sup> Refer to NHLBI guidelines at [https://www.nhlbi.nih.gov/sites/default/files/media/docs/peds\\_guidelines\\_full.pdf](https://www.nhlbi.nih.gov/sites/default/files/media/docs/peds_guidelines_full.pdf).

<sup>c</sup> The risks of new treatment-related toxicities and virologic failure that could occur with changes in therapy must be weighed against the potential risk of drug interactions and toxicities associated with the use of lipid-lowering agents.

<sup>d</sup> Statins (HMG-CoA reductase inhibitors) are contraindicated in pregnancy (due to being potentially teratogenic) and should not be used in patients who may become pregnant. Multiple drug interactions exist between ARV drugs and statins (except for pravastatin, which is not dependent on CYP3A4 for metabolism). Pravastatin, atorvastatin, rosuvastatin (Crestor®), fluvastatin, and ezetimibe (Zetia®) are approved for use in children aged ≥10 years. For additional information, see the [PI](#), [NNRTI](#), [NRTI](#), and [INSTI](#) Drug Interactions Tables in the Adult and Adolescent Guidelines.

<sup>e</sup> **d4T is no longer recommended for use in an ARV regimen**

**Key to Acronyms:** ALT = alanine aminotransferase; ART = antiretroviral therapy; ARV = antiretroviral; AST = aspartate aminotransferase; ATV = atazanavir; CK = creatine kinase; COBI = cobicistat; CVD = cardiovascular disease; CYP3A4 = cytochrome P450 3A4; d4T = stavudine; DRV/r = darunavir/ritonavir; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir; FLP = fasting lipid profile; FTC = emtricitabine; HDL-C = high-density lipoprotein cholesterol; INSTI = integrase strand transfer inhibitor; LDL-C = low-density lipoprotein cholesterol; LFT = liver function test; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NHLBI = National Heart, Lung, and Blood Institute; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PUFA = polyunsaturated fatty acid; RPV = rilpivirine; RTV = ritonavir; TAF = tenofovir alafenamide; TC = total cholesterol; TDF = tenofovir disoproxil fumarate; TG = triglyceride

## References

1. Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. *Pediatrics*. 2007;119(2):370-380. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17272627>.
2. McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A, First Pediatric Switch Study. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. *Pediatrics*. 2003;111(3):e275-281. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12612284>.
3. Vigano A, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. *Antivir Ther*. 2005;10(8):917-924. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16430197>.
4. Tassiopoulos K, Williams PL, Seage GR 3rd, et al. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. *J Acquir Immune Defic Syndr*. 2008;47(5):607-614. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18209684>.
5. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. *AIDS*. 2009;23(6):661-672. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19279441>.
6. Rhoads MP, Lanigan J, Smith CJ, Lyall EG. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. *J Acquir Immune Defic Syndr*. 2011;57(5):404-412. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21499114>.
7. Jacobson DL, Williams P, Tassiopoulos K, Melvin A, Hazra R, Farley J. Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. *J Acquir Immune Defic Syndr*. 2011;57(5):413-420. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21602698>.
8. O’Gorman CS, O’Neill MB, Conwell LS. Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. *Vasc Health Risk Manag*. 2011;7:1-14. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21339908>.
9. Dube MP, Cadden JJ. Lipid metabolism in treated HIV infection. *Best Pract Res Clin Endocrinol Metab*. 2011;25(3):429-442. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21663837>.
10. Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. *Clin Infect Dis*. 2011;52(3):387-395. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21189273>.
11. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Integrated guidelines for cardiovascular health and risk reduction in children and adolescents. The report of the expert panel. 2011. Available at [http://www.nhlbi.nih.gov/guidelines/cvd\\_ped/summary.htm](http://www.nhlbi.nih.gov/guidelines/cvd_ped/summary.htm).
12. Food and Drug Administration. FDA drug safety communication: interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. 2012. Available at <http://www.fda.gov/Drugs/DrugSafety/ucm293877.htm>. Accessed February 6, 2018.
13. Langat A, Benki-Nugent S, Wamalwa D, et al. Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age. *Pediatr Infect Dis J*. 2013;32(7):e298-304. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23385950>.
14. Casado JL, de Los Santos I, Del Palacio M, et al. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART. *HIV Clin Trials*. 2013;14(1):1-9. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23372109>.
15. Calza L, Manfredi R, Colangeli V, et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. *AIDS Res Hum Retroviruses*. 2013;29(3):547-556. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23098891>.
16. Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial. *J Am Coll Cardiol*. 2012;59(11):979-988. Available at <http://www.ncbi.nlm.nih.gov/>

[pubmed/22402068](http://pubmed/22402068).

17. Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2012;60(4):369-376. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22134152>.
18. Hazra R, Cohen RA, Gonin R, et al. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children. *AIDS*. 2012;26(2):235-240. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22008654>.
19. Arpadi S, Shiao S, Strehlau R, et al. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. *Arch Dis Child*. 2013;98(4):258-264. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23220209>.
20. Calvo M, Martinez E. Update on metabolic issues in HIV patients. *Curr Opin HIV AIDS*. 2014;9(4):332-339. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24824886>.
21. Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. *J Int AIDS Soc*. 2013;16:18600. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23782481>.
22. Blazquez D, Ramos-Amador JT, Sainz T, et al. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. *BMC Infect Dis*. 2015;15:119. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25880777>.
23. Bwakura-Dangarembizi M, Musiime V, Szubert AJ, et al. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. *Pediatr Infect Dis J*. 2015;34(2):e23-31. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25068287>.
24. Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. *J Pediatr Endocrinol Metab*. 2014;27(5-6):403-412. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24259240>.
25. Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH. High prevalence of dyslipidemia and insulin resistance in HIV-infected pre-pubertal African children on antiretroviral therapy. *Pediatr Infect Dis J*. 2015. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26421804>.
26. Tauber WB, Lewis LL. Clinical review of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya). 2015. Available at <http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm478088.pdf>. Accessed February 6, 2018.
27. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. *Lancet*. 2015;385(9987):2606-2615. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25890673>.
28. Murnane P, Strehlau R, Shiao S, et al. Three-year outcomes in PMTCT-exposed children switched to EFV once suppressed on LPV/r. Presented at: 23rd Conference on Retroviruses and Opportunistic Infections. 2016. Boston, MA.
29. Lee FJ, Monteiro P, Baker D, et al. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial. *HIV Med*. 2016;17(8):605-614. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26987376>.
30. Lichtenstein KA, Hart RL, Wood KC, et al. Statin use is associated with incident diabetes mellitus among patients in the HIV outpatient study. *J Acquir Immune Defic Syndr*. 2015;69(3):306-311. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26181706>.
31. Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Rosuvastatin worsens insulin resistance in HIV-infected adults on antiretroviral therapy. *Clin Infect Dis*. 2015;61(10):1566-1572. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26157049>.
32. Spagnuolo V, Galli L, Poli A, et al. Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. *BMC Infect Dis*. 2017;17(1):43. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28061820>.
33. Calza L, Colangeli V, Magistrelli E, et al. No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination

- antiretroviral therapy. *HIV Med.* 2016;17(8):631-633. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27028348>.
34. Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. *Lancet HIV.* 2017;4(7):e284-e294. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28416195>.
35. Ramteke SM, Shiau S, Foca M, et al. Patterns of growth, body composition, and lipid profiles in a South African cohort of Human Immunodeficiency Virus-infected and uninfected children: a cross-sectional study. *J Pediatric Infect Dis Soc.* 2017. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28481997>.
36. Melvin AJ, Montepiedra G, Aaron L, et al. Safety and efficacy of atorvastatin in Human Immunodeficiency Virus-infected children, adolescents, and young adults with hyperlipidemia. *Pediatr Infect Dis J.* 2017;36(1):53-60. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27749649>.

**Table 15c. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects (Last updated May 22, 2018; last reviewed May 22, 2018) (page 1 of 2)**

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Nausea/Vomiting</b>	<p>All ARVs, but most notably—</p> <p><b>NRTIs:</b></p> <ul style="list-style-type: none"> <li>• ddI and ZDV at a higher rate than others</li> </ul> <p><b>PIs:</b></p> <ul style="list-style-type: none"> <li>• Especially with RTV boosting (e.g., LPV/r, DRV/r)</li> </ul>	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• Early</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Nausea, emesis—may be associated with anorexia and/or abdominal pain</li> </ul>	Varies with ARV agent; 10% to 30% in some series	Unknown	<p>Instruct patient to take PIs with food.</p> <p>Monitor for weight loss, ARV adherence.</p> <p><b>Do not use ddI, d4T, or NFV (individually or together) as part of an ARV regimen.<sup>a</sup></b></p>	<p>Reassure patient that these adverse effects generally improve over time (usually 6–8 weeks).</p> <p>Supportive care.</p> <p>In extreme or persistent cases, <b>use antiemetics or switch ARV regimen.</b></p>
<b>Diarrhea</b>	<p><b>PIs:</b></p> <ul style="list-style-type: none"> <li>• Particularly NFV, LPV/r, and DRV/r</li> </ul> <p><b>NRTIs:</b></p> <ul style="list-style-type: none"> <li>• ddI and d4T at a higher rate than 3TC or FTC</li> </ul>	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• Early</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Generally soft, more frequent stools</li> </ul>	Varies with ARV agent; <b>generally &lt;15% (range 5% to 30%)</b>	Unknown	<p>Monitor for weight loss, dehydration.</p> <p><b>Do not use ddI, d4T, or NFV (individually or together) as part of an ARV regimen.<sup>a</sup></b></p>	<p>If prolonged or severe, exclude infectious or noninfectious (e.g., lactose intolerance) causes of diarrhea.</p> <p>Reassure patient that this adverse effect generally improves over time (usually 6–8 weeks). <b>Consider switching ARV regimen in persistent and severe cases.</b></p> <p>Although treatment data in children are lacking, potentially useful modalities include:</p> <ul style="list-style-type: none"> <li>• Dietary modification</li> <li>• Bulk-forming agents (psyllium)</li> <li>• Antimotility agents (loperamide)</li> <li>• Crofelemer is FDA-approved for treatment of ART-associated diarrhea <b>only</b> in adults <b>≥18 years of age; no pediatric data available.</b></li> </ul>

**Table 15c. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects (Last updated May 22, 2018; last reviewed May 22, 2018) (page 2 of 2)**

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Pancreatitis</b>	<p><b>More Common:</b></p> <ul style="list-style-type: none"> <li>• ddl, d4T (especially if administered concurrently)</li> </ul> <p><b>Rare:</b></p> <ul style="list-style-type: none"> <li>• RTV-boosted PIs</li> <li>• Other ARVs</li> </ul>	<p><b>Onset:</b></p> <ul style="list-style-type: none"> <li>• Anytime, usually after months of therapy</li> </ul> <p><b>Presentation:</b></p> <ul style="list-style-type: none"> <li>• Emesis, abdominal pain, elevated amylase and lipase (asymptomatic hyperamylasemia or elevated lipase do not in and of themselves indicate pancreatitis)</li> </ul>	<2% in recent series	<p>Use of concomitant medications associated with pancreatitis (e.g., TMP-SMX, pentamidine, ribavirin)</p> <p>Hypertriglyceridemia</p> <p>Advanced disease</p> <p>Previous episode of pancreatitis</p> <p>Alcohol use</p>	<b>Do not use</b> ddl or d4T (individually or together) as part of an ARV regimen. <sup>a</sup>	<p>Discontinue offending agent—<b>avoid reintroduction</b>.</p> <p>Manage symptoms of acute episode.</p> <p>If associated with hypertriglyceridemia, consider interventions to lower TG levels.</p>

<sup>a</sup> ddl, d4T, and NFV are **no longer recommended**; these ARVs should not be used (individually or together) as part of an ARV regimen. Co-administration of ddl and d4T is **contraindicated (no exceptions)**.

**Key to Acronyms:** 3TC = lamivudine; ART = antiretroviral therapy; ARV = antiretroviral; d4T = stavudine; ddl = didanosine; DRV/r = darunavir/ritonavir; FDA = Food and Drug Administration; FTC = emtricitabine; LPV/r = lopinavir/ritonavir; NFV = nelfinavir; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RTV = ritonavir; TG = triglyceride; TMP-SMX = trimethoprim sulfamethoxazole; ZDV = zidovudine

## References

1. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. *J Int AIDS Soc*. 2010;13:31. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20691049>.
2. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. *Arch Pediatr Adolesc Med*. 2009;163(2):164-171. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19188649>.
3. Hoffmann CJ, Fielding KL, Charalambous S, et al. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. *AIDS*. 2008;22(1):67-74. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18090393>.
4. Malan N, Su J, Mancini M, et al. Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study. *AIDS Care*. 2010;22(6):677-686. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20467943>.
5. Manfredi R, Calza L. HIV infection and the pancreas: risk factors and potential management guidelines. *Int J STD AIDS*. 2008;19(2):99-105. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18334062>.

6. Tukei VJ, Asimwe A, Maganda A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. *J Acquir Immune Defic Syndr*. 2012;59(3):274-280. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22126740>.
7. Wegzyn CM, Fredrick LM, Stubbs RO, Woodward WC, Norton M. Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants. *J Int Assoc Physicians AIDS Care (Chic)*. 2012;11(4):252-259. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22544446>.
8. Oumar AA, Diallo K, Dembele JP, et al. Adverse drug reactions to antiretroviral therapy: prospective study in children in sikasso (mali). *J Pediatr Pharmacol Ther*. 2012;17(4):382-388. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23411444>.
9. Wattanuchariya N, Sirisanthana V, Oberdorfer P. Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment. *HIV Med*. 2013;14(4):226-232. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23094820>.
10. Van Dyke RB, Wang L, Williams PL, Pediatric ACTGCT. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. *J Infect Dis*. 2008;198(11):1599-1608. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19000014>.
11. Clay PG, Crutchley RD. Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy. *Infect Dis Ther*. 2014. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25388760>.
12. Szoke D, Ridolfo A, Valente C, Galli M, Panteghini M. Frequency of pancreatic hyperamylasemia in Human Immunodeficiency Virus-positive patients in the highly active antiretroviral therapy era. *Am J Clin Pathol*. 2016;145(1):128-133. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26712880>.
13. Castro JG, Chin-Beckford N. Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. *Expert Rev Clin Pharmacol*. 2015;8(6):683-690. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26517110>.
14. Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human Immunodeficiency Virus-associated diarrhea: still an issue in the era of antiretroviral therapy. *Digestive Diseases and Sciences*. 2015;60(8):2236-2245. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25772777>.

**Table 15d. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects** (Last updated May 22, 2018; last reviewed May 22, 2018) (page 1 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Anemia<sup>a</sup></b>	ZDV	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• Variable, weeks to months</li> </ul> <p><u>Presentation</u></p> <p><i>Most Commonly:</i></p> <ul style="list-style-type: none"> <li>• Asymptomatic or mild fatigue</li> <li>• Pallor</li> <li>• Tachypnea</li> </ul> <p><i>Rarely:</i></p> <ul style="list-style-type: none"> <li>• Congestive heart failure</li> </ul>	<p><u>Newborns Exposed to HIV:</u></p> <ul style="list-style-type: none"> <li>• Severe anemia is uncommon, but may be seen coincident with physiologic Hgb nadir.</li> </ul> <p><u>Children with HIV Taking ARVs:</u></p> <ul style="list-style-type: none"> <li>• 2–3 times more common with ZDV-containing regimens</li> </ul>	<p><u>Newborns Exposed to HIV:</u></p> <ul style="list-style-type: none"> <li>• Premature birth</li> <li>• <i>In utero</i> exposure to <b>ZDV-containing regimens</b></li> <li>• Advanced maternal HIV</li> <li>• Neonatal blood loss</li> <li>• Combination ARV prophylaxis, particularly with ZDV plus 3TC</li> </ul> <p><u>Children with HIV Taking ARVs:</u></p> <ul style="list-style-type: none"> <li>• Underlying hemoglobinopathy (e.g., sickle cell disease, G6PD deficiency)</li> <li>• Myelosuppressive drugs (e.g., TMP-SMX, rifabutin)</li> <li>• Iron deficiency</li> <li>• Advanced or poorly controlled HIV disease</li> <li>• Malnutrition</li> </ul>	<p><u>Newborns Exposed to HIV:</u></p> <ul style="list-style-type: none"> <li>• Obtain CBC at birth.</li> <li>• Consider repeat CBC at 4 weeks for neonates who are at higher risk (e.g., those born prematurely or known to have low birth Hgb) and if ZDV is continued beyond 4 weeks.</li> </ul> <p><u>Children with HIV Taking ARVs:</u></p> <ul style="list-style-type: none"> <li>• Avoid ZDV in children with severe anemia when alternative agents are available.</li> <li>• Obtain CBC as part of routine care (see <b>Clinical and Laboratory Monitoring</b>)</li> </ul>	<p><u>Newborns Exposed to HIV:</u></p> <ul style="list-style-type: none"> <li>• Anemia rarely requires intervention unless Hgb is &lt;7.0 g/dL or it is associated with symptoms.</li> <li>• <b>ZDV administration can be limited to 4 weeks in low-risk neonates (see <a href="#">Antiretroviral Management of Newborns with Perinatal HIV Exposure or Perinatal HIV</a>).</b></li> </ul> <p><u>Children with HIV Taking ARVs:</u></p> <ul style="list-style-type: none"> <li>• Discontinue non-ARV, marrow-toxic drugs, if feasible.</li> <li>• Treat coexisting iron deficiency, OIs, and malignancies.</li> <li>• For persistent severe anemia thought to be associated with ARVs (<b>typically macrocytic anemia</b>), switch to a regimen that does not contain ZDV.</li> </ul>
<b>Macrocytosis</b>	ZDV	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• Within days to weeks of starting therapy</li> <li>• MCV often &gt;100 fL</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Asymptomatic</li> <li>• Sometimes associated with anemia</li> </ul>	>90% to 95%, all ages	None	<p><b>None required—detected if CBC obtained</b> as part of routine care (see <a href="#">Clinical and Laboratory Monitoring section</a>).</p>	None required

**Table 15d. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects** (Last updated May 22, 2018; last reviewed May 22, 2018) (page 2 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
Neutropenia <sup>a</sup>	ZDV	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• Variable</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Asymptomatic</li> </ul>	<p><u>Newborns Exposed to HIV:</u></p> <ul style="list-style-type: none"> <li>• Rare</li> </ul> <p><u>Children with HIV Taking ARVs:</u></p> <ul style="list-style-type: none"> <li>• 2% to 4% of children on ARVs</li> <li>• Highest rates with ZDV-containing regimens</li> </ul>	<p><u>Newborns Exposed to HIV:</u></p> <ul style="list-style-type: none"> <li>• <i>In utero</i> exposure to ARVs</li> <li>• Combination ARV prophylaxis, particularly with ZDV plus 3TC</li> </ul> <p><u>Children with HIV Taking ARVs:</u></p> <ul style="list-style-type: none"> <li>• Advanced or poorly controlled HIV infection</li> <li>• Myelosuppressive drugs (e.g., TMP-SMX, ganciclovir, hydroxyurea, rifabutin)</li> </ul>	<p><u>Children with HIV Taking ARVs:</u></p> <ul style="list-style-type: none"> <li>• Obtain CBC as part of routine care.</li> </ul>	<p><u>Newborns Exposed to HIV:</u></p> <ul style="list-style-type: none"> <li>• No established threshold for intervention; some experts would consider using an alternative NRTI for prophylaxis if ANC reaches &lt;500 cells/mm<sup>3</sup>. ZDV administration can be limited to 4 weeks in low-risk neonates (see <u>Antiretroviral Management of Newborns with Perinatal HIV Exposure or Perinatal HIV</u>).</li> </ul> <p><u>Children with HIV Taking ARVs:</u></p> <ul style="list-style-type: none"> <li>• Discontinue non-ARV marrow-toxic drugs, if feasible.</li> <li>• Treat coexisting OIs and malignancies.</li> <li>• For persistent severe neutropenia thought to be associated with ARVs, change to a regimen that does not contain ZDV.</li> </ul>

<sup>a</sup> HIV infection itself, OIs, and medications used to prevent OIs, such as TMP-SMX, may all contribute to anemia, neutropenia, and thrombocytopenia.

**Key to Acronyms:** 3TC = lamivudine; ANC = absolute neutrophil count; ARV = antiretroviral; CBC = complete blood count; dL = deciliter; fL = femtoliter; G6PD = glucose-6-phosphate dehydrogenase; Hgb = hemoglobin; MCV = mean cell volume; NRTI = nucleoside reverse transcriptase inhibitor; OI = opportunistic infection; TMP-SMX = trimethoprim-sulfamethoxazole; ZDV = zidovudine

## References

1. Najean Y, Rain JD. The mechanism of thrombocytopenia in patients with HIV infection. *The Journal of Laboratory and Clinical Medicine*. 1994;123(3):415-420. Available at <http://www.ncbi.nlm.nih.gov/pubmed/8133154>.
2. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. *Blood*. 1997;89(8):2689-2700. Available at <http://www.ncbi.nlm.nih.gov/pubmed/9108386>.
3. Lahoz R, Noguera A, Rovira N, et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. *Pediatr Infect Dis J*. 2010;29(4):376-379. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19949355>.

4. Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. *J Acquir Immune Defic Syndr*. 2011;56(5):428-436. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21266910>.
5. Mocroft A, Lifson AR, Touloumi G, et al. Haemoglobin and anaemia in the SMART study. *Antivir Ther*. 2011;16(3):329-337. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21555815>.
6. Nyesigire Ruhinda E, Bajunirwe F, Kiwanuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART. *BMC Pediatr*. 2012;12:170. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23114115>.
7. Esan MO, Jonker FA, Hensbroek MB, Calis JC, Phiri KS. Iron deficiency in children with HIV-associated anaemia: a systematic review and meta-analysis. *Trans R Soc Trop Med Hyg*. 2012;106(10):579-587. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22846115>.
8. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *N Engl J Med*. 2012;366(25):2368-2379. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22716975>.
9. Renner LA, Dicko F, Koueta F, et al. Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS. *J Int AIDS Soc*. 2013;16(1):18024. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24047928>.
10. Arrow Trial team, Kekitiinwa A, Cook A, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. *Lancet*. 2013;381(9875):1391-1403. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23473847>.
11. Bunupuradah T, Kariminia A, Chan KC, et al. Incidence and predictors of severe anemia in Asian HIV-infected children using first-line antiretroviral therapy. *Int J Infect Dis*. 2013;17(10):e806-810. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23764352>.
12. Singh A, Hemal A, Agarwal S, Dubey N, Buxi G. A prospective study of haematological changes after switching from stavudine to zidovudine-based antiretroviral treatment in HIV-infected children. *Int J STD AIDS*. 2014. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24516076>.
13. Van Dyke RB, Wang L, Williams PL, Pediatric ACTGCT. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. *J Infect Dis*. 2008;198(11):1599-1608. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19000014>.
14. Smith C, Forster JE, Levin MJ, et al. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. *PLoS One*. 2015;10(5):e0127062. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26000984>.
15. Smith C, Weinberg A, Forster JE, et al. Maternal lopinavir/ritonavir is associated with fewer adverse events in infants than nelfinavir or atazanavir. *Infectious Diseases in Obstetrics and Gynecology*. 2016;2016:9848041. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27127401>.
16. Shet A, Bhavani PK, Kumarasamy N, et al. Anemia, diet and therapeutic iron among children living with HIV: a prospective cohort study. *BMC Pediatr*. 2015;15:164. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26482352>.
17. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. *AIDS Res Ther*. 2015;12:26. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26279668>.
18. Mulenga V, Musiime V, Kekitiinwa A, et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. *Lancet Infect Dis*. 2016;16(2):169-179. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26481928>.
19. Lau E, Brophy J, Samson L, et al. Nevirapine pharmacokinetics and safety in neonates receiving combination antiretroviral therapy for prevention of vertical HIV transmission. *J Acquir Immune Defic Syndr*. 2017;74(5):493-498. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28114187>.
20. The European Pregnancy and Paediatric HIV Cohort Collaboration Study Group in EuroCoord. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand. *European Journal of Clinical Pharmacology*. 2017;73(4):463-468.

**Table 15e. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Hepatic Events**  
 (Last updated May 22, 2018; last reviewed May 22, 2018) (page 1 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Hepatitis</b>	<p>Most ARVs have been associated with hepatitis, but there is a strong association with NVP, EFV, and TPV.</p> <p>NVP, EFV, ABC, RAL, and MVC have been associated with hepatitis in context of HSRs.</p> <p>NRTIs have been associated with lactic acidosis and hepatic steatosis, especially ZDV, d4T, and ddI (co-administering d4T and ddI poses the highest risk).</p> <p>d4T or ddI are no longer recommended for use in an ARV regimen.</p>	<p><b>Onset:</b></p> <ul style="list-style-type: none"> <li>An acute toxic hepatitis most commonly occurs within the first few months of therapy (but can occur later).</li> <li>Steatosis presents after months to years of therapy.</li> <li>Patients with HBV coinfection may develop flare of hepatitis with the initiation or withdrawal of 3TC, FTC, TDF, or TAF. Flare may also occur with the emergence of resistance to 3TC or FTC (especially if receiving only 1 anti-HBV agent). Note that HBV has a high genetic barrier for resistance to TDF and TAF.</li> <li>Hepatitis may represent IRIS early in therapy, especially in patients with HBV- and HCV-coinfection.</li> </ul> <p><b>Presentation:</b></p> <ul style="list-style-type: none"> <li>Asymptomatic elevation of AST and ALT</li> <li>Symptomatic hepatitis with nausea, fatigue, and jaundice</li> <li>Hepatitis may present in context of HSR with rash, lactic acidosis, and hepatic steatosis.</li> </ul>	Uncommon	<p>HBV or HCV coinfection</p> <p>Underlying liver disease</p> <p>Use of other hepatotoxic medications and supplements (e.g., St. John's wort [<i>Hypericum perforatum</i>], chaparral [<i>Larrea tridentate</i>], germander [<i>Teucrium chamaedrys</i>])</p> <p>Alcohol use</p> <p>Pregnancy</p> <p><b>Obesity</b></p> <p><u>For NVP-Associated Hepatic Events in Adults:</u></p> <ul style="list-style-type: none"> <li>Female with pre-NVP CD4 count &gt;250 cells/mm<sup>3</sup></li> <li>Male with pre-NVP CD4 count &gt;400 cells/mm<sup>3</sup></li> <li>Population-specific HLA types<sup>a</sup></li> <li>Higher drug concentrations for PIs, particularly TPV</li> </ul>	<p><b>Prevention:</b></p> <ul style="list-style-type: none"> <li>Avoid concomitant use of hepatotoxic medications.</li> <li><b>Do not use d4T or ddI (individually or together); co-administration is contraindicated (no exceptions).</b></li> <li>In patients with elevated hepatic enzymes (&gt;5 to 10 times ULN) or chronic liver disease, most clinicians would avoid NVP.</li> </ul> <p><b>Monitoring</b></p> <p><i>For ARVs Other Than NVP:</i></p> <ul style="list-style-type: none"> <li>Obtain AST and ALT at baseline and thereafter at least every 3–4 months,<sup>b</sup> or more frequently in at-risk patients (e.g., those with HBV or HCV coinfection or elevated baseline AST and ALT).</li> </ul> <p><i>For NVP:</i></p> <ul style="list-style-type: none"> <li>Obtain AST and ALT at baseline, at 2 and 4 weeks, and then every 3 months.</li> </ul>	<p>Evaluate for other infectious and non-infectious causes and monitor closely.</p> <p><b>Asymptomatic:</b></p> <ul style="list-style-type: none"> <li>Potentially offending ARVs should be discontinued if ALT or AST is &gt;5 times ULN.</li> </ul> <p><b>Symptomatic:</b></p> <ul style="list-style-type: none"> <li>Discontinue all ARVs and other potentially hepatotoxic drugs.</li> <li>If a patient experiences hepatitis attributed to NVP, it should be permanently discontinued.</li> <li>Consider viral causes of hepatitis: HAV, HBV, HCV, EBV, and CMV.</li> </ul>

**Table 15e. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Hepatic Events**  
(Last updated May 22, 2018; last reviewed May 22, 2018) (page 2 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Indirect Hyperbilirubinemia</b>	ATV (with either RTV or COBI), IDV	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• First months of therapy</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• May be asymptomatic or associated with jaundice</li> <li>• Direct bilirubin may be normal or slightly elevated when levels of indirect bilirubin are very high.</li> <li>• Normal AST and ALT</li> </ul>	In long-term follow-up, 9% of children receiving ATV had at least 1 total bilirubin level >5 times ULN and 1.4% experienced jaundice.	N/A	<p><u>Prevention:</u></p> <ul style="list-style-type: none"> <li>• IDV is not FDA-approved or recommended for use in the pediatric population.</li> </ul> <p><u>Monitoring:</u></p> <ul style="list-style-type: none"> <li>• No ongoing monitoring needed.</li> </ul> <p>After an initial rise over the first few months of therapy, unconjugated bilirubin levels generally stabilize; levels may improve over time.</p>	<p>Isolated indirect hyperbilirubinemia is not indication for cessation of a potentially offending ARV.</p> <p>Psychological impact of jaundice should be evaluated, and alternative agents considered.</p>
<b>Non-Cirrhotic Portal Hypertension</b>	d4T, ddl <b>d4T or ddl are no longer recommended for use in an ARV regimen.</b>	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• Generally after years of therapy</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• GI bleeding, esophageal varices, hypersplenism</li> <li>• Mild elevations in AST and ALT, moderate increases in ALP, and pancytopenia (due to hypersplenism)</li> </ul> <p><u>Liver Biopsy</u></p> <p><i>Variety of Findings, Most Commonly:</i></p> <ul style="list-style-type: none"> <li>• Nodular regenerative hyperplasia</li> <li>• Hepatoportal sclerosis</li> </ul>	Rare	Prolonged exposure to ARV therapy, especially ddl and the combination of d4T and ddl.	<p><u>Prevention:</u></p> <ul style="list-style-type: none"> <li>• Do not use d4T, or ddl (individually or together); co-administration is contraindicated (no exceptions).</li> </ul> <p><u>Monitoring:</u></p> <ul style="list-style-type: none"> <li>• No specific monitoring</li> </ul>	<p>Discontinue potentially offending agents.</p> <p>Manage complications of GI bleeding and esophageal varices.</p>

<sup>a</sup> For example, HLA-DRB1\*0101 in whites, HLA-DRB1\*0102 in South Africans, and HLA-B35 in Thai and whites.

<sup>b</sup> Less frequent monitoring can be considered in children whose clinical status is stable for more than 2–3 years (see [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)).

**Key to Acronyms:** 3TC = lamivudine; ABC = abacavir; ALP = alkaline phosphatase; ALT = alanine transaminase; ARV = antiretroviral; AST = aspartate aminotransferase; ATV = atazanavir; CD4 = CD4 T lymphocyte; CMV = cytomegalovirus; COBI = cobicistat; d4T = stavudine; ddl = didanosine; EBV = Epstein-Barr virus; EFV = efavirenz; **FDA = Food and Drug Administration**; FTC = emtricitabine; GI = gastrointestinal; HAV = hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HLA = human leukocyte antigen; **HSR = hypersensitivity reaction**; IDV = indinavir; IRIS = immune reconstitution inflammatory syndrome; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; RTV = ritonavir; **TAF = tenofovir alafenamide**; TDF = tenofovir disoproxil fumarate; TPV = tipranavir; ULN = upper limit of normal; ZDV = zidovudine

## References

### General Reviews

1. Aурpibul L, Bunupuradah T, Sophan S, et al. Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children. *Pediatr Infect Dis J*. 2015;34(6):e153-158. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25970117>.
2. Huntington S, Thorne C, Newell ML, et al. Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. *AIDS*. 2015;29(7):801-809. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25710412>.
3. Kovari H, Sabin CA, Ledergerber B, et al. Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: the data collection on adverse events of anti-HIV drugs study. *Open Forum Infect Dis*. 2016;3(1):ofw009. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26925429>.
4. Navarro VJ, Khan I, Bjornsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. *Hepatology*. 2017;65(1):363-373. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27677775>.
5. Sonderup MW, Wainwright HC. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Liver Pathology. *Gastroenterol Clin North Am*. 2017;46(2):327-343. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28506368>.
6. The National Institute of Diabetes and Digestive and Kidney Diseases. Clinical and Research Information on Drug-Induced Liver Injury. 2017. Available at <https://livertox.nlm.nih.gov>.

### Hepatic Events and NRTIs

7. Van Dyke RB, Wang L, Williams PL, Pediatric ACTGCT. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. *J Infect Dis*. 2008;198(11):1599-1608. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19000014>.
8. Logan S, Rodger A, Maynard-Smith L, et al. Prevalence of significant liver disease in human immunodeficiency virus-infected patients exposed to Didanosine: A cross sectional study. *World J Hepatol*. 2016;8(36):1623-1628. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28083085>.

### Hepatic Events and NNRTIs

9. Phillips E, Bartlett JA, Sanne I, et al. Associations between HLA-DRB1\*0102, HLA-B\*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. *J Acquir Immune Defic Syndr*. 2013;62(2):e55-57. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23328091>.
10. Sonderup MW, Maughan D, Gogela N, et al. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. *AIDS*. 2016;30(9):1483-1485. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26959511>.

### Hepatic Events and NRTIs plus NNRTIs

11. Wu PY, Cheng CY, Liu CE, et al. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naive HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. *PLoS One*. 2017;12(2):e0171596. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28222098>.

### Hepatic Events and PIs including Indirect Hyperbilirubinemia

12. McDonald C, Uy J, Hu W, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. *AIDS Patient Care STDS*. 2012;26(5):259-264. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22404426>.
13. Strehlau R, Donati AP, Arce PM, et al. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naive and

- experienced infants and children aged  $\geq 3$  months to  $< 6$  years. *J Int AIDS Soc.* 2015;18:19467. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26066346>.
14. Rutstein RM, Samson, P, Fenton, T, Fletcher, CV, Kiser, JJ, Mofenson, LM, et al. for the PACTG 1020A Study Team. Long-Term Safety and Efficacy of Atazanavir-Based Therapy in HIV-Infected Infants, Children and Adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A. *Pediatr Infect Dis J.* 2015;34:162-167.
  15. Crutchley RD, Guduru RC, Cheng AM. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. *HIV/AIDS.* 2016;8:47-65. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27022304>.
  16. The European Pregnancy and Paediatric HIV Cohort Collaboration, (EPPICC) study group in EuroCoord. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand. *European Journal of Clinical Pharmacology.* 2017;73(4):463-468.

#### **HIV and Hepatitis B/C Coinfections**

17. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. *Clin Infect Dis.* 2010;50(4):502-511. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20085465>.
18. Gowda C, Newcomb CW, Liu Q, et al. Risk of acute liver injury with antiretroviral therapy by viral hepatitis status. *Open Forum Infect Dis.* 2017;4(2):ofx012. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28470014>.
19. Phung BC, Sogni P, Launay O. Hepatitis B and human immunodeficiency virus co-infection. *World J Gastroenterol.* 2014;20(46):17360-17367. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25516647>.

#### **Nodular Regenerative Hyperplasia and Noncirrhotic Portal Hypertension**

20. Cotte L, Benet T, Billioud C, et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. *J Hepatol.* 2011;54(3):489-496. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21056493>.
21. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. *Clin Infect Dis.* 2009;49(4):626-635. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19589079>.
22. Schouten JN, Van der Ende ME, Koeter T, et al. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension. *Aliment Pharmacol Ther.* 2012;36(9):875-885. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22971050>.
23. Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. *Curr Opin Infect Dis.* 2011;24(1):12-18. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21157331>.
24. Parikh ND, Martel-Laferriere V, Kushner T, et al. Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm. *J Infect Dis.* 2014;209(5):734-738. Available at <https://www.ncbi.nlm.nih.gov/pubmed/23911709>.
25. Scherpbier HJ, Terpstra V, Pajkrt D, et al. Noncirrhotic portal hypertension in perinatally HIV-infected adolescents treated with didanosine-containing antiretroviral regimens in childhood. *Pediatr Infect Dis J.* 2016. Available at <http://www.ncbi.nlm.nih.gov/pubmed/27167116>.
26. Sood A, Castrejon M, Saab S. Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review. *World J Hepatol.* 2014;6(1):55-63. Available at <https://www.ncbi.nlm.nih.gov/pubmed/24653794>.

**Table 15f. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Insulin Resistance, Asymptomatic Hyperglycemia, Diabetes Mellitus (Last updated May 22, 2018; last reviewed May 22, 2018)**

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Insulin Resistance, Asymptomatic Hyperglycemia, DM<sup>a</sup></b>	<p><b>NRTIs:</b></p> <ul style="list-style-type: none"> <li>• ZDV</li> <li>• d4T</li> <li>• ddI</li> </ul> <p><b>d4T or ddI are no longer recommended for use in an ARV regimen.</b></p> <p><b>PIs:</b></p> <ul style="list-style-type: none"> <li>• LPV/r</li> <li>• Rarely other PIs</li> </ul>	<p><b>Onset:</b></p> <ul style="list-style-type: none"> <li>• Weeks to months after beginning therapy</li> </ul> <p><b>Presentation:</b></p> <ul style="list-style-type: none"> <li>• Asymptomatic fasting hyperglycemia (possibly in the setting of lipodystrophy), metabolic syndrome, or growth delay</li> <li>• Symptomatic DM (rare)</li> </ul>	<p><b>Children:</b></p> <ul style="list-style-type: none"> <li>• Insulin resistance, 6% to 12%</li> <li>• Impaired fasting glucose, 0% to 7%</li> <li>• Impaired glucose tolerance, 3% to 4%</li> <li>• DM, 0.2 per 100-child-years</li> </ul>	<p><b>Risk Factors for Type 2 DM:</b></p> <ul style="list-style-type: none"> <li>• Lipodystrophy</li> <li>• Metabolic syndrome</li> <li>• Family history of DM</li> <li>• High BMI (obesity)</li> </ul>	<p><b>Prevention:</b></p> <ul style="list-style-type: none"> <li>• Lifestyle modification</li> <li>• <b>Do not use d4T or ddI (individually or together); co-administration is contraindicated (no exceptions).</b></li> <li>• <b>Avoid ZDV when possible.</b></li> </ul> <p><b>Monitoring:</b></p> <ul style="list-style-type: none"> <li>• Monitor for signs of DM, change in body habitus, and acanthosis nigricans.</li> </ul> <p><i>Obtain RPG Levels at:</i></p> <ul style="list-style-type: none"> <li>• Initiation of ARV therapy</li> <li>• 3–6 months after therapy initiation</li> <li>• Once a year thereafter</li> </ul> <p>For RPG <math>\geq 140</math> mg/dL:</p> <ul style="list-style-type: none"> <li>• Obtain FPG performed after 8-hour fast and consider referral to endocrinologist.</li> </ul>	<p>Counsel on lifestyle modification (e.g., a diet low in saturated fat, cholesterol, trans fat, and refined sugars; increased physical activity; cessation of smoking); recommend consultation with dietician.</p> <p>Change NRTI backbone (e.g., from ZDV, d4T, or ddI to TAF, TDF, or ABC).</p> <p><b>For Either RPG <math>\geq 200</math> mg/dL plus Symptoms of DM or FPG <math>\geq 126</math> mg/dL:</b></p> <ul style="list-style-type: none"> <li>• Patient meets diagnostic criteria for DM; consult endocrinologist.</li> </ul> <p><b>FPG 100–125 mg/dL:</b></p> <ul style="list-style-type: none"> <li>• Impaired FPG is suggestive of insulin resistance; consult endocrinologist.</li> </ul> <p><b>FPG &lt;100 mg/dL</b></p> <p><i>Normal FPG, but Does Not Exclude Insulin Resistance:</i></p> <ul style="list-style-type: none"> <li>• Recheck FPG in 6–12 months.</li> </ul>

<sup>a</sup> Insulin resistance, asymptomatic hyperglycemia, and DM form a spectrum of increasing severity. Insulin resistance is often defined as elevated insulin levels for the level of glucose observed; *impaired FPG* as an FPG of 100–125 mg/dL; *impaired glucose tolerance* as an elevated 2-hour PG of 140–199 mg/dL in a 75 g-OGTT (or if <43 kg, 1.75 g/kg of glucose up to a maximum of 75 g); and *diabetes mellitus* as either an FPG  $\geq 126$  mg/dL, a random PG  $\geq 200$  mg/dL in a patient with hyperglycemia symptoms, an HgbA1c of  $\geq 6.5\%$ , or a 2-hour PG after OGTT  $\geq 200$  mg/dL. However, the Panel does not recommend routine determinations of insulin levels, HgbA1c, or glucose tolerance without consultation with an endocrinologist. These guidelines are instead based on the readily available RPG and FPG levels.

**Key to Acronyms:** ABC = abacavir; ARV = antiretroviral; BMI = body mass index; d4T = stavudine; ddI = didanosine; dL = deciliter; DM = diabetes mellitus; FPG = fasting plasma glucose; HgbA1c = glycosylated hemoglobin; LPV/r = lopinavir/ritonavir; NRTI = nucleoside reverse transcriptase inhibitor; OGTT = oral glucose tolerance test; PG = plasma glucose; PI = protease inhibitor; RPG = random plasma glucose; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

## References

1. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. *AIDS*. 2009;23(6):661-672. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19279441>.
2. Chantry CJ, Hughes MD, Alvero C, et al. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. *Pediatrics*. 2008;122(1):e129-138. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18519448>.
3. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2009;50(5):499-505. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19223782>.
4. Geffner ME, Patel K, Miller TL, et al. Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study. *Hormone Research in Paediatrics*. 2011;76(6):386-391. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22042056>.
5. Hazra R, Hance LF, Monteiro JP, et al. Insulin resistance and glucose and lipid concentrations in a cohort of perinatally HIV-infected Latin American children. *Pediatr Infect Dis J*. 2013;32(7):757-759. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23360832>.
6. Patel K, Wang J, Jacobson DL, et al. Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus. *Circulation*. 2014;129(11):1204-1212. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24366631>.
7. Hadigan C, Kattakuzhy S. Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. *Endocrinology and Metabolism Clinics of North America*. 2014;43(3):685-696. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25169561>.
8. Fortuny C, Deya-Martinez A, Chiappini E, Galli L, de Martino M, Noguera-Julian A. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. *Pediatr Infect Dis J*. 2015;34(5 Suppl 1):S36-43. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25629891>.
9. Loomba-Albrecht LA, Bregman T, Chantry CJ. Endocrinopathies in children infected with human immunodeficiency virus. *Endocrinology and metabolism clinics of North America*. 2014;43(3):807-828. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25169569>.
10. Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH. High prevalence of dyslipidemia and insulin resistance in HIV-infected pre-pubertal African children on antiretroviral therapy. *Pediatr Infect Dis J*. 2015. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26421804>.
11. American Diabetes Association. Sec 2. Classification and diagnosis of diabetes. *Diabetes Care*. 2016;39 Suppl 1:S13-22. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26696675>.
12. Espiau M, Yeste D, Noguera-Julian A, et al. Metabolic syndrome in children and adolescents living with HIV. *Pediatr Infect Dis J*. 2016;35(6):e171-176. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26910591>.
13. Mirani G, Williams PL, Chernoff M, et al. Changing trends in complications and mortality rates among U.S. youth and young adults with HIV infection in the era of combination antiretroviral therapy. *Clin Infect Dis*. 2015;61(12):1850-1861. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26270680>.
14. Nduka CU, Stranges S, Kimani PK, Sarki AM, Uthman OA. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. *Diabetes Metab Res Rev*. 2017. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28437854>.
15. Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. *Transl Res*. 2017;183:41-56. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28068521>.
16. Paganella MP, Cohen RA, Harris DR, et al. Association of dyslipidemia and glucose abnormalities with antiretroviral treatment in a cohort of HIV-infected Latin-American children. *J Acquir Immune Defic Syndr*. 2017;74(1):e1-e8. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27570910>.
17. Takemoto JK, Miller TL, Wang J, et al. Insulin resistance in HIV-infected youth is associated with decreased mitochondrial respiration. *AIDS*. 2017;31(1):15-23. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27755108>.
18. Dirajlal-Fargo S, Musiime V, Cook A, et al. Insulin resistance and markers of inflammation in HIV-infected Ugandan children in the CHAPAS-3 Trial. *Pediatr Infect Dis J*. 2017;36(8):761-767. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28067719>.

**Table 15g. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Lactic Acidosis**

(Last updated May 22, 2018; last reviewed May 22, 2018)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Lactic Acidosis</b>	<p><u>NRTIs:</u></p> <ul style="list-style-type: none"> <li>d4T and ddI have the highest risk when co-administered, followed by ZDV.</li> <li>d4T or ddI are not recommended in an ARV regimen.</li> <li>3TC, FTC, ABC, TAF, and TDF are less likely to induce mitochondrial dysfunction of clinical significance.</li> </ul>	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>1–20 months after starting therapy (median onset was 4 months in 1 case series)</li> </ul> <p><u>Presentation</u></p> <p><i>Usually Insidious Onset of a Combination of Signs and Symptoms:</i></p> <ul style="list-style-type: none"> <li>Generalized fatigue, weakness, and myalgias</li> <li>Vague abdominal pain, weight loss, unexplained nausea, or vomiting</li> <li>Dyspnea</li> <li>Peripheral neuropathy</li> </ul> <p><b>Note:</b> Patients may present with acute multi-organ failure (e.g., fulminant hepatic, pancreatic, respiratory failure).</p>	<p><u>The following information is based on studies that included d4T and ddI.</u></p> <p><u>Chronic, Asymptomatic Mild Hyperlactatemia (2.1–5.0 mmol/L)</u></p> <p><i>Adults:</i></p> <ul style="list-style-type: none"> <li>15% to 35% of adults receiving NRTI therapy for &gt;6 months</li> </ul> <p><i>Children:</i></p> <ul style="list-style-type: none"> <li>29% to 32%</li> </ul> <p><u>Symptomatic Severe Hyperlactatemia (&gt;5.0 mmol/L)</u></p> <p><i>Adults:</i></p> <ul style="list-style-type: none"> <li>0.2% to 5.7%</li> </ul> <p><u>Symptomatic Lactic Acidosis/Hepatic Steatosis:</u></p> <ul style="list-style-type: none"> <li>Rare in all age groups (1.3–11 episodes per 1,000 person-years; increased incidence with the use of d4T/ddI when co-administered), but associated with a high fatality rate (33% to 58%)</li> </ul>	<p><u>Adults:</u></p> <ul style="list-style-type: none"> <li>Female sex</li> <li>High BMI</li> <li>Chronic HCV infection</li> <li>African-American race</li> <li>Prolonged NRTI use (particularly d4T and ddI)</li> <li>Co-administration of ddI with other agents (e.g., d4T, TDF, RBV, tetracycline)</li> <li>Co-administration of TDF with metformin</li> <li>Overdose of propylene glycol</li> <li>CD4 count &lt;350 cells/mm<sup>3</sup></li> <li>Acquired riboflavin or thiamine deficiency</li> <li>Possibly pregnancy</li> </ul> <p><u>Preterm Infants or Any Neonates before Post-Menstrual Age of 42 Weeks and a Postnatal Age of ≥14 Days has Been Attained:</u></p> <ul style="list-style-type: none"> <li>Exposure to propylene glycol (e.g., present as a diluent in LPV/r oral solution). A diminished ability to metabolize propylene glycol may lead to accumulation and potential adverse events.</li> </ul>	<p><u>Prevention:</u></p> <ul style="list-style-type: none"> <li>Do not use d4T or ddI (individually or together) in an ARV regimen; co-administration is contraindicated (no exceptions).</li> <li>Due to the presence of propylene glycol as a diluent, LPV/r oral solution should not be used in preterm neonates or any neonate before a postmenstrual age of 42 weeks and a postnatal age of ≥14 days has been attained.</li> <li>Monitor for clinical manifestations of lactic acidosis and promptly adjust therapy.</li> </ul> <p><u>Monitoring</u></p> <p><i>Asymptomatic:</i></p> <ul style="list-style-type: none"> <li>Measurement of serum lactate is not recommended.</li> </ul> <p><i>Clinical Signs or Symptoms Consistent with Lactic Acidosis:</i></p> <ul style="list-style-type: none"> <li>Obtain blood lactate level.<sup>a</sup></li> <li>Additional diagnostic evaluations should include serum bicarbonate and anion gap and/or arterial blood gas, amylase and lipase, serum albumin, and hepatic transaminases.</li> </ul>	<p><u>Lactate 2.1–5.0 mmol/L (Confirmed with Second Test):</u></p> <ul style="list-style-type: none"> <li>Replace ddI and d4T with other ARVs.</li> <li>As an alternative, temporarily discontinue all ARVs while conducting additional diagnostic workup.</li> </ul> <p><u>Lactate &gt;5.0 mmol/L (Confirmed with Second Test)<sup>b</sup> or &gt;10.0 mmol/L (Any 1 Test):</u></p> <ul style="list-style-type: none"> <li>Discontinue all ARVs.</li> <li>Provide supportive therapy (IV fluids; some patients may require sedation and respiratory support to reduce oxygen demand and ensure adequate oxygenation of tissues).</li> </ul> <p><u>Anecdotal (Unproven) Supportive Therapies:</u></p> <ul style="list-style-type: none"> <li>Bicarbonate infusions, THAM, high-dose thiamine and riboflavin, oral antioxidants (e.g., L-carnitine, co-enzyme Q10, vitamin C)</li> </ul> <p>Following resolution of clinical and laboratory abnormalities, resume therapy, either with a NRTI-sparing regimen or a revised NRTI-containing regimen instituted with caution, using NRTIs less likely to induce mitochondrial dysfunction (ABC, TAF, or TDF preferred; possibly FTC or 3TC), and lactate should be monitored monthly for at least 3 months.</p>

<sup>a</sup> Blood for lactate determination should be collected, without prolonged tourniquet application or fist clenching, into a pre-chilled, gray-top, fluoride-oxalate-containing tube and transported on ice to the laboratory to be processed within 4 hours of collection.

<sup>b</sup> Management can be initiated before the results of the confirmatory test.

**Key to Acronyms:** 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BMI = body mass index; CD4 = CD4 T lymphocyte; d4T = stavudine; ddl = didanosine; FTC = emtricitabine; HCV = hepatitis C virus; IV = intravenous; LPV/r = lopinavir/ritonavir; NRTI = nucleoside reverse transcriptase inhibitor; RBV = ribavirin; **TAF = tenofovir alafenamide**; TDF = tenofovir disoproxil fumarate; THAM = tris (hydroxymethyl) aminomethane; **ZDV = zidovudine**

## References

### General Reviews

1. Fortuny C, Deya-Martinez A, Chiappini E, Galli L, de Martino M, Noguera-Julian A. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. *Pediatr Infect Dis J*. 2015;34(5 Suppl 1):S36-43. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25629891>.
2. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV Medications. *J Med Toxicol*. 2014;10(1):26-39. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23963694>.
3. Tukei VJ, Asiimwe A, Maganda A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. *J Acquir Immune Defic Syndr*. 2012;59(3):274-280. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22126740>.

### Fatal Lactic Acidosis

4. Arenas-Pinto A, Grant A, Bhaskaran K, et al. Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. *Antivir Ther*. 2011;16(2):219-226. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21447871>.
5. Leung L, Wilson D, Manini AF. Fatal toxicity from symptomatic hyperlactataemia: a retrospective cohort study of factors implicated with long-term nucleoside reverse transcriptase inhibitor use in a South African hospital. *Drug Saf*. 2011;34(6):521-527. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21488705>.
6. Manosuthi W, Prasithsirikul W, Chumpathat N, et al. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. *Int J Infect Dis*. 2008;12(6):582-586. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18337140>.

### Risk Factors

7. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivannis P. Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. *J Ren Care*. 2011;37(1):25-29. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21288314>.
8. Lopinavir/ritonavir [package insert]. Food and Drug Administration. 2016. Available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/021251s052\\_02\\_1906s046lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021251s052_02_1906s046lbl.pdf).
9. Dragovic G, Jevtovic D. The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients. *Biomed Pharmacother*. 2012;66(4):308-311. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22658063>.
10. Feeney ER, Chazallon C, O'Brien N, et al. Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial). *HIV Med*. 2011;12(10):602-609. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21599820>.
11. Firnhaber C, Smeaton LM, Grinsztejn B, et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. *HIV Clin Trials*. 2015;16(3):89-99. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25979186>.
12. Fortuin-de Smidt M, de Waal R, Cohen K, et al. First-line antiretroviral drug discontinuations in children. *PLoS One*. 2017;12(2):e0169762. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28192529>.
13. Lim TY, Poole RL, Pageler NM. Propylene glycol toxicity in children. *J Pediatr Pharmacol Ther*. 2014;19(4):277-282. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25762872>.

14. Mamiako CT, Moor VJ, Nansseu JR, Pieme CA, Tayou C, Yonkeu JN. Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon. *AIDS Res Ther*. 2014;11(1):2. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24428886>.
15. Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. *J Int AIDS Soc*. 2012;15(1):13. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22410312>.
16. Matthews LT, Giddy J, Ghebremichael M, et al. A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy. *PLoS One*. 2011;6(4):e18736. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21494566>.
17. Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. *BMC Infect Dis*. 2011;11:244. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21923929>.
18. Moren C, Noguera-Julian A, Garrabou G, et al. Mitochondrial evolution in HIV-infected children receiving first- or second-generation nucleoside analogues. *J Acquir Immune Defic Syndr*. 2012;60(2):111-116. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22362155>.
19. Osler M, Stead D, Rebe K, Meintjes G, Boule A. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. *HIV Med*. 2010;11(2):121-129. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19702629>.
20. Palmer M, Chersich M, Moultrie H, Kuhn L, Fairlie L, Meyers T. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. *AIDS*. 2013;27(5):781-785. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23169331>.
21. Phan V, Thai S, Choun K, Lynen L, van Griensven J. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. *PLoS One*. 2012;7(1):e30647. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22303447>.
22. Tetteh RA, Nartey ET, Lartey M, et al. Association between the occurrence of adverse drug events and modification of first-line highly active antiretroviral therapy in Ghanaian HIV Patients. *Drug Saf*. 2016;39(11):1139-1149. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27638659>.
23. Wester CW, Eden SK, Shepherd BE, et al. Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. *AIDS Res Hum Retroviruses*. 2012;28(8):759-765. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22540188>.

### Monitoring and Management

24. Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. *J Int AIDS Soc*. 2013;16:18600. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23782481>.
25. Chagoma N, Mallewa J, Kaunda S, et al. Longitudinal lactate levels from routine point-of-care monitoring in adult Malawian antiretroviral therapy patients: associations with stavudine toxicities. *Trans R Soc Trop Med Hyg*. 2013;107(10):615-619. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23926161>.
26. Claessens YE, Cariou A, Monchi M, et al. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. *Crit Care Med*. 2003;31(4):1042-1047. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12682470>.
27. Kraut JA, Madias NE. Lactic acidosis. *N Engl J Med*. 2014;371(24):2309-2319. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25494270>.
28. Marfo K, Garala M, Kvetan V, Gasperino J. Use of Tris-hydroxymethyl aminomethane in severe lactic acidosis due to highly active antiretroviral therapy: a case report. *J Clin Pharm Ther*. 2009;34(1):119-123. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19125910>.

**Table 15h. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Lipodystrophy, Lipohypertrophy, Lipoatrophy (Last updated May 22, 2018; last reviewed May 22, 2018) (page 1 of 2)**

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Lipodystrophy (Fat Maldistribution)</b> General Information	See below for specific associations.	<u>Onset:</u> • Trunk and limb fat initially increase; peripheral fat wasting may not appear for 12–24 months after ART initiation.	Varies greatly depending upon measure and comparator group.  Frequency may be up to 15% with current regimens.	Genetic predisposition  Puberty  HIV-associated inflammation  Older age  Longer duration of ART  Body habitus	See below.	See below.  Physicians should perform a regimen review and consider changing the regimen when lipodystrophy occurs.  Improvement following regimen change is variable. Improvement may occur after several months or years, or it may not occur at all.
<b>Central Lipohypertrophy or Lipo-accumulation</b>	Can occur in the absence of ART, but most often associated with PIs and EFV.	<u>Presentation:</u> • Central fat accumulation with increased abdominal girth, which may include dorsocervical fat pad (buffalo hump) and/or gynecomastia in males or breast hypertrophy in females, particularly with EFV.	Up to 15% with current regimens	Obesity before initiation of therapy  Sedentary lifestyle	<u>Prevention:</u> • Calorically appropriate low-fat diet and exercise  <u>Monitoring:</u> • BMI measurement • Body circumference and waist-hip ratio	<b>Counsel patient on lifestyle modification and dietary interventions (e.g., maintaining a calorically appropriate healthy diet that is low in saturated fats and simple carbohydrates, and starting an exercise regimen, especially strength training).</b>  Recommend smoking cessation (if applicable) to decrease future CVD risk.  Consider switching patient from PIs and EFV to an INSTI.  <u>Data are Insufficient to Allow the Panel to Safely Recommend Use of Any of the Following Modalities in Children:</u> • Recombinant human growth hormone • Growth hormone-releasing hormone • Metformin • Thiazolidinediones • Recombinant human leptin • Anabolic steroids • Liposuction

**Table 15h. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Lipodystrophy, Lipohypertrophy, Lipoatrophy (Last updated May 22, 2018; last reviewed May 22, 2018) (page 2 of 2)**

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Facial/Peripheral Lipoatrophy</b>	Most associated with thymidine analogue NRTIs (d4T > ZDV)	<p><b>Presentation:</b></p> <ul style="list-style-type: none"> <li>• Thinning of subcutaneous fat in face, buttocks, and extremities, measured as a decrease in trunk/limb fat by DXA or triceps skinfold thickness. Preservation of lean body mass distinguishes lipoatrophy from HIV-associated wasting.</li> </ul>	<ul style="list-style-type: none"> <li>• Up to 15% with currently used regimens</li> </ul>	Underweight before ART	<p><b>Prevention:</b></p> <ul style="list-style-type: none"> <li>• Do not use ddI or d4T (individually or together); they are no longer recommended as part of an ARV regimen. <b>Co-administration of ddI and d4T is contraindicated (no exceptions).</b></li> </ul> <p><b>Monitoring:</b></p> <ul style="list-style-type: none"> <li>• Patient self-report and physical exam are the most sensitive methods of monitoring lipoatrophy.</li> </ul>	<p>Replace ZDV with other NRTIs if possible. d4T should never be used.</p> <p>Data are Insufficient to Allow the Panel to Safely Recommend Use of Any of the Following Modalities in Children:</p> <ul style="list-style-type: none"> <li>• Injections of poly-L-lactic acid</li> <li>• Recombinant human leptin</li> <li>• Autologous fat transplantation</li> <li>• Thiazolidinediones</li> </ul>

**Key to Acronyms:** ART = antiretroviral therapy; ARV = antiretroviral; BMI = body mass index; CVD = cardiovascular disease; d4T = stavudine; DXA = dual energy x-ray absorptiometry; EFV = efavirenz; INSTI = integrase strand transfer inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; ZDV = zidovudine

## References

See the archived version of [Supplement III](#), February 23, 2009 [Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection](#) (<https://www.aidsinfo.nih.gov>) for a more complete discussion and reference list.

### General Reviews

1. Fernandez JR, Redden DT, Pietrobelli A, Allison DB. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. *J Pediatr*. 2004;145(4):439-444. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15480363>.
2. Moyle G, Moutschen M, Martinez E, et al. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. *AIDS Reviews*. 2010;12(1):3-14. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20216906>.
3. Innes S, Cotton MF, Haubrich R, et al. High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. *BMC Pediatr*. 2012;12:183. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23176441>.
4. Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kamya MR. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. *J Int AIDS Soc*. 2012;15(2):17427. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22814353>.
5. Prendergast AJ. Complications of long-term antiretroviral therapy in HIV-infected children. *Arch Dis Child*. 2013;98(4):245-246. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23413313>.

6. Arbeitman LE, O'Brien RC, Somarriba G, et al. Body mass index and waist circumference of HIV-infected youth in a Miami cohort: comparison to local and national cohorts. *Journal of Pediatric Gastroenterology and Nutrition*. 2014;59(4):449-454. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24709829>.
7. Bwakura-Dangarembizi M, Musiime V, Szubert AJ, et al. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. *Pediatr Infect Dis J*. 2015;34(2):e23-31. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25068287>.
8. Nduka CU, Uthman OA, Kimani PK, Stranges S. Body fat changes in people living with HIV on antiretroviral therapy. *AIDS Reviews*. 2016;18(4):198-211. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27438580>.
9. Kenny J, Doerholt K, Gibb DM, Judd A, Collaborative HIVPSSC. Who gets severe gynecomastia among HIV-infected children in the United Kingdom and Ireland? *Pediatr Infect Dis J*. 2017;36(3):307-310. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27879556>.
10. Ramteke SM, Shiao S, Foca M, et al. Patterns of growth, body composition, and lipid profiles in a South African cohort of human immunodeficiency virus-infected and uninfected children: A cross-sectional study. *J Pediatric Infect Dis Soc*. 2017. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28481997>.

#### Associated ARVs/Etiology

11. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. *AIDS*. 2009;23(9):1109-1118. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19417580>.
12. Hulgán T, Tebas P, Canter JA, et al. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipodystrophy during antiretroviral therapy. *J Infect Dis*. 2008;197(6):858-866. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18419350>.
13. McComsey GA, Libutti DE, O'Riordan M, et al. Mitochondrial RNA and DNA alterations in HIV lipodystrophy are linked to antiretroviral therapy and not to HIV infection. *Antivir Ther*. 2008;13(5):715-722. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18771055>.
14. Van Dyke RB, Wang L, Williams PL, Pediatric ACTGCT. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. *J Infect Dis*. 2008;198(11):1599-1608. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19000014>.
15. Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. *J Acquir Immune Defic Syndr*. 2006;41(5):590-597. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16652032>.
16. Scherzer R, Shen W, Bacchetti P, et al. Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. *The American Journal of Clinical Nutrition*. 2008;88(4):1088-1096. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18842798>.
17. Benn P, Sauret-Jackson V, Cartledge J, et al. Improvements in cheek volume in lipodystrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. *HIV Med*. 2009;10(6):351-355. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19490181>.
18. Arpadi S, Shiao S, Strehlau R, et al. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. *Arch Dis Child*. 2013;98(4):258-264. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23220209>.
19. Foca M, Wang L, Ramteke R, et al. Changes in mitochondrial enzyme function as a predictor of lipodystrophy. Presented at: 7th International AIDS Society; 2015; Vancouver, Canada.
20. Cohen S, Innes S, Geelen SP, et al. Long-term changes of subcutaneous fat mass in HIV-infected children on antiretroviral therapy: a retrospective analysis of longitudinal data from two pediatric HIV-cohorts. *PLoS One*. 2015;10(7):e0120927. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26148119>.
21. Dos Reis LC, de Carvalho Rondo PH, de Sousa Marques HH, Jose Segri N. Anthropometry and body composition of vertically HIV-infected children and adolescents under therapy with and without protease inhibitors. *Public Health Nutr*. 2015;18(7):1255-1261. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25115797>.
22. McComsey GA, Moser C, Currier J, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. *Clin Infect Dis*. 2016;62(7):853-862. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26797215>.
23. Moure R, Domingo P, Gallego-Escuredo JM, et al. Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines. *Antiviral Res*. 2016;132:59-65. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27216995>.

24. Group BT. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. *Lancet HIV*. 2016;3(9):e421-e430. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27562743>.

## Management

25. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. *N Engl J Med*. 2007;357(23):2359-2370. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18057338>.
26. Hadigan C. Peroxisome proliferator-activated receptor gamma agonists and the treatment of HIV-associated lipoatrophy: unraveling the molecular mechanism of their shortcomings. *J Infect Dis*. 2008;198(12):1729-1731. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18954262>.
27. Lindegaard B, Hansen T, Hvid T, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. *J Clin Endocrinol Metab*. 2008;93(10):3860-3869. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18628529>.
28. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. *JAMA*. 2008;300(5):509-519. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18677023>.
29. Tebas P, Zhang J, Hafner R, et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. *J Antimicrob Chemother*. 2009;63(5):998-1005. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19299471>.
30. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. *J Clin Endocrinol Metab*. 2010;95(9):4291-4304. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20554713>.
31. Ferrer E, del Rio L, Martinez E, et al. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. *AIDS Res Hum Retroviruses*. 2011;27(10):1061-1065. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21166602>.
32. Innes S, Harvey J, Collins I, Cotton M, Judd A. Lipoatrophy/lipohypertrophy outcomes after ART switch in children in UK/Ireland. 22nd Conference on Retroviruses and Opportunistic Infections; 2016; Boston, MA.
33. Negro E, Miro O, Rodriguez-Santiago B, et al. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). *Clin Infect Dis*. 2009;49(6):892-900. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19663689>.
34. Raboud JM, Diong C, Carr A, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. *HIV Clin Trials*. 2010;11(1):39-50. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20400410>.
35. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. *BMC Infect Dis*. 2010;10:183. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20573187>.
36. Tungsiripat M, Bejjani DE, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. *AIDS*. 2010;24(9):1291-1298. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20453626>.
37. Spoulou V, Kanaka-Gantenbein C, Bathrellou I, et al. Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy. *Hormones*. 2011;10(2):149-155. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21724540>.
38. Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. *Journal of Infection and Chemotherapy*. 2011;17(2):183-188. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20706762>.
39. Young L, Wohl DA, Hyslop WB, Lee YZ, Napravnik S, Wilkin A. Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy. *HIV Clin Trials*. 2015;16(5):163-169. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26249671>.

**Table 15i. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects**  
 (Last updated May 22, 2018; last reviewed May 22, 2018) (page 1 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Urolithiasis/ Nephrolithiasis</b>	ATV, IDV  DRV causes crystalluria, but it is not associated with nephrolithiasis.	<u>Onset:</u> <ul style="list-style-type: none"> <li>Weeks to months after starting therapy</li> </ul> <u>Clinical Findings:</u> <ul style="list-style-type: none"> <li>Crystalluria</li> <li>Hematuria</li> <li>Pyuria</li> <li>Flank pain</li> <li>Sometimes increased creatinine</li> </ul>	ATV-related nephrolithiasis occurs in <10% of patients.  IDV-related <b>nephrolithiasis occurs more often</b> in children (29%) than adults (12.4%).	In adults, elevated urine pH (>5.7)  Unknown in children	<u>Prevention:</u> <ul style="list-style-type: none"> <li>Maintain adequate hydration.</li> <li>IDV is not FDA-approved for use in children and should be avoided.</li> </ul> <u>Monitoring:</u> <ul style="list-style-type: none"> <li>Obtain urinalysis at least every 6–12 months.</li> </ul>	Provide adequate hydration and pain control; consider using alternative ARV. If patient is on IDV, discontinue.
<b>Renal Dysfunction</b>	TDF	<u>Onset:</u> <ul style="list-style-type: none"> <li>Variable; in adults, weeks to months after initiation of therapy</li> <li>Hypophosphatemia appears at a median of 18 months.</li> <li>Glucosuria may occur after a year of therapy.</li> <li>Abnormal urine protein/ osmolality ratio may be an early indicator.</li> </ul> <u>Presentation</u> <i>More Common:</i> <ul style="list-style-type: none"> <li>Increased serum creatinine, proteinuria, normoglycemic glucosuria. Hypophosphatemia, usually asymptomatic; may present with bone and muscle pain, weakness</li> </ul> <i>Less Common:</i> <ul style="list-style-type: none"> <li>Renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus with polyuria</li> </ul>	<u>Adults:</u> <ul style="list-style-type: none"> <li>Approximately 2% with increased serum creatinine</li> <li>Approximately 0.5% with severe renal complications</li> </ul> <u>Children:</u> <ul style="list-style-type: none"> <li>Approximately 4% with hypophosphatemia or proximal tubulopathy; frequency increases with prolonged TDF therapy, advanced HIV infection, or concomitant use of ddl.</li> </ul>	<u>Risk May Increase in Children with the Following Characteristics:</u> <ul style="list-style-type: none"> <li>Aged &gt;6 years</li> <li>Black race, Hispanic/ Latino ethnicity</li> <li>Advanced HIV infection</li> <li>Hypertension</li> <li>Diabetes</li> <li>Concurrent use of ddl or PIs (especially LPV/r), and preexisting renal dysfunction</li> <li>Risk increases with longer duration of TDF treatment.</li> </ul>	Monitor urine protein, glucose or urinalysis, and serum creatinine at 3- to 6-month intervals. For patients taking TDF, some panelists add serum phosphate to the list of routine labs to monitor.  <b>Measure serum phosphate if the patient experiences persistent proteinuria or glucosuria, or has symptoms of bone pain, muscle pain, or weakness.</b>  Because toxicity risk increases with duration of TDF treatment, do not decrease the frequency of monitoring over time.	If TDF is the likely cause, consider using alternative ARV. TAF has significantly less toxicity than TDF.  <b>ddl is no longer recommended and should be discontinued.</b>

**Table 15i. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects**  
 (Last updated May 22, 2018; last reviewed May 22, 2018) (page 2 of 2)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Elevation in Serum Creatinine</b>	DTG, COBI, RPV	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• Within a month of starting treatment</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Asymptomatic. These drugs decrease renal tubular secretion of creatinine, leading to an increase in measured serum creatinine without a true change in eGFR.</li> </ul>	<p>Common</p> <p>Need to distinguish between true change in eGFR and other causes. True change might be associated with other medical conditions, continuing rise of serum creatinine with time, and albuminuria.</p>	N/A	Monitor serum creatinine. Assess for renal dysfunction if serum creatinine increases by >0.4 mg/dL or if increases continue over time.	<p>No need to change therapy.</p> <p>Reassure patient about the benign nature of the laboratory abnormality.</p>

**Key to Acronyms:** ARV = antiretroviral; ATV = atazanavir; COBI = cobicistat; ddl = didanosine; DRV = darunavir; DTG = dolutegravir; eGFR = estimated glomerular filtration rate; FDA = Food and Drug Administration; IDV = indinavir; LPV/r = lopinavir/ritonavir; PI = protease inhibitor; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

## References

1. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. *Pediatr Infect Dis J.* 2009;28(7):619-625. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19561425>.
2. Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. *AIDS.* 2010;24(4):525-534. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20139752>.
3. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. *Arch Pediatr Adolesc Med.* 2009;163(2):164-171. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19188649>.
4. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. *Pediatr Infect Dis J.* 2009;28(3):204-209. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19209091>.
5. Soler-Palacin P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. *AIDS.* 2011;25(2):171-176. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21076275>.
6. van Rossum AM, Dieleman JP, Fraaij PL, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. *AIDS.* 2001;15(13):1745-1747. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11546957>.
7. van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. *Pediatrics.* 2002;110(2 Pt 1):e19. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12165618>.
8. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. *Am J Kid Dis.* 2011;57(5):773-780. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21435764>.

9. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. *Clin Infect Dis*. 2010;51(5):496-505. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20673002>.
10. Vigano A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. *Clin Drug Investig*. 2011;31(6):407-415. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21528939>.
11. Fraaij PL, Verweel G, van Rossum AM, Hartwig NG, Burger DM, de Groot R. Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment. *Infection*. 2007;35(3):186-189. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17565462>.
12. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. *Pediatr Infect Dis J*. 2013;32(5):495-500. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23249917>.
13. Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. *PLoS One*. 2013;8(10):e77268. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24130871>.
14. de Lastours V, Ferrari Rafael De Silva E, Daudon M, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. *J Antimicrob Chemother*. 2013;68(8):1850-1856. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23599359>.
15. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. *J Acquir Immune Defic Syndr*. 2012;61(1):32-40. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22732469>.
16. Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. *AIDS*. 2014;28(5):621-632. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24983540>.
17. Lim Y, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally-acquired HIV infection: a single-centre cohort study. *Clin Drug Investig*. 2015;35(5):327-333. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25861908>.
18. Samarawickrama A, Cai M, Smith ER, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. *HIV Med*. 2012;13(9):526-532. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22413854>.
19. Marcelin JR, Berg ML, Tan EM, Amer H, Cummins NW, Rizza SA. Is abnormal urine protein/osmolality ratio associated with abnormal renal function in patients receiving tenofovir disoproxil fumarate? *PLoS One*. 2016;11(2):e0149562. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26872144>.
20. Lin KY, Liao SH, Liu WC, et al. Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy. *PLoS One*. 2015;10(9):e0137660. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26360703>.
21. Bunupuradah T, Phupitakphol T, Sophonphan J, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected Thai adolescents. *Pediatr Infect Dis J*. 2017. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28719505>.
22. Purswani MU, Patel K, Winkler CA, et al. Brief Report: APOL1 Renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. *J Acquir Immune Defic Syndr*. 2016;73(1):63-68. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27035887>.
23. Soares DS, Cavalcante MG, Ribeiro SM, et al. Acute kidney injury in HIV-infected children: comparison of patients according to the use of highly active antiretroviral therapy. *Jornal de Pediatria*. 2016;92(6):631-637. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27542916>.

**Table 15j. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis** (Last updated May 22, 2018; last reviewed May 22, 2018)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Osteopenia and Osteoporosis</b>	Any ART regimen  <u>Specific Agents of Concern:</u> • TDF • PIs, especially LPV/r	<u>Onset:</u> • Any age; decrease in BMD usually seen soon after initiation of ART.  <u>Presentation:</u> • Usually asymptomatic • Rarely presents as osteoporosis, a clinical diagnosis defined by evidence of bone fragility (e.g., fracture with minimal trauma).	<u>BMD z Score Less Than -2.0:</u> • <10% in U.S. cohorts • Approximately 20% to 30% in international cohorts	Longer duration and greater severity of HIV disease  <b>Vitamin D insufficiency/deficiency</b>  Delayed growth or pubertal delay  Low BMI  Lipodystrophy  Non-black race  Smoking  Prolonged systemic corticosteroid use  Medroxyprogesterone use  Lack of weight-bearing exercise	<u>Prevention:</u> • Ensure sufficient calcium intake and vitamin D sufficiency. • Encourage weight-bearing exercise. • Minimize modifiable risk factors (e.g., smoking, low BMI, use of steroids or medroxyprogesterone).  • <b>Use TAF instead of TDF whenever possible.</b>  <u>Monitoring:</u> • Assess nutritional intake (calcium, vitamin D, and total calories). • <b>Strongly</b> consider measuring serum 25-OH-vitamin D levels, <b>particularly in those patients taking ARVs of concern.</b> <sup>a</sup> • Obtain a DXA. <sup>b</sup>	Same options as for prevention.  Consider changing the ARV regimen (e.g., <b>switching from TDF to TAF, and/or from LPV/r to EFV or an INSTI whenever possible</b> ).  <b>Treat with vitamin D3 to raise serum 25-OH-vitamin D concentrations to &gt;30 ng/mL.</b>  The role of bisphosphonates <b>in managing osteopenia and osteoporosis in children with HIV</b> has not been established.

<sup>a</sup> Some experts periodically measure 25-OH-vitamin D. This is especially important in youth with HIV infection who live in urban areas; the prevalence of vitamin D insufficiency is high in that population.

<sup>b</sup> Until more data are available about the long-term effects of TDF on bone mineral acquisition in childhood, some experts obtain a DXA at baseline and every 6 to 12 months for prepubertal children and for children in early puberty who are initiating treatment with TDF. Obtaining a DXA could also be considered for adolescent women on TDF and medroxyprogesterone and for children with indications not uniquely related to HIV infection (such as cerebral palsy).

**Key to Acronyms:** ART = antiretroviral therapy; ARV = antiretroviral; BMD = bone mineral density; BMI = body mass index; DXA = dual-energy x-ray absorptiometry; EFV = efavirenz; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; PI = protease inhibitor; TAF= tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

## References

### Osteopenia and Osteoporosis

- Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. *Pediatrics*. 2006;118(3):e711-718. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16923923>.
- Jacobson DL, Lindsey JC, Gordon CM, et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. *AIDS*. 2010;24(5):687-696. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20168204>.
- Jacobson DL, Spiegelman D, Duggan C, et al. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. *J Pediatr Gastroenterol Nutr*. 2005;41(3):339-346. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16131991>.
- Kalkwarf HJ, Zemel BS, Gilsanz V, et al. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. *J Clin*

- Endocrinol Metab.* 2007;92(6):2087-2099. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17311856>.
5. Lima LR, Silva RC, Giuliano Ide C, Sakuno T, Brincas SM, Carvalho AP. Bone mass in children and adolescents infected with human immunodeficiency virus. *Jornal de Pediatria.* 2013;89(1):91-99. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23544816>.
  6. Puthanakit T, Saksawad R, Bunupuradah T, et al. Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2012;61(4):477-483. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22918157>.
  7. Siberry GK, Li H, Jacobson D, Pediatric ACTGCS. Fracture risk by HIV infection status in perinatally HIV-exposed children. *AIDS Res Hum Retroviruses.* 2012;28(3):247-250. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22471877>.
  8. DiMeglio LA, Wang J, Siberry GK, et al. Bone mineral density in children and adolescents with perinatal HIV infection. *AIDS.* 2013;27(2):211-220. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23032412>.
  9. Bunders MJ, Frinking O, Scherpbier HJ, et al. Bone mineral density increases in HIV-infected children treated with long-term combination antiretroviral therapy. *Clin Infect Dis.* 2013;56(4):583-586. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23097583>.
  10. Huang JS, Hughes MD, Riddler SA, Haubrich RH, AIDS Clinical Trials Group AST. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. *HIV Clin Trials.* 2013;14(5):224-234. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24144899>.
  11. Puthanakit T, Siberry GK. Bone health in children and adolescents with perinatal HIV infection. *J Int AIDS Soc.* 2013;16:18575. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23782476>.
  12. Aupibul L, Cressey TR, Sricharoenchai S, et al. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. *Pediatr Infect Dis J.* 2015;34(4):392-397. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25760566>.
  13. Overton ET, Chan ES, Brown TT, et al. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. *Ann Intern Med.* 2015;162(12):815-824. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26075752>.
  14. Ross AC. The 2011 report on dietary reference intakes for calcium and vitamin D. *Public Health Nutr.* 2011;14(5):938-939. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21492489>.
  15. Mirani G, Williams PL, Chernoff M, et al. Changing trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy. *Clin Infect Dis.* 2015;61(12):1850-1861. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26270680>.
  16. Eckard AR, Mora S. Bone health in HIV-infected children and adolescents. *Curr Opin HIV AIDS.* 2016;11(3):294-300. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26890208>.
  17. Okonkwo RI, Weidmann AE, Effa EE. Renal and bone adverse effects of a tenofovir-based regimen in the treatment of HIV-infected children: A systematic review. *Drug Saf.* 2016;39(3):209-218. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26692394>.
  18. Palchetti CZ, Szejnfeld VL, de Menezes Succi RC, et al. Impaired bone mineral accrual in prepubertal HIV-infected children: a cohort study. *Braz J Infect Dis.* 2015;19(6):623-630. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26477385>.
  19. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. *Lancet Infect Dis.* 2016;16(1):43-52. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26538525>.
  20. Tebas P, Kumar P, Hicks C, et al. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naïve adults over 144 weeks. *AIDS.* 2015;29(18):2459-2464. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26355674>.
  21. Kizito H, Gaur A, Prasitsuebsai W, et al. Changes in renal laboratory parameters and bone mineral density in treatment-naïve HIV-1-infected adolescents

initiating therapy with INSTI-based single-tablet regimens containing tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF). Presented at: The 21st International AIDS Conference. 2016. Durban, South Africa.

22. Arpadi SM, Shiao S, Strehlau R, et al. Efavirenz is associated with higher bone mass in South African children with HIV. *AIDS*. 2016;30(16):2459-2467. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27427876>.
23. Havens P, Stephensen CB, Van Loan M, et al. High dose vitamin D3 increases spine bone density in HIV+ youth on tenofovir (TDF). Presented at: Conference on Retroviruses and Opportunistic Infections. 2017. Seattle, WA.
24. Eckard AR, O'Riordan MA, Rosebush JC, et al. Effects of Vitamin D supplementation on bone mineral density and bone markers in HIV-infected youth. *J Acquir Immune Defic Syndr*. 2017;76(5):539-546. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28902705>.
25. Bachrach LK, Gordon CM, Section On E. Bone densitometry in children and adolescents. *Pediatrics*. 2016;138(4). Available at <https://www.ncbi.nlm.nih.gov/pubmed/27669735>.

**Table 15k. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Peripheral Nervous System Toxicity (Last updated May 22, 2018; last reviewed May 22, 2018)**

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency <sup>a</sup>	Risk Factors	Prevention/Monitoring	Management
ARV Toxic Neuropathy <sup>b</sup>	d4T, ddl d4T or ddl are <b>no longer recommended</b> for use in an ARV regimen. PIs rarely, primarily IDV	<b>Onset:</b> • Weeks to months <b>Presentation:</b> • Decreased sensation • Aching, burning, painful numbness • Hyperalgesia • Allodynia • Decreased or absent ankle reflexes <b>Distribution:</b> • Bilateral soles of feet, ascending to legs and fingertips	<b>Children:</b> • Around 1% overall • 10% to 25% in children taking d4T <b>Adults:</b> • Up to 50% in adults taking d4T	<ul style="list-style-type: none"> <li>• Pre-existing neuropathy</li> <li>• Elevated triglyceride levels</li> <li>• Poor nutrition</li> <li>• More advanced HIV disease</li> <li>• Concomitant use of other neurotoxic agents (e.g., INH)</li> <li>• Some mitochondrial DNA haplogroups may have increased risk.</li> </ul>	<p>Do not use d4T, ddl, or IDV. Co-administration of ddl and d4T is <b>contraindicated (no exceptions)</b>.</p> <p>Monitor for symptoms and signs of peripheral neuropathy.</p>	<p>Investigate potential causes, including non-ARV medications and nutritional deficiencies.</p> <p>Discontinue offending agent.</p> <p>Topical capsaicin 8% may be helpful.</p> <p>Consider referral to a neurologist.</p> <p>Data are insufficient to allow the Panel to recommend use of any of the following modalities: tricyclic antidepressants, gabapentin, pregabalin, mexiletine, lamotrigine, and acupuncture or other complementary approaches.</p>

<sup>a</sup> Peripheral neuropathy may be underreported in children because symptoms are difficult to evaluate in young children.

<sup>b</sup> HIV infection itself may cause a distal sensory neuropathy that is phenotypically identical to ARV toxic neuropathy.

**Key to Acronyms:** ARV = antiretroviral; d4T = stavudine; ddl = didanosine; IDV = indinavir; INH = isoniazid; PI = protease inhibitor; the Panel = The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV

## References

1. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. *Arch Pediatr Adolesc Med.* 2009;163(2):164-171. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19188649>.
2. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1,434 Malawian children. *J Int AIDS Soc.* 2010;13:31. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20691049>.
3. Ances BM, Vaida F, Rosario D, et al. Role of metabolic syndrome components in HIV-associated sensory neuropathy. *AIDS.* 2009;23(17):2317-2322. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19823068>.
4. Banerjee S, McCutchan JA, Ances BM, et al. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. *AIDS.* 2011;25(2):F1-6. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21150557>.
5. Canter JA, Robbins GK, Selph D, et al. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. *J Infect Dis.* 2010;201(11):1703-1707. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20402593>.
6. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. *PLoS One.* 2010;5(12):e14433. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21203440>.

7. Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. *BMC Infect Dis*. 2011;11:244. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21923929>.
8. Wadley AL, Cherry CL, Price P, Kamerman PR. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. *Journal of Pain and Symptom Management*. 2011;41(4):700-706. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21145196>.
9. Tukei VJ, Asiimwe A, Maganda A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. *J Acquir Immune Defic Syndr*. 2012;59(3):274-280. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22126740>.
10. Webster LR, Peppin JF, Murphy FT, Tobias JK, Vanhove GF. Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. *Journal of Pain Research*. 2012;5:7-13. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22328830>.
11. Phan V, Thai S, Choun K, Lynen L, van Griensven J. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. *PLoS One*. 2012;7(1):e30647. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22303447>.
12. Palmer M, Chersich M, Moultrie H, Kuhn L, Fairlie L, Meyers T. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. *AIDS*. 2013;27(5):781-785. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23169331>.
13. Peters RP, Van Ramshorst MS, Struthers HE, McIntyre JA. Clinical assessment of peripheral neuropathy in HIV-infected children on antiretroviral therapy in rural South Africa. *Eur J Pediatr*. 2014;173(9):1245-1248. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24691679>.
14. Kaku M, Simpson DM. HIV neuropathy. *Curr Opin HIV AIDS*. 2014;9(6):521-526. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25275705>.
15. Sankhyan N, Lodha R, Sharma S, et al. Peripheral neuropathy in children on stavudine therapy. *Indian Journal of Pediatrics*. 2015;82(2):136-139. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24874810>.
16. Chen H, Clifford DB, Deng L, et al. Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. *J Neurovirol*. 2013;19(6):557-564. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24297499>.
17. Cherry CL, Wadley AL, Kamerman PR. Diagnosing and treating HIV-associated sensory neuropathy: a global perspective. *Pain Manag*. 2016;6(2):191-199. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26988147>.
18. Birbal S, Dheda M, Ojewole E, Oosthuizen F. Adverse drug reactions associated with antiretroviral therapy in South Africa. *Afr J AIDS Res*. 2016;15(3):243-248. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27681148>.
19. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. *Cochrane Database Syst Rev*. 2017;1:CD007393. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28085183>.
20. Centner CM, Little F, Van Der Watt JJ, et al. Evolution of sensory neuropathy after initiation of antiretroviral therapy. *Muscle Nerve*. 2017. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28561925>.
21. Smyth K, Affandi JS, McArthur JC, et al. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. *HIV Med*. 2007;8(6):367-373. Available at <https://www.ncbi.nlm.nih.gov/pubmed/17661844>.
22. Arenas-Pinto A, Thompson J, Musoro G, et al. Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial. *J Neurovirol*. 2016;22(1):104-113. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26323809>.
23. Aziz-Donnelly A, Harrison TB. Update of HIV-associated sensory neuropathies. *Curr Treat Options Neurol*. 2017;19(10):36. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28861848>.
24. Ellis RJ, Marquie-Beck J, Delaney P, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. *Ann Neurol*. 2008;64(5):566-572. Available at <https://www.ncbi.nlm.nih.gov/pubmed/19067367>.

**Table 15I. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions** (Last updated May 22, 2018; last reviewed May 22, 2018) (page 1 of 5)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
Rash	Any ARV can cause rash	<p><b>Onset:</b></p> <ul style="list-style-type: none"> <li>First few days to weeks after starting <b>new ARV(s)</b></li> </ul> <p><b>Presentation:</b></p> <ul style="list-style-type: none"> <li>Most rashes are mild-to-moderate, diffuse maculopapular eruptions</li> </ul> <p><b>Note:</b> A rash can be the initial manifestation of systemic hypersensitivity (see SJS/TEN/EM Major and HSR sections below).</p>	<p><b>Common (&gt;10% Adults and/or Children):</b></p> <ul style="list-style-type: none"> <li>NVP</li> <li>EFV</li> <li>ETR</li> <li>FPV</li> <li>FTC</li> </ul> <p><b>Less Common (5% to 10%):</b></p> <ul style="list-style-type: none"> <li>ABC</li> <li>DRV</li> <li>TPV</li> <li>TDF</li> </ul> <p><b>Unusual (2% to 4%):</b></p> <ul style="list-style-type: none"> <li>LPV/r</li> <li>RAL</li> <li>MVC</li> <li>RPV</li> </ul>	<ul style="list-style-type: none"> <li>Sulfonamide allergy is a risk factor for rash with PIs containing a sulfonamide moiety (FPV, DRV, and TPV)</li> <li>Polymorphisms in CYP2B6 and multiple HLA loci may confer increased risk of rash with NVP</li> </ul>	<p><b>When Starting NVP or Restarting After Interruptions &gt;14 Days:</b></p> <ul style="list-style-type: none"> <li>Utilize once-daily lead-in dosing (<a href="#">see NVP section</a>).<sup>a</sup></li> <li>Avoid the use of systemic corticosteroids during NVP dose escalation.</li> <li>Assess patient for rash severity, mucosal involvement, and other signs of systemic reaction.</li> </ul>	<p><b>Mild-to-Moderate Maculopapular Rash Without Systemic or Mucosal Involvement:</b></p> <ul style="list-style-type: none"> <li>Most rashes will resolve without intervention; ARVs can be continued while monitoring.<sup>a</sup></li> <li>Antihistamines may provide some relief.</li> </ul> <p><b>Severe Rash (e.g., Blisters, Bullae, Ulcers, Skin Necrosis) and/or Rash Accompanied by Systemic Symptoms (e.g., Fever, Arthralgia, Edema) and/or Rash Accompanied by Mucous Membrane Involvement (e.g., conjunctivitis):</b></p> <ul style="list-style-type: none"> <li>Manage as SJS/TEN/EM major (see below)</li> </ul> <p><b>Rash in Patients Receiving NVP:</b></p> <ul style="list-style-type: none"> <li>Given elevated risk of HSR, measure hepatic transaminases.</li> <li>If hepatic transaminases are elevated, NVP should be discontinued and not restarted (see HSR-NVP below).</li> </ul>
	T-20	<p><b>Onset:</b></p> <ul style="list-style-type: none"> <li>First few days to weeks after starting <b>new ARV(s)</b></li> </ul> <p><b>Presentation:</b></p> <ul style="list-style-type: none"> <li>Local injection site reactions with pain, erythema, induration, nodules and cysts, pruritus, and ecchymosis</li> <li>Often multiple reactions at the same time</li> </ul>	<p><b>Children and Adults:</b></p> <ul style="list-style-type: none"> <li>&gt;90%</li> </ul>	Unknown	<ul style="list-style-type: none"> <li>Routinely assess patient for local reactions.</li> <li>Rotate injection sites.</li> <li>Massage area after injection.</li> </ul>	<ul style="list-style-type: none"> <li>Continue the agent as tolerated by the patient.</li> <li>Ensure patient is injecting as per instructions.</li> <li>Rotate injection sites.</li> </ul>

**Table 15I. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions** (Last updated May 22, 2018; last reviewed May 22, 2018) (page 2 of 5)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>SJS/TEN/EM Major</b>	Many ARVs, especially NNRTIs (see Estimated Frequency column)	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• First few days to weeks <b>after starting new ARV(s)</b></li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Initial rash may be mild, but often becomes painful, evolving to blister/bulla formation with necrosis in severe cases. Usually involves mucous membrane ulceration and/or conjunctivitis. Systemic symptoms may also include fever, tachycardia, malaise, myalgia, and arthralgia.</li> </ul>	<p><u>Infrequent:</u></p> <ul style="list-style-type: none"> <li>• NVP (0.3%)</li> <li>• EFV (0.1%)</li> <li>• ETR (&lt;0.1%)</li> </ul> <p><u>Case Reports:</u></p> <ul style="list-style-type: none"> <li>• FPV</li> <li>• ABC</li> <li>• DRV</li> <li>• ZDV</li> <li>• ddi</li> <li>• IDV</li> <li>• LPV/r</li> <li>• ATV</li> <li>• RAL</li> </ul>	<p><u>Adults:</u></p> <ul style="list-style-type: none"> <li>• Female gender</li> <li>• Race/ethnicity (black, Asian, Hispanic)</li> </ul>	<p><u>When Starting NVP or Restarting After Interruptions &gt;14 Days:</u></p> <ul style="list-style-type: none"> <li>• Utilize once-daily lead-in dosing (see NVP section).<sup>a</sup></li> <li>• Counsel families to report symptoms as soon as they appear.</li> </ul>	<ul style="list-style-type: none"> <li>• Discontinue all ARVs and other possible causative agents (e.g., TMP-SMX).</li> <li>• Provide intensive supportive care, IV hydration, aggressive wound care, pain management, antipyretics, parenteral nutrition, and antibiotics as needed in case of superinfection.</li> <li>• Corticosteroids and/or IVIG are sometimes used, but use of each is controversial.</li> <li>• Do not reintroduce the offending medication.</li> <li>• In case of SJS/TEN/EM major occurring with 1 NNRTI, many experts would avoid use of other NNRTIs.</li> </ul>
<b>DRESS</b>	EFV, ETR, NVP, RAL, RPV, DRV	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• 1–8 weeks <b>after starting new ARV(s)</b></li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Fever</li> <li>• Lymphadenopathy</li> <li>• Facial swelling</li> <li>• Morbilliform to polymorphous rash</li> <li>• Peripheral eosinophilia</li> <li>• Atypical circulating lymphocytes</li> <li>• Internal organ involvement (particularly liver and/or renal)</li> </ul>	Rare	Unknown	<ul style="list-style-type: none"> <li>• Obtain CBC, AST, ALT, and creatinine from a patient presenting with suggestive symptoms.</li> </ul>	<ul style="list-style-type: none"> <li>• Discontinue all ARVs and other possible causative agents (e.g., TMP-SMX).</li> <li>• Role for steroids unclear; suggest consultation with specialist.</li> <li>• Provide supportive care for end-organ disease.</li> <li>• Do not reintroduce the offending medication.</li> </ul>

**Table 15I. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions** (Last updated May 22, 2018; last reviewed May 22, 2018) (page 3 of 5)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<p><b>HSR</b></p> <p>With or without skin involvement and excluding SJS/TEN</p>	ABC	<p><u>Onset</u></p> <p><i>With First Use:</i></p> <ul style="list-style-type: none"> <li>• Within first 6 weeks</li> </ul> <p><i>With Reintroduction:</i></p> <ul style="list-style-type: none"> <li>• Within hours</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Symptoms include high fever, diffuse skin rash, malaise, nausea, headache, myalgia, arthralgia, diarrhea, vomiting, abdominal pain, pharyngitis, and respiratory symptoms (e.g., dyspnea).</li> <li>• Symptoms worsen to include hypotension and vascular collapse with continuation of ABC. With rechallenge, symptoms can mimic anaphylaxis.</li> </ul>	2.3% to 9% (varies by ethnicity).	<ul style="list-style-type: none"> <li>• HLA-B*5701 (HSR very uncommon in people who are HLA-B*5701-negative); combination of HLA-DR7 plus HLA-DQ3 also confers risk.</li> <li>• HSR risk is higher in those of white race compared to those of black or East Asian race.</li> </ul>	<ul style="list-style-type: none"> <li>• Screen for HLA-B*5701. <b>ABC should not be prescribed if HLA-B*5701 is present.</b> The medical record should clearly indicate that ABC is <b>contraindicated.</b></li> <li>• When starting ABC, counsel patients and families about the signs and symptoms of HSR to ensure prompt reporting of reactions.</li> </ul>	<ul style="list-style-type: none"> <li>• Discontinue ARVs and investigate for other causes of the symptoms (e.g., a concurrent viral illness).</li> <li>• Treat symptoms as necessary.</li> <li>• Most symptoms resolve within 48 hours after discontinuation of ABC.</li> <li>• Do not rechallenge with ABC even if the patient is HLA-B*5701-negative.</li> </ul>

**Table 15I. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions** (Last updated May 22, 2018; last reviewed May 22, 2018) (page 4 of 5)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
HSR  With or without skin involvement and excluding SJS/TEN	NVP	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• Most frequent in the first few weeks of therapy, but can occur through 18 weeks</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Flu-like symptoms (including nausea, vomiting, myalgia, fatigue, fever, abdominal pain, and jaundice) with or without skin rash that may progress to hepatic failure with encephalopathy</li> </ul>	4% (2.5% to 11%)	<p><u>Adults:</u></p> <ul style="list-style-type: none"> <li>• Treatment-naïve with higher CD4 count (&gt;250 cells/mm<sup>3</sup> in women; &gt;400 cells/mm<sup>3</sup> in men).</li> <li>• Female sex (risk is 3-fold higher in females compared with males).</li> </ul> <p><u>Children:</u></p> <ul style="list-style-type: none"> <li>• NVP hepatotoxicity and HSR are less common in pre-pubertal children than in adults and uncommon in infants.</li> <li>• High CD4 percentage is associated with increased risk of NVP toxicity. In the PREDICT study, the risk of NVP toxicity (rash, hepatotoxicity, hypersensitivity) was 2.65 times greater in children who had CD4 percentages ≥15% than in children who had CD4 percentages &lt;15%.</li> </ul>	<p><u>When Starting NVP or Restarting After Interruptions &gt;14 Days:</u></p> <ul style="list-style-type: none"> <li>• A 2-week lead-in period with once-daily dosing, followed by dose escalation to twice daily as recommended, may reduce the risk of reaction.<sup>a</sup></li> <li>• Counsel families about signs and symptoms of HSR to ensure prompt reporting of reactions.</li> <li>• Obtain AST and ALT in patients with rash. Obtain AST and ALT at baseline, before dose escalation, 2 weeks post-dose escalation, and thereafter at 3-month intervals.</li> <li>• Avoid NVP use in women with CD4 counts &gt;250 cells/mm<sup>3</sup> and in men with CD4 counts &gt;400 cells/mm<sup>3</sup> unless benefits outweigh risks.</li> <li>• Do not use NVP as post-exposure prophylaxis outside of the neonatal period.</li> </ul>	<ul style="list-style-type: none"> <li>• Discontinue ARVs.</li> <li>• Consider other causes for hepatitis and discontinue all hepatotoxic medications.</li> <li>• Provide supportive care as indicated and monitor the patient closely.</li> <li>• Do not re-introduce NVP. The safety of other NNRTIs is unknown following symptomatic hepatitis due to NVP, and many experts would avoid the NNRTI drug class when restarting treatment.</li> </ul>
	T-20, ETR	<p><u>Onset:</u></p> <ul style="list-style-type: none"> <li>• Any time during therapy</li> </ul> <p><u>Presentation:</u></p> <ul style="list-style-type: none"> <li>• Symptoms may include rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.</li> </ul>	Rare	Unknown	<ul style="list-style-type: none"> <li>• Evaluate for hypersensitivity if the patient is symptomatic.</li> </ul>	<p>Discontinue ARVs.</p> <p>Rechallenge with T-20 or ETR is not recommended.</p>

**Table 15I. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions** (Last updated May 22, 2018; last reviewed May 22, 2018) (page 5 of 5)

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
HSR  With or without skin involvement and excluding SJS/TEN	MVC	Rash preceding hepatotoxicity	Rare	Unknown	<ul style="list-style-type: none"> <li>Obtain AST and ALT in patients with rash or other symptoms of hypersensitivity.</li> </ul>	<ul style="list-style-type: none"> <li>Discontinue all ARVs.</li> <li>Rechallenge with MVC is not recommended.</li> </ul>
	DTG	Rash with hepatic dysfunction	Rare	Unknown	<ul style="list-style-type: none"> <li>Obtain AST and ALT in patients with rash or other symptoms of hypersensitivity.</li> </ul>	<ul style="list-style-type: none"> <li>Discontinue all ARVs.</li> <li>Rechallenge with DTG is contraindicated</li> </ul>

<sup>a</sup> The prescribing information for NVP states that patients experiencing rash during the 14-day lead-in period should not have the NVP dose increased until the rash has resolved. However, prolonging the lead-in phase beyond 14 days may increase risk of NVP resistance because of sub-therapeutic drug levels. Management of children who have persistent mild or moderate rash after the lead-in period should be individualized and an expert in HIV care should be consulted. **NVP should be stopped and not restarted** if the rash is severe or is worsening or progressing.

**Key to Acronyms:** ABC = abacavir; ALT = alanine transaminase; ARV = antiretroviral; AST = aspartate aminotransferase; ATV = atazanavir; CBC = complete blood count; CD4 = CD4 T lymphocyte; CYP = cytochrome P; ddl = didanosine; DRESS = drug rash with eosinophilia and systemic symptoms; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; EM = erythema multiforme; ETR = etravirine; FPV = fosamprenavir; FTC = emtricitabine; HLA = human leukocyte antigen; HSR = hypersensitivity reaction; IDV = indinavir; IV = intravenous; IVIG = intravenous immune globulin; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PEP = post-exposure prophylaxis; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; SJS = Stevens-Johnson syndrome; T-20 = enfuvirtide TDF = tenofovir disoproxil fumarate; TEN = toxic epidermal necrolysis; TPV = tipranavir; ZDV = zidovudine

## References

- Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. *J Antimicrob Chemother.* 2008;62(5):879-888. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18653488>.
- Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. *J Allergy Clin Immunol.* 2008;121(4):826-832 e825. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18190954>.
- Kea C, Puthanakit T, Apornpong T, et al. Incidence and risk factors for nevirapine related toxicities among HIV-infected Asian children randomized to starting ART at different CD4%. Abstract MOPE240. Presented at: 6th International AIDS Society Conference on HIV Pathogenesis and Treatment and Prevention. 2011. Rome, Italy.
- Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B\*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *Lancet.* 2002;359(9308):727-732. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11888582>.
- Mallal S, Phillips E, Carosi G, et al. HLA-B\*5701 screening for hypersensitivity to abacavir. *N Engl J Med.* 2008;358(6):568-579. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18256392>.
- Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. *Clinical Pharmacokinetics.* 2000;39(4):281-293. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11069214>.
- Puthanakit T, Bunupuradah T, Kosalaraksa P, et al. Prevalence of human leukocyte antigen-B\*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use. *Pediatr Infect Dis J.* 2013;32(3):252-253. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22986704>.

8. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. *J Acquir Immune Defic Syndr*. 2003;34 Suppl 1(Suppl 1):S21-33. Available at <http://www.ncbi.nlm.nih.gov/pubmed/14562855>.
9. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. *AIDS*. 2013;27(9):1403-1412. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23343913>.
10. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. *Dermatology*. 2003;206(4):353-356. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12771485>.
11. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. *J Acquir Immune Defic Syndr*. 2005;40(4):413-421. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16280695>.
12. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1\*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. *AIDS*. 2008;22(4):540-541. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18301070>.
13. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. *AIDS*. 2011;25(10):1271-1280. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21505298>.
14. Dziuban EJ, Hughey AB, Stewart DA, et al. Stevens-Johnson syndrome and HIV in children in Swaziland. *Pediatr Infect Dis J*. 2013;32(12):1354-1358. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23743542>.
15. Rutstein RM, Samson P, Fenton T, with the PACTG 1020A Study Team. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A. *Pediatr Infect Dis J*. 2015;34:162-167.
16. Perry ME, Almaani N, Desai N, Larbaestier N, Fox J, Chilton D. Raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome—implications for clinical practice and patient safety. *Int J STD AIDS*. 2013;24(8):639-642. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23970584>.
17. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. *Clin Infect Dis*. 1998;27(5):1321-1322. Available at <http://www.ncbi.nlm.nih.gov/pubmed/9827291>.
18. Ripamonti D, Benatti SV, Di Filippo E, Ravasio V, Rizzi M. Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature. *AIDS*. 2014;28(7):1077-1079. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24685746>.
19. Noguera-Morel L, Hernandez-Martin A, Torreló A. Cutaneous drug reactions in the pediatric population. *Pediatric Clinics of North America*. 2014;61(2):403-426. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24636653>.
20. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. *Clin Infect Dis*. 2000;30(1):227-228. Available at <http://www.ncbi.nlm.nih.gov/pubmed/10619772>.
21. Darunavir [package insert]. Food and Drug Administration. 2015. Available at [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/021976s036,202895s013lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021976s036,202895s013lbl.pdf). Accessed January 13, 2017.
22. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Complera) [package insert]. Food and Drug Administration. 2015. Available at [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/021976s036,202895s013lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021976s036,202895s013lbl.pdf). Accessed January 20, 2017.
23. Dolutegravir [package insert]. Food and Drug Administration. 2015. Available at [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/204790s005lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204790s005lbl.pdf). Accessed January 20, 2017.

**Table 16. Examples of Changes in Antiretroviral Regimen Components that Are Made for Reasons of Simplification, Convenience, and Safety Profile in Children Who Have Sustained Virologic Suppression on Their Current Regimen (page 1 of 2)**

**Note:** This list is not exhaustive and does not necessarily contain all potential treatment options. Instead, it shows examples of what kinds of changes can be made. The comments provided in the table are relevant only to the potential ARV change are listed and do not include all relevant information. Please refer to the individual drug sections in [Appendix A: Pediatric Antiretroviral Drug Information](#) for further information.

Current ARV Drug(s)	Age, Weight, and SMR Requirements	Potential ARV Switch	Comment
<b>NRTIs</b>			
ABC or 3TC Twice Daily	Aged ≥1 year	ABC once daily	See <a href="#">Abacavir<sup>a</sup></a> and <a href="#">Lamivudine</a> sections in <a href="#">Appendix A: Pediatric Antiretroviral Drug Information</a> for full discussion of <b>once-daily dosing</b> .
	Aged ≥3 years	3TC once daily	
ZDV, ddl, or d4T <sup>b</sup>	Aged ≥3 months	ABC	<b>Less long-term mitochondrial toxicity.</b> Children aged ≥1 year can take ABC once daily (see <a href="#">Abacavir<sup>a</sup></a> in <a href="#">Appendix A: Pediatric Antiretroviral Drug Information</a> ).
	Aged ≥2 years	TDF	TDF is a reasonable, once-daily option for HLA-B*5701–positive children who are unable to take ABC. TDF is available <b>in low-strength combination tablets with FTC for use in children weighing ≥17 kg</b> . TAF is preferred for children weighing ≥25 kg.
	Weighing ≥25 kg	TAF <sup>c</sup>	<b>Less long-term mitochondrial toxicity. Once-daily dosing. Co-formulation with other ARV drugs can further reduce pill burden. TAF preferred over TDF for lower bone and renal toxicity. See <a href="#">TAF</a> in <a href="#">Appendix A: Pediatric Antiretroviral Drug Information</a> for full discussion.</b>
<b>NNRTIs</b>			
EFV	N/A	RAL <sup>d</sup>	None
	Aged ≥3 months Weighing ≥5 kg	ATV/r	None
	Aged ≥3 years Weighing ≥10 kg	DRV/r	DRV/r may be administered once daily in children aged ≥12 years who do not have DRV resistance mutations.
	Weighing ≥25 kg	EVG as Genvoya	<b>EVG is available as a component of the FDC EVG/COBI/FTC/TAF (Genvoya). Genvoya is a complete ARV regimen.</b>
	Weighing ≥30 kg	DTG	Smaller pill, higher barrier to resistance given concern for adherence challenges developing in adolescents.
	Aged ≥ 12 years Weighing ≥35 kg	RPV	None
<b>PIs</b>			
LPV/r Twice Daily	N/A	RAL <sup>d</sup>	None
	Aged ≥3 years Weighing ≥10 kg	EFV	Once-daily dosing. Better palatability. Lower incidence of adverse lipid effects. See <a href="#">Efavirenz</a> in <a href="#">Appendix A: Pediatric Antiretroviral Drug Information</a> regarding concerns about dosing for children aged <3 years.
	Aged ≥3 months Weighing ≥5 kg	ATV/r	Once-daily dosing.
	Aged ≥3 years Weighing ≥10 kg	DRV/r	<b>DRV/r is administered twice daily to patients aged &lt;12 years, but may be administered once daily only in children aged ≥12 years who do not have DRV resistance mutations.</b>
	Weighing ≥25 kg	EVG as Genvoya	<b>EVG is available as a component of the FDC EVG/COBI/FTC/TAF (Genvoya). Genvoya is a complete ARV regimen.</b>

**Table 16. Examples of Changes in Antiretroviral Regimen Components that Are Made for Reasons of Simplification, Convenience, and Safety Profile in Children Who Have Sustained Virologic Suppression on Their Current Regimen (page 2 of 2)**

Current ARV Drug(s)	Age, Weight, and SMR Requirements	Potential ARV Switch	Comment
LPV/r  Twice Daily, continued	Weighing ≥30 kg	DTG	None
	Aged ≥12 years Weighing ≥35 kg	RPV <b>BIC as Biktarvy</b>	None <b>Once-daily dosing. BIC is available as a component of the FDC BIC/FTC/TAF (Biktarvy). Biktarvy is a complete ARV regimen; pediatric use is investigational.</b>
<b>Other</b>			
<b>Any Multi-Pill and/or Twice-Daily Regimen</b>	Weighing ≥25 kg	EVG/COBI/FTC/TAF (Genvoya)	Once-daily dosing. Single pill. Alignment with adult regimens.
	<b>Weighing ≥30 kg</b>	FTC/TAF <sup>b</sup> (Descovy) plus DTG	Once-daily dosing. May be more desirable because of small pill sizes, even though it increases pill burden to 2 pills instead of 1.
	<b>Weighing ≥35 kg SMR 4 or 5</b>	EVG/COBI/FTC/TDF (Stribild)	Once-daily dosing. Single pill. Alignment with adult regimens.
	<b>Aged ≥12 years Weighing ≥35 kg</b>	FTC/RPV/TAF (Odefsey)	Once-daily dosing. Single pill. Alignment with adult regimens.
	<b>Aged ≥12 years Weighing ≥35 kg</b>	<b>BIC/FTC/TAF<sup>e</sup> (Biktarvy)</b>	<b>Once-daily dosing. Single pill. Pediatric use is investigational.</b>
	<b>Aged ≥12 years Weighing ≥35 kg SMR 4 or 5</b>	FTC/RPV/TDF (Complera)	Once-daily dosing. Single pill. Alignment with adult regimens.
	<b>Weighing ≥40 kg</b>	ABC/DTG/3TC (Triumeq)	Once-daily dosing. Single pill. Alignment with adult regimens. <b>Large pill size may be a deterrent.</b>
	<b>Weighing ≥40 kg SMR 4 or 5</b>	EFV/FTC/TDF (Atripla)	Once-daily dosing. Single pill. Alignment with adult regimens.

<sup>a</sup> For infants and young children being treated with liquid formulations of ABC, initiation with once-daily ABC is not generally recommended. In clinically stable patients with undetectable viral loads who have had stable CD4 T lymphocyte cell counts for more than 6 months (24 weeks) on twice-daily ABC, the dose can be changed from twice daily to once daily.

<sup>b</sup> d4T and ddl should be replaced with a safer drug **as soon as possible** because of concerns about long-term adverse events (see [Stavudine and Didanosine](#) in [Appendix A: Pediatric Antiretroviral Drug Information](#)).

<sup>c</sup> For children and adolescents weighing 25 kg to <35 kg, TAF can be used in combination with an INSTI or an NNRTI, but not a boosted PI. For children and adolescents weighing ≥35 kg, TAF can be used in combination with an INSTI, NNRTI, or a boosted PI.

<sup>d</sup> RAL HD once daily is only recommended for virologically suppressed children weighing ≥50 kg.

<sup>e</sup> Biktarvy has not been FDA-approved for use in patients aged <18 years but is being studied in children and adolescents aged ≥12 years to 18 years and weighing ≥35 kg.

**Key to Acronyms:** 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV/r = atazanavir/ritonavir; **BIC = bictegravir**, COBI = cobicistat; d4T = stavudine; ddl = didanosine; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FDA = Food and Drug Administration; **FDC = fixed-dose combination**; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; SMR = sexual maturity rating (previously Tanner stages); TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TFV= tenofovir; ZDV = zidovudine

**Table 17. Discordance Among Virologic, Immunologic, and Clinical Responses**

<b>Differential Diagnosis of Poor Immunologic Response Despite Virologic Suppression</b>
<p>Poor Immunologic Response Despite Virologic Suppression and Good Clinical Response:</p> <ul style="list-style-type: none"> <li>• Lab error (in CD4 or viral load result)</li> <li>• Misinterpretation of normal, age-related CD4 decline (i.e., the immunologic response is not actually poor)</li> <li>• Low pretreatment CD4 cell count or percentage</li> <li>• Adverse effects of using ZDV or the combination of TDF and ddl</li> <li>• Use of systemic corticosteroids or chemotherapeutic agents</li> <li>• Conditions that can cause low CD4 values, such as HCV, acute viral infections, TB, malnutrition, Sjogren's syndrome, sarcoidosis, and syphilis</li> </ul> <p>Poor Immunologic and Clinical Responses Despite Virologic Suppression:</p> <ul style="list-style-type: none"> <li>• Lab error</li> <li>• Falsely low viral load result for an HIV strain/type that is not detected by viral load assay (HIV-1 non-M groups, non-B subtypes; HIV-2)</li> <li>• Persistent immunodeficiency soon after initiation of ART but before ART-related reconstitution</li> <li>• Primary protein-calorie malnutrition</li> <li>• Untreated TB</li> <li>• Malignancy</li> </ul>
<b>Differential Diagnosis of Poor Clinical Response Despite Adequate Virologic and Immunologic Responses</b>
<ul style="list-style-type: none"> <li>• IRIS</li> <li>• Previously unrecognized, pre-existing infection or condition (e.g., TB, malignancy)</li> <li>• Malnutrition</li> <li>• Clinical manifestations of previous organ damage: brain (e.g., strokes, vasculopathy), lungs (e.g., bronchiectasis)</li> <li>• New clinical event due to non-HIV illness or condition</li> <li>• New, otherwise unexplained HIV-related clinical event (treatment failure)</li> </ul>

**Key to Acronyms:** ART = antiretroviral therapy; CD4 = CD4 T lymphocyte; ddl = didanosine; HCV = hepatitis C virus; IRIS = immune reconstitution inflammatory syndrome; TB = tuberculosis; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

**Table 18. Options for Regimens with at Least Two Fully Active Agents with Goal of Virologic Suppression in Patients with Failed Antiretroviral Therapy and Evidence of Viral Resistance<sup>a</sup>**

Prior Regimen	New Regimen Options <sup>a</sup>
2 NRTIs plus NNRTI	<ul style="list-style-type: none"> <li>• 2 NRTIs plus PI</li> <li>• 2 NRTIs plus INSTI</li> </ul>
2 NRTIs plus PI	<ul style="list-style-type: none"> <li>• 2 NRTIs plus INSTI</li> <li>• 2 NRTIs plus a different RTV-boosted PI</li> <li>• INSTI plus different RTV-boosted PI plus or minus an NNRTI and plus or minus NRTI(s)</li> </ul>
2 NRTIs plus INSTI	<ul style="list-style-type: none"> <li>• 2 NRTIs plus RTV-boosted PI</li> <li>• DTG (if not used in the prior regimen) plus RTV-boosted PI plus or minus 1 or 2 NRTIs</li> </ul>
<b>Failed Regimen(s) That Included NRTI(s), NNRTI(s), and PI(s)</b>	<ul style="list-style-type: none"> <li>• INSTI plus 2 NRTIs (if NRTIs are fully active)</li> <li>• INSTI plus 2 NRTIs plus or minus RTV-boosted PI (if NRTIs are not fully active)</li> <li>• INSTI plus or minus RTV-boosted PI plus or minus (ETR or RPV) plus or minus NRTI(s) (if minimal NRTI activity). Consider adding T-20 and/or MVC if additional active drug[s] needed.</li> </ul>

<sup>a</sup> ART regimens should be chosen based on treatment history and drug-resistance testing to optimize ARV drug effectiveness. This is particularly important in selecting NRTI components of an NNRTI-based regimen, where drug resistance to the NNRTI can occur rapidly if the virus is not sufficiently sensitive to the NRTIs. Regimens should contain at least two, but preferably three, fully active drugs for durable and potent virologic suppression. **Please see individual drug profiles for information about age limitations (e.g., do not use DRV in children aged <3 years), drug interactions, and dose adjustments when devising a regimen for children with multiclass drug resistance.** Collaboration with a pediatric HIV specialist is especially important when choosing regimens for children with multiclass drug resistance. Regimens in this table are provided as examples, but the list is not exhaustive.

**Key to Acronyms:** DTG = dolutegravir; ETR = etravirine; INSTI = integrase strand transfer inhibitor; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RPV = rilpivirine; RTV = ritonavir; T-20 = enfuvirtide

## Appendix A: Pediatric Antiretroviral Drug Information

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets<sup>a</sup>

Brand Name by Class	NRTIs						NNRTIs		INSTIs			PIs			PK Enhancers	
	ABC	3TC	ZDV	FTC	TDF	TAF <sup>b</sup>	EFV	RPV	BIC <sup>b</sup>	DTG	EVG <sup>b</sup>	ATV	DRV	LPV <sup>c</sup>	COBI	RTV
<b>NRTI</b>																
Cimduo		X			X											
Combivir, Generic		X	X													
Descovy				X		X										
Epzicom, Generic	X	X														
Temixys		X			X											
Trizivir, Generic	X	X	X													
Truvada				X	X											
<b>NRTI/NNRTI</b>																
Atripla				X	X		X									
Complera				X	X			X								
Odefsey				X		X		X								
Symfi or Symfi Lo		X			X		X									
<b>NRTI/INSTI</b>																
Biktarvy				X		X			X							
Triumeq	X	X								X						
<b>NNRTI/INSTI</b>																
Juluca								X		X						
<b>NRTI/INSTI/COBI</b>																
Genvoya				X		X					X				X	
Stribild				X	X						X				X	
<b>NRTI/PI/COBI</b>																
Symtuza				X		X							X		X	
<b>PI/COBI</b>																
Evotaz												X			X	
Prezcobix													X		X	
<b>PI/RTV</b>																
Kaletra														X		X

## Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets<sup>a</sup>

<sup>a</sup> This table may include recently approved FDCs that have not yet been added to individual drug sections in the [Pediatric Antiretroviral Drug Information Appendix](#) (see individual drug components for details), and it does not include FDCs for individual component drugs that were recently approved and have not been added to the Pediatric Antiretroviral Drug Appendix (e.g., Doravirine and the FDC Delstrigo).

<sup>b</sup> TAF, BIC, and EVG are only available in FDC tablets. However, TAF 25 mg tablets (Vemlidy) are FDA-approved for treatment of HBV. In select circumstances, TAF might be used as one component of a combination ARV regimen, with dosing recommendations similar to those for Descovy.

<sup>c</sup> LPV is only available in fixed-dose tablets or solution.

**Key to Acronyms:** 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV = atazanavir; BIC = bictegravir; COBI = cobicistat; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FDA = Food and Drug Administration; FDC = fixed-dose combination; FTC = emtricitabine; HBV = hepatitis B virus; LPV = lopinavir; LPV/r = lopinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside and nucleotide reverse transcriptase inhibitor; PI = protease inhibitor; PK = pharmacokinetic; RPV = rilpivirine; RTV = ritonavir; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

## Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents (page 1 of 3)

This table may include recently approved FDCs that have not yet been added to individual drug sections in the [Pediatric Antiretroviral Drug Information Appendix](#) (see individual drug components for details), and it does not include FDCs for individual component drugs that were recently approved and have not been added to the Pediatric Antiretroviral Drug Appendix (e.g., Doravirine and the FDC Delstrigo).

### General Considerations When Considering a Fixed-Dose Combination Tablet:

- ABC and TAF are favored over ZDV because of lower risk of NRTI-associated mitochondrial toxicity.
- TDF is more potent than ABC at high viral loads when used in regimens that do not contain an INSTI.
- TAF is favored over TDF because of the lower risk of TDF-associated bone and renal toxicity.
- TDF is generally **not recommended** for children with SMR 1–3 because of TDF-associated bone toxicity; however, for a child weighing <25 kg who can swallow pills, Truvada low-strength tablets offer a reasonable, once daily combination alternative to twice daily ZDV plus 3TC or an alternative to ABC.
- RPV has low potency at high viral loads, a low barrier to resistance, and requires a high fat meal for optimal absorption, so EFV or an INSTI are favored.
- BIC and DTG, second-generation INSTIs, have a higher barrier to resistance than EVG, a first-generation INSTI.
- INSTI FDC dosing for children and adolescents:
  - 25 kg: Genvoya
  - 30 kg: Descovy plus DTG (2 pills, but each is small); there is no agreed-upon DTG dose yet below 30 kg
  - Recent data identified a possible increased risk of NTDs among women who were receiving DTG at the time of conception. Specific recommendations about the initiation and use of DTG in adolescents and women of childbearing potential and in pregnant women are available in the Adult and Adolescent Antiretroviral Guidelines (See [Table 6b](#) and [Adolescents and Young Adults with HIV](#)) and in the Perinatal Guidelines (see [Teratogenicity](#) and [Recommendations for the Use of Antiretroviral Drugs in Pregnancy](#)).
  - Biktarvy has been studied in youth aged  $\geq 6$  years and weighing  $\geq 25$  kg but is not FDA approved for use in children or adolescents.
  - For images of most of the FDCs listed in this table, see the Antiretroviral Medications section of the [National HIV curriculum](#). In addition, [a resource from the United Kingdom](#) illustrates the relative sizes of FDCs (see the “Intro ARV chart”). Although most of the drugs listed in the chart are the same as those in the United States, a few of the brand names are not the same as those listed in Appendix A, Table 2 below.

**Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents (page 2 of 3)**

<b>FDC by Class</b> Brand name and generic products, when available	<b>FDC Components</b>	<b>Minimum Body Weight (kg) or Age</b>	<b>Pill Size (mm x mm)</b>	<b>Food Required for Optimal Absorption</b>
<b>NRTI</b>				
Cimduo	3TC 300 mg plus TDF 300 mg	35 kg	N/A	No
Combivir and Generic 3TC/ZDV	3TC 150 mg plus ZDV 300 mg (scored tablet)	30 kg	18 x 7	No
Descovy	FTC 200 mg plus TAF 25 mg	25 kg: With INSTI or NNRTI 35 kg: With boosted PI	12.5 x 6.4	No
Epzicom and Generic ABC/3TC	ABC 600 mg plus 3TC 300 mg	25 kg	21 x 9	No
Temixys	3TC 300 mg plus TDF 300 mg	35 kg	N/A	No
Trizivir and Generic ABC/3TC/ZDV	ABC 300 mg plus 3TC 150 mg plus ZDV 300 mg	40 kg	21 x 10	No
Truvada	FTC 200 mg plus TDF 300 mg	35 kg	19 x 8.5	No
Truvada Low Strength	FTC 167 mg plus TDF 250 mg	28 kg	N/A	No
	FTC 133 mg plus TDF 200 mg	22 kg	N/A	No
	FTC 100 mg plus TDF 150 mg	17 kg	N/A	No
<b>NRTI/NNRTI</b>				
Atripla	EFV 600 mg plus FTC 200 mg plus TDF 300 mg	40 kg	N/A	Fasting
Complera	FTC 200 mg plus RPV 25 mg plus TDF 300 mg	35 kg and ≥12 years	N/A	Yes
Odefsey	FTC 200 mg plus RPV 25 mg plus TAF 25 mg	35 kg and ≥12 years	N/A	Yes
Symfi	EFV 600 mg plus 3TC 300 mg plus TDF 300 mg	40 kg	N/A	Unevaluated
Symfi Lo	EFV 400 mg plus 3TC 300 mg plus TDF 300 mg	35 kg	N/A	Unevaluated
<b>NRTI/INSTI</b>				
Biktarvy	BIC 50 mg plus FTC 200 mg plus TAF 25 mg	Adults	15 x 8	No
Triumeq	ABC 600 mg plus DTG 50 mg plus 3TC 300 mg	40 kg	22 x 11	No

**Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents (page 3 of 3)**

<b>FDC by Class</b> Brand name and generic products, when available	<b>FDC Components</b>	<b>Minimum Body Weight (kg) or Age</b>	<b>Pill Size (mm x mm)</b>	<b>Food Required for Optimal Absorption</b>
<b>NNRTI/INSTI</b>				
Juluca	DTG 50 mg plus RPV 25 mg	Adults	N/A	Yes
<b>NRTI/INSTI/COBI</b>				
Genvoya	EVG 150 mg plus COBI 150 mg plus FTC 200 mg plus TAF 10 mg	25 kg	19 x 8.5	Yes
Stribild	EVG 150 mg plus COBI 150 mg plus FTC 200 mg plus TDF 300 mg	35 kg	N/A	Yes
<b>NRTI/PI/COBI</b>				
Symtuza	DRV 800 mg plus COBI 150 mg plus FTC 200 mg plus TAF 10 mg	Adults	N/A	Yes
<b>PI/COBI</b>				
Evotaz	ATV 300 mg plus COBI 150 mg	35 kg	N/A	Yes
Prezcobix	DRV 800 mg plus COBI 150 mg	35 kg	N/A	Yes
<b>PI/RTV</b>				
Kaletra	<p><b>LPV/r Oral Solution:</b></p> <ul style="list-style-type: none"> <li>• 80 mg/mL LPV plus 20 mg/mL RTV</li> </ul> <p><b>Tablets:</b></p> <ul style="list-style-type: none"> <li>• LPV 200 mg plus RTV 50 mg</li> <li>• LPV 100 mg plus RTV 25 mg</li> </ul>	<p>Post-menstrual age of 42 weeks and a postnatal age of <math>\geq 14</math> days::</p> <ul style="list-style-type: none"> <li>• No minimum weight</li> </ul>	N/A	No

**Key to Abbreviations:** 3TC = lamivudine; ABC = abacavir; ATV = atazanavir; BIC = bictegravir; COBI = cobicistat; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FDC = fixed-dose combination; FTC = emtricitabine; INSTI = integrase inhibitor; LPV = lopinavir; LPV/r = lopinavir/ritonavir; mm = millimetre; N/A = information not available; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside and nucleotide reverse transcriptase inhibitor; RPV = rilpivirine; RTV = ritonavir; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine